


**CUMULATIVE  
SUPPLEMENT 4  
APRIL 2020**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**40th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2020**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**40<sup>th</sup> EDITION**

**Cumulative Supplement 4  
April 2020**

**CONTENTS**

*PAGE*

**Contents**

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
<b>DRUG PRODUCT LISTS</b>		
	Prescription Drug Product List .....	1-1
	OTC Drug Product List .....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
	Orphan Product Designations and Approvals List .....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>		
A.	Patent and Exclusivity Lists .....	A-1
B.	Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**40<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 4  
APRIL 2020**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME  
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME  
(NEW ABBREVIATED NAME)

AMNEAL PHARMACEUTICALS CO GMBH  
(AMNEAL PHARMS CO)

AMNEAL EU LTD  
(AMNEAL EU)

ANDA REPOSITORY LLC  
(ANDA REPOSITORY)

PHARMACEUTICS INTERNATIONAL INC  
(PII)

AMERICAN ANTIBIOTICS INC  
(AM ANTIBIOTICS)

BELCHER PHARMACEUTICALS INC  
(BELCHER PHARMS)

#### 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

---

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).



Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2019</u>	<u>MAR</u> <u>2020</u>	<u>JUN</u> <u>2020</u>	<u>SEP</u> <u>2020</u>	<u>DEC</u> <u>2020</u>
DRUG PRODUCTS	20567	20367			
LISTED SINGLE	2743	2635			
SOURCE	(13.3%)	(12.9%)			

MULTISOURCE	17824 (86.7%)	17732 (87.1%)
THERAPEUTICALLY EQUIVALENT	17740 (86.3%)	17659 (86.7%)
NOT THERAPEUTICALLY EQUIVALENT	84 (0.4%)	73 (0.4%)
EXCEPTIONS <sup>4</sup>	54 (0.3%)	54 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	17	24
NUMBER OF APPLICANTS	1162	1166

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR Change. Dosage Form; Route of Administration

CFTG Change. A TE Code is added when a first time generic for an innovator is approved.

CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMS1 Change. Miscellaneous addition to list.

CMS2 Change. Miscellaneous deletion from list.

CPOT Change. Potency amount/unit.

CRLD Change. Reference Listed Drug

CHRS Change. Reference Standard

CTEC Change. Therapeutic Equivalence Code

CTNA Change. Trade Name

DISC Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ACARBOSE

TABLET;ORAL  
 ACARBOSE

@	EMCURE PHARMS LTD	25MG	A202271	001	Feb 07, 2012	Mar	DISC
@		50MG	A202271	002	Feb 07, 2012	Mar	DISC
@		100MG	A202271	003	Feb 07, 2012	Mar	DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@	HIKMA PHARMS	325MG;50MG;40MG	A089718	001	Jun 12, 1995	Feb	DISC
---	--------------	-----------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@	ACTAVIS LABS FL INC	300MG;5MG	A206470	001	Jun 02, 2016	Feb	DISC
@		300MG;7.5MG	A206470	002	Jun 02, 2016	Feb	DISC
@		300MG;10MG	A206470	003	Jun 02, 2016	Feb	DISC
@	XIROMED	325MG;5MG	A211690	001	Feb 07, 2020	Mar	DISC
AA		325MG;5MG	A211690	001	Feb 07, 2020	Feb	CAHN
AA		325MG;5MG	A211690	001	Feb 07, 2020	Jan	NEWA
@		325MG;7.5MG	A211690	002	Feb 07, 2020	Mar	DISC
AA		325MG;7.5MG	A211690	002	Feb 07, 2020	Feb	CAHN
AA		325MG;7.5MG	A211690	002	Feb 07, 2020	Jan	NEWA
@		325MG;10MG	A211690	003	Feb 07, 2020	Mar	DISC
AA		325MG;10MG	A211690	003	Feb 07, 2020	Feb	CAHN
AA		325MG;10MG	A211690	003	Feb 07, 2020	Jan	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL  
 OXYCODONE AND ACETAMINOPHEN

	MIKART INC	300MG/5ML;10MG/5ML	A202142	001	Nov 27, 2018	Feb	CMFD
--	------------	--------------------	---------	-----	--------------	-----	------

TABLET;ORAL  
 OXYCODONE AND ACETAMINOPHEN

>D>	AA	WATSON LABS	325MG;5MG	A040171	001	Oct 30, 1997	Apr	DISC
>A>		@	325MG;5MG	A040171	001	Oct 30, 1997	Apr	DISC
>D>	AA		325MG;7.5MG	A040535	001	Sep 05, 2003	Apr	DISC
>A>		@	325MG;7.5MG	A040535	001	Sep 05, 2003	Apr	DISC
>D>	AA		325MG;10MG	A040535	002	Sep 05, 2003	Apr	DISC
>A>		@	325MG;10MG	A040535	002	Sep 05, 2003	Apr	DISC
		@	325MG;5MG	A207574	001	Dec 13, 2016	Mar	DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL  
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>D>		@	APOTEX	325MG;37.5MG	A078778	001	Apr 07, 2014	Apr	CAHN
		@		325MG;37.5MG	A078778	001	Apr 07, 2014	Feb	DISC
>D>		@	CSPC OUYI	325MG;37.5MG	A076914	001	Jul 26, 2006	Apr	CAHN
>A>		@	GRAVITI PHARMS	325MG;37.5MG	A076914	001	Jul 26, 2006	Apr	CAHN
>A>		@	NOSTRUM LABS INC	325MG;37.5MG	A078778	001	Apr 07, 2014	Apr	CAHN

ACETAZOLAMIDE

TABLET;ORAL  
 ACETAZOLAMIDE

>A>	AB	BRECKENRIDGE	125MG	A207503	001	Apr 30, 2020	Apr	NEWA
>A>	AB		250MG	A207503	002	Apr 30, 2020	Apr	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION  
 ACETAZOLAMIDE SODIUM

AP	!	XGEN PHARMS	EQ 500MG BASE/VIAL	A040784	001	Dec 10, 2008	Feb	CAHN
----	---	-------------	--------------------	---------	-----	--------------	-----	------

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC  
 ACETIC ACID

AT		SAPTALIS PHARMS	2%	A040607	001	Feb 24, 2005	Mar	CAHN
----	--	-----------------	----	---------	-----	--------------	-----	------

ACYCLOVIR

		CREAM;TOPICAL							
		ACYCLOVIR							
AB	!	PERRIGO UK FINCO	5%		A208702	001	Feb 04, 2019	Jan	CHRS
		ZOVIRAX							
AB	+	BAUSCH	5%		N021478	001	Dec 30, 2002	Jan	CHRS
		OINTMENT;TOPICAL							
		ACYCLOVIR							
AB		SOLARIS PHARMA CORP	5%		A212495	001	Apr 07, 2020	Mar	NEWA
AB		XIROMED	5%		A201501	001	Jan 29, 2020	Jan	NEWA
		SUSPENSION;ORAL							
		ACYCLOVIR							
>A>	AB	HERITAGE PHARMS INC	200MG/5ML		A212718	001	Apr 23, 2020	Apr	NEWA
		TABLET;ORAL							
		ACYCLOVIR							
AB	!	HETERO LABS LTD V	800MG		A203834	002	Oct 29, 2013	Jan	CHRS
		ZOVIRAX							
		+ @ MYLAN	400MG		N020089	001	Apr 30, 1991	Jan	DISC
		+ @	800MG		N020089	002	Apr 30, 1991	Jan	DISC

ADAPALENE

		GEL;TOPICAL							
		ADAPALENE							
>D>	AB	P AND L	0.1%		A090962	001	Jun 02, 2010	Apr	CMS1

ADENOSINE

		INJECTABLE;INJECTION							
		ADENOSINE							
>D>	AP	MYLAN LABS LTD	3MG/ML		A078640	001	Mar 21, 2014	Apr	DISC
>A>		@	3MG/ML		A078640	001	Mar 21, 2014	Apr	DISC

ALBUTEROL SULFATE

		AEROSOL, METERED;INHALATION							
		ALBUTEROL SULFATE							
AB1		CIPLA	EQ 0.09MG BASE/INH		A209959	001	Apr 08, 2020	Mar	NFTG
AB2		PERRIGO PHARMS CO	EQ 0.09MG BASE/INH		A203760	001	Feb 24, 2020	Mar	CTEC
AB			EQ 0.09MG BASE/INH		A203760	001	Feb 24, 2020	Feb	NFTG
		PROAIR HFA							
AB2	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH		N021457	001	Oct 29, 2004	Mar	CTEC
AB	+		EQ 0.09MG BASE/INH		N021457	001	Oct 29, 2004	Feb	CFTG
		PROVENTIL-HFA							
AB1	+	3M DRUG DELIVERY	EQ 0.09MG BASE/INH		N020503	001	Aug 15, 1996	Mar	CFTG
		SOLUTION;INHALATION							
		ALBUTEROL SULFATE							
>A>	AN	AUROBINDO PHARMA LTD	EQ 0.021% BASE		A211888	001	Apr 20, 2020	Apr	NEWA
>A>	AN		EQ 0.042% BASE		A211888	002	Apr 20, 2020	Apr	NEWA
		@ BAUSCH AND LOMB	EQ 0.5% BASE		A075050	001	Jun 18, 1998	Feb	DISC
AN	!	NEPHRON	EQ 0.5% BASE		A075664	001	Jun 26, 2001	Feb	CHRS
		TABLET, EXTENDED RELEASE;ORAL							
		VOLMAX							
		+ @ MURO	EQ 4MG BASE		N019604	002	Dec 23, 1992	Mar	CRLD
		+ @	EQ 8MG BASE		N019604	001	Dec 23, 1992	Mar	CRLD

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

		SOLUTION;INHALATION							
		ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE							
>D>	AN	WATSON LABS TEVA	EQ 0.083% BASE;0.017%		A077063	001	Dec 31, 2007	Apr	DISC
>A>		@	EQ 0.083% BASE;0.017%		A077063	001	Dec 31, 2007	Apr	DISC

ALOSETRON HYDROCHLORIDE

		TABLET;ORAL							
		ALOSETRON HYDROCHLORIDE							
>D>	AB	EYWA PHARMA	EQ 0.5MG BASE		A211621	001	Sep 16, 2019	Apr	DISC
>A>		@	EQ 0.5MG BASE		A211621	001	Sep 16, 2019	Apr	DISC
>D>	AB		EQ 1MG BASE		A211621	002	Sep 16, 2019	Apr	DISC
>A>		@	EQ 1MG BASE		A211621	002	Sep 16, 2019	Apr	DISC

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

@	DAVA INTL INC	0.25MG	A074174	001	Oct 19, 1993	Feb	DISC
@		0.5MG	A074174	002	Oct 19, 1993	Feb	DISC
@		1MG	A074174	003	Oct 19, 1993	Feb	DISC
@		2MG	A074174	004	Oct 19, 1993	Feb	DISC

XANAX

>D>	AB	+	PHARMACIA AND UPJOHN	0.25MG	N018276	001		Apr	CAHN
>D>	AB	+		0.5MG	N018276	002		Apr	CAHN
>D>	AB	+	!	1MG	N018276	003		Apr	CAHN
>D>	AB	+		2MG	N018276	004	Nov 27, 1985	Apr	CAHN
>A>	AB	+	UPJOHN	0.25MG	N018276	001		Apr	CAHN
>A>	AB	+		0.5MG	N018276	002		Apr	CAHN
>A>	AB	+	!	1MG	N018276	003		Apr	CAHN
>A>	AB	+		2MG	N018276	004	Nov 27, 1985	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

XANAX XR

>D>	AB	+	PHARMACIA AND UPJOHN	0.5MG	N021434	001	Jan 17, 2003	Apr	CAHN
>D>	AB	+		1MG	N021434	002	Jan 17, 2003	Apr	CAHN
>D>	AB	+		2MG	N021434	003	Jan 17, 2003	Apr	CAHN
>D>	AB	+	!	3MG	N021434	004	Jan 17, 2003	Apr	CAHN
>A>	AB	+	UPJOHN	0.5MG	N021434	001	Jan 17, 2003	Apr	CAHN
>A>	AB	+		1MG	N021434	002	Jan 17, 2003	Apr	CAHN
>A>	AB	+		2MG	N021434	003	Jan 17, 2003	Apr	CAHN
>A>	AB	+	!	3MG	N021434	004	Jan 17, 2003	Apr	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB			INVATECH	100MG	A210129	001	Mar 02, 2020	Feb	NEWA
----	--	--	----------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

AB			INVATECH	100MG	A210215	001	Mar 10, 2020	Feb	NEWA
----	--	--	----------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OSMOLEX ER

>A>		+	OSMOTICA PHARM	EQ 161MG BASE	N209410	004	Apr 22, 2020	Apr	NEWA
-----	--	---	----------------	---------------	---------	-----	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP			TEVA PHARMS USA	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Mar	CMFD
----	--	--	-----------------	------------------	---------	-----	--------------	-----	------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; INTRAVENOUS

PERIKABIVEN IN PLASTIC CONTAINER

+	!	FRESENIUS KABI USA	2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Jan	CHRS
---	---	--------------------	--	---------	-----	--------------	-----	------

AMINOCAPROIC ACID

SYRUP; ORAL

AMINOCAPROIC ACID

AA			VISTAPHARM	1.25GM/5ML	A212814	001	Feb 26, 2020	Feb	NEWA
----	--	--	------------	------------	---------	-----	--------------	-----	------

AMISULPRIDE

SOLUTION; INTRAVENOUS

BARHEMSYS

+	!	ACACIA PHARMA LTD	5MG/2ML (2.5MG/ML)	N209510	001	Feb 26, 2020	Feb	NEWA
---	---	-------------------	--------------------	---------	-----	--------------	-----	------

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB			SANDOZ	10MG	A085968	004		Jan	CMS1
AB		!		25MG	A085968	002		Jan	CMS1
AB				75MG	A085968	006		Jan	CMS1
AB				100MG	A085968	003		Jan	CMS1
AB				150MG	A085968	005		Jan	CMS1

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

	@ HIKMA	EQ 2.5MG BASE	A077262	001	Jul 09, 2007	Feb	DISC
	@	EQ 5MG BASE	A077262	002	Jul 09, 2007	Feb	DISC
	@	EQ 10MG BASE	A077262	003	Jul 09, 2007	Feb	DISC
>D>	AB WATSON LABS	EQ 2.5MG BASE	A077671	001	Jul 19, 2007	Apr	DISC
>A>	@	EQ 2.5MG BASE	A077671	001	Jul 19, 2007	Apr	DISC
>D>	AB	EQ 5MG BASE	A077671	002	Jul 19, 2007	Apr	DISC
>A>	@	EQ 5MG BASE	A077671	002	Jul 19, 2007	Apr	DISC
>D>	AB	EQ 10MG BASE	A077671	003	Jul 19, 2007	Apr	DISC
>A>	@	EQ 10MG BASE	A077671	003	Jul 19, 2007	Apr	DISC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Feb	CMFD
AB		EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Feb	CMFD
AB		EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Feb	CMFD
AB		EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Feb	CMFD
AB		EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Feb	CMFD
AB		EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Feb	CMFD
AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb	CMFD
AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb	CMFD
AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb	CMFD
AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb	CMFD
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb	CMFD

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;12.5MG;160MG	A206180	001	Dec 19, 2017	Mar	CPOT
AB		EQ 5MG BASE;25MG;160MG	A206180	002	Dec 19, 2017	Mar	CPOT
AB		EQ 10MG BASE;12.5MG;160MG	A206180	003	Dec 19, 2017	Mar	CPOT
AB		EQ 10MG BASE;25MG;160MG	A206180	004	Dec 19, 2017	Mar	CPOT
AB		EQ 10MG BASE;25MG;320MG	A206180	005	Dec 19, 2017	Mar	CPOT
AB	LUPIN LTD	EQ 5MG BASE;12.5MG;160MG	A200797	001	Jun 03, 2015	Mar	CPOT
AB		EQ 5MG BASE;25MG;160MG	A200797	002	Jun 03, 2015	Mar	CPOT
AB		EQ 10MG BASE;12.5MG;160MG	A200797	003	Jun 03, 2015	Mar	CPOT
AB		EQ 10MG BASE;25MG;160MG	A200797	004	Jun 03, 2015	Mar	CPOT
AB		EQ 10MG BASE;25MG;320MG	A200797	005	Jun 03, 2015	Mar	CPOT
AB	PAR PHARM	EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	Mar	CPOT
AB		EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	Mar	CPOT
AB		EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	Mar	CPOT
AB		EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	Mar	CPOT
AB		EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	Mar	CPOT
	@ TEVA PHARMS	EQ 5MG BASE;12.5MG;160MG	A200435	001	Sep 25, 2012	Mar	CPOT
	@	EQ 5MG BASE;25MG;160MG	A200435	002	Sep 25, 2012	Mar	CPOT
	@	EQ 10MG BASE;12.5MG;160MG	A200435	005	Sep 25, 2012	Mar	CPOT
	@	EQ 10MG BASE;25MG;160MG	A200435	003	Sep 25, 2012	Mar	CPOT
	@	EQ 10MG BASE;25MG;320MG	A200435	004	Sep 25, 2012	Mar	CPOT
	@ TORRENT	EQ 5MG BASE;12.5MG;160MG	A201593	001	Jun 03, 2015	Mar	CPOT
	@	EQ 5MG BASE;25MG;160MG	A201593	002	Jun 03, 2015	Mar	CPOT
	@	EQ 10MG BASE;12.5MG;160MG	A201593	003	Jun 03, 2015	Mar	CPOT
	@	EQ 10MG BASE;25MG;160MG	A201593	004	Jun 03, 2015	Mar	CPOT
	@	EQ 10MG BASE;25MG;320MG	A201593	005	Jun 03, 2015	Mar	CPOT
	EXFORGE HCT						
AB	+ NOVARTIS	EQ 5MG BASE;12.5MG;160MG	N022314	001	Apr 30, 2009	Mar	CPOT
AB	+	EQ 5MG BASE;25MG;160MG	N022314	002	Apr 30, 2009	Mar	CPOT
AB	+	EQ 10MG BASE;12.5MG;160MG	N022314	003	Apr 30, 2009	Mar	CPOT
AB	+	EQ 10MG BASE;25MG;160MG	N022314	004	Apr 30, 2009	Mar	CPOT
AB	+!	EQ 10MG BASE;25MG;320MG	N022314	005	Apr 30, 2009	Mar	CPOT

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

>D>	AB WATSON LABS INC	EQ 12% BASE	A076829	001	Feb 07, 2006	Apr	DISC
>A>	@	EQ 12% BASE	A076829	001	Feb 07, 2006	Apr	DISC

LOTION; TOPICAL

AMMONIUM LACTATE

>D>	AB WATSON LABS INC	EQ 12% BASE	A075575	001	Jun 11, 2002	Apr	DISC
>A>	@	EQ 12% BASE	A075575	001	Jun 11, 2002	Apr	DISC

AMOXAPINE

TABLET; ORAL

AMOXAPINE

@	WATSON PHARMS TEVA	25MG	A072418	001	Aug 01, 1989	Jan CMS1
@		50MG	A072419	001	Aug 01, 1989	Jan CMS1

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ANI PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A205401	001	Jan 22, 2019	Jan CAHN	
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A205401	002	Jan 22, 2019	Jan CAHN	
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A205401	003	Jan 22, 2019	Jan CAHN	
AB		5MG; 5MG; 5MG; 5MG	A205401	004	Jan 22, 2019	Jan CAHN	
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A205401	005	Jan 22, 2019	Jan CAHN	
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A205401	006	Jan 22, 2019	Jan CAHN	
	@ NESHER PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210080	001	Jul 17, 2019	Jan DISC	
	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A210080	002	Jul 17, 2019	Jan DISC	
	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A210080	003	Jul 17, 2019	Jan DISC	
	@	5MG; 5MG; 5MG; 5MG	A210080	004	Jul 17, 2019	Jan DISC	
	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A210080	005	Jul 17, 2019	Jan DISC	
	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A210080	006	Jul 17, 2019	Jan DISC	
>D>	@ SUN PHARM INDUSTRIES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	Apr CMFD	
>A>	AB	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	Apr CMFD	
>D>	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	Apr CMFD	
>A>	AB	2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	Apr CMFD	
>D>	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	Apr CMFD	
>A>	AB	3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	Apr CMFD	
>D>	@	5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	Apr CMFD	
>A>	AB	5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	Apr CMFD	
>D>	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	Apr CMFD	
>A>	AB	6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	Apr CMFD	
>D>	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	Apr CMFD	
>A>	AB	7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	Apr CMFD	
>D>	AB	TEVA	1.25MG; 1.25MG; 1.25MG; 1.25MG	A077488	001	Apr 29, 2013	Apr DISC
>A>	@	1.25MG; 1.25MG; 1.25MG; 1.25MG	A077488	001	Apr 29, 2013	Apr DISC	
>D>	AB	2.5MG; 2.5MG; 2.5MG; 2.5MG	A077488	002	Apr 29, 2013	Apr DISC	
>A>	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A077488	002	Apr 29, 2013	Apr DISC	
>D>	AB	3.75MG; 3.75MG; 3.75MG; 3.75MG	A077488	003	Apr 29, 2013	Apr DISC	
>A>	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A077488	003	Apr 29, 2013	Apr DISC	
>D>	AB	5MG; 5MG; 5MG; 5MG	A077488	004	Apr 29, 2013	Apr DISC	
>A>	@	5MG; 5MG; 5MG; 5MG	A077488	004	Apr 29, 2013	Apr DISC	
>D>	AB	6.25MG; 6.25MG; 6.25MG; 6.25MG	A077488	005	Apr 29, 2013	Apr DISC	
>A>	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A077488	005	Apr 29, 2013	Apr DISC	
>D>	AB	7.5MG; 7.5MG; 7.5MG; 7.5MG	A077488	006	Apr 29, 2013	Apr DISC	
>A>	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A077488	006	Apr 29, 2013	Apr DISC	

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>D>	AB	BARR LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A076536	001	Feb 12, 2013	Apr DISC
>A>	@		1.25MG; 1.25MG; 1.25MG; 1.25MG	A076536	001	Feb 12, 2013	Apr DISC
>D>	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A076536	002	Feb 12, 2013	Apr DISC
>A>	@		2.5MG; 2.5MG; 2.5MG; 2.5MG	A076536	002	Feb 12, 2013	Apr DISC
>D>	AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A076536	003	Feb 12, 2013	Apr DISC
>A>	@		3.75MG; 3.75MG; 3.75MG; 3.75MG	A076536	003	Feb 12, 2013	Apr DISC
>D>	AB		5MG; 5MG; 5MG; 5MG	A076536	004	Feb 12, 2013	Apr DISC
>A>	@		5MG; 5MG; 5MG; 5MG	A076536	004	Feb 12, 2013	Apr DISC
>D>	AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A076536	005	Feb 12, 2013	Apr DISC
>A>	@		6.25MG; 6.25MG; 6.25MG; 6.25MG	A076536	005	Feb 12, 2013	Apr DISC
>D>	AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A076536	006	Feb 12, 2013	Apr DISC
>A>	@		7.5MG; 7.5MG; 7.5MG; 7.5MG	A076536	006	Feb 12, 2013	Apr DISC

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	BIONPHARMA INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210293	001	Apr 03, 2020	Mar NEWA
AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A210293	002	Apr 03, 2020	Mar NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210293	003	Apr 03, 2020	Mar NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210293	004	Apr 03, 2020	Mar NEWA
AB		5MG; 5MG; 5MG; 5MG	A210293	005	Apr 03, 2020	Mar NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210293	006	Apr 03, 2020	Mar NEWA



AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

AA	CEROVENE INC	5MG	A212582	001	Feb 04, 2020	Jan	NEWA
AA		10MG	A212582	002	Feb 04, 2020	Jan	NEWA
AA	PRINSTON INC	5MG	A211861	001	Mar 11, 2020	Feb	NEWA
AA		10MG	A211861	002	Mar 11, 2020	Feb	NEWA

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

!	XGEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992	Feb	CAHN
---	-------------	-----------	---------	-----	--------------	-----	------

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

@	PHARM ASSOC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Jan	CAHN
---	-------------	--	---------	-----	--------------	-----	------

@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Jan	CAHN
---	--	-----------------------------------	---------	-----	--------------	-----	------

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

@	DAVA PHARMS INC	EQ 500MG BASE	A062882	001	Feb 25, 1988	Mar	DISC
---	-----------------	---------------	---------	-----	--------------	-----	------

!	SANDOZ	EQ 500MG BASE	A064082	002	Aug 29, 1995	Mar	CHRS
---	--------	---------------	---------	-----	--------------	-----	------

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

>D>	AB	BARR	EQ 0.5MG BASE	A076530	001	Apr 18, 2005	Apr	DISC
-----	----	------	---------------	---------	-----	--------------	-----	------

>A>	@		EQ 0.5MG BASE	A076530	001	Apr 18, 2005	Apr	DISC
-----	---	--	---------------	---------	-----	--------------	-----	------

>D>	AB		EQ 1MG BASE	A076530	002	Apr 18, 2005	Apr	DISC
-----	----	--	-------------	---------	-----	--------------	-----	------

>A>	@		EQ 1MG BASE	A076530	002	Apr 18, 2005	Apr	DISC
-----	---	--	-------------	---------	-----	--------------	-----	------

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

@	APOTEX INC	1MG	A200654	001	May 11, 2012	Feb	DISC
---	------------	-----	---------	-----	--------------	-----	------

@	MYLAN	1MG	A091051	001	Jun 28, 2010	Jan	DISC
---	-------	-----	---------	-----	--------------	-----	------

APIXABAN

TABLET; ORAL

APIXABAN

AB	BIONPHARMA INC	2.5MG	A210152	001	Apr 08, 2020	Mar	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

AB		5MG	A210152	002	Apr 08, 2020	Mar	NEWA
----	--	-----	---------	-----	--------------	-----	------

@	MYLAN	2.5MG	A210128	001	Dec 23, 2019	Jan	DISC
---	-------	-------	---------	-----	--------------	-----	------

@		5MG	A210128	002	Dec 23, 2019	Jan	DISC
---	--	-----	---------	-----	--------------	-----	------

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP	+!	HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Mar	CHRS
----	----	--------------------	------------------------	---------	-----	--------------	-----	------

AP	+		250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Mar	CRLD
----	---	--	------------------------	---------	-----	--------------	-----	------

INJECTABLE; INTRAVENOUS

ARGATROBAN IN 0.9% SODIUM CHLORIDE

@	TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014	Mar	DISC
---	-----------------	----------------------	---------	-----	--------------	-----	------

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SEPTOCAINE

+!	DEPROCO	4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N022010	001	Mar 30, 2006	Mar	CTEC
----	---------	--	---------	-----	--------------	-----	------

+!		4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971	001	Apr 03, 2000	Feb	CTEC
----	--	--	---------	-----	--------------	-----	------

ULTACAN

@	HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751	001	Jul 11, 2017	Mar	DISC
---	--------------	---	---------	-----	--------------	-----	------

ULTACAN FORTE

@	HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017	Feb	DISC
---	--------------	---	---------	-----	--------------	-----	------

ASENAPINE MALEATETABLET;SUBLINGUAL  
SAPHRIS

+ ALLERGAN EQ 2.5MG BASE N022117 003 Mar 12, 2015 Jan CMS1

ASPIRIN; BUTALBITAL; CAFFEINETABLET;ORAL  
BUTALBITAL, ASPIRIN AND CAFFEINE

AA STRIDES PHARMA 325MG;50MG;40MG A204195 001 Sep 22, 2016 Mar CAHN

ATAZANAVIR SULFATECAPSULE;ORAL  
ATAZANAVIR SULFATE

@ MYLAN	EQ 150MG BASE	A208177	001	Sep 24, 2018	Feb DISC
@	EQ 200MG BASE	A208177	002	Sep 24, 2018	Feb DISC
@	EQ 300MG BASE	A208177	003	Sep 24, 2018	Feb DISC

ATORVASTATIN CALCIUMTABLET;ORAL  
ATORVASTATIN CALCIUM

AB	LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Jan CMFD
AB		EQ 20MG BASE	A204991	002	Mar 06, 2019	Jan CMFD
AB		EQ 40MG BASE	A204991	003	Mar 06, 2019	Jan CMFD
AB		EQ 80MG BASE	A204991	004	Mar 06, 2019	Jan CMFD

ATORVASTATIN CALCIUM; EZETIMIBETABLET;ORAL  
EZETIMIBE AND ATORVASTATIN CALCIUM

>D>	SCOV3	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Apr DISC
>A>	@	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Apr DISC
		EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Mar CAHN
>D>		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Apr DISC
>A>	@	EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Apr DISC
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Mar CAHN
>D>		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Apr DISC
>A>	@	EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Apr DISC
		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Mar CAHN
>D>	!	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Apr DISC
>A>	@	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Apr DISC
	!	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Mar CAHN

ATROPINE SULFATESOLUTION/DROPS;OPHTHALMIC  
ISOPTO ATROPINE

+!	ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Feb CRLD
!		1%	N208151	001	Dec 01, 2016	Feb CHRS

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDETABLET;ORAL  
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA LEADING PHARMA LLC 0.025MG;2.5MG A213413 001 Feb 20, 2020 Feb NEWA

AVAPRITINIBTABLET;ORAL  
AYVAKIT

+	BLUEPRINT MEDICINES	100MG	N212608	001	Jan 09, 2020	Jan NEWA
+		200MG	N212608	002	Jan 09, 2020	Jan NEWA
+!		300MG	N212608	003	Jan 09, 2020	Jan NEWA

AZATHIOPRINETABLET;ORAL  
AZATHIOPRINE

AB	ALKEM LABS LTD	25MG	A208687	001	Mar 27, 2020	Mar NEWA
AB		50MG	A208687	002	Mar 27, 2020	Mar NEWA
AB		75MG	A208687	003	Mar 27, 2020	Mar NEWA
AB		100MG	A208687	004	Mar 27, 2020	Mar NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
 AZELASTINE HYDROCHLORIDE  
 GLAND PHARMA LTD 0.05%  
 SPRAY, METERED;NASAL  
 AZELASTINE HYDROCHLORIDE

AT A210092 001 Feb 25, 2020 Feb NEWA

>A> AB AUROBINDO PHARMA LTD EQ 0.125MG BASE/SPRAY A212289 001 May 08, 2020 Apr NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL  
 AZITHROMYCIN

>D> AB TEVA PHARMS EQ 100MG BASE/5ML A065419 001 Jun 24, 2008 Apr DISC  
 >A> @ EQ 100MG BASE/5ML A065419 001 Jun 24, 2008 Apr DISC  
 >D> AB EQ 200MG BASE/5ML A065419 002 Jun 24, 2008 Apr DISC  
 >A> @ EQ 200MG BASE/5ML A065419 002 Jun 24, 2008 Apr DISC

INJECTABLE;INJECTION  
 AZITHROMYCIN

@ HIKMA EQ 500MG BASE/VIAL A065265 001 Jan 18, 2007 Mar CAHN  
 @ MYLAN LABS LTD EQ 500MG BASE/VIAL A204732 001 Jan 26, 2017 Mar DISC

TABLET;ORAL

AZITHROMYCIN

AB ALEMBIC PHARMS LTD EQ 250MG BASE A211791 001 Jan 28, 2020 Jan NEWA  
 AB EQ 500MG BASE A211792 001 Jan 28, 2020 Jan NEWA  
 AB EQ 600MG BASE A211793 001 Jan 27, 2020 Jan NEWA  
 @ MYLAN EQ 600MG BASE A065360 001 Jan 08, 2007 Jan DISC  
 >A> AB YUNG SHIN PHARM EQ 600MG BASE A211068 001 May 08, 2020 Apr NEWA

BACITRACIN

INJECTABLE;INJECTION  
 BACIIM

@ X GEN PHARMS 50,000 UNITS/VIAL A064153 001 May 09, 1997 Mar DISC  
 BACITRACIN

@ AKORN 50,000 UNITS/VIAL A206719 001 Oct 20, 2017 Mar DISC  
 @ FRESENIUS KABI USA 50,000 UNITS/VIAL A065116 001 Dec 03, 2002 Mar DISC

BACLOFEN

INJECTABLE;INTRATHECAL  
 BACLOFEN

@ MAIA PHARMS INC 0.5MG/ML A210048 001 Sep 11, 2019 Mar DISC  
 @ 2MG/ML A210048 002 Sep 11, 2019 Mar DISC

TABLET;ORAL

BACLOFEN

@ MYLAN 20MG A077121 002 Jul 29, 2005 Jan DISC  
 >D> AB MYLAN PHARMS INC 10MG A090334 001 Feb 18, 2010 Apr DISC  
 >A> @ 10MG A090334 001 Feb 18, 2010 Apr DISC  
 >D> AB 20MG A090334 002 Feb 18, 2010 Apr DISC  
 >A> @ 20MG A090334 002 Feb 18, 2010 Apr DISC  
 >D> RUBICON 5MG A209102 001 Nov 28, 2017 Apr CTEC  
 >A> AB 5MG A209102 001 Nov 28, 2017 Apr CTEC  
 >A> AB ZYDUS 5MG A211659 003 Apr 17, 2020 Apr NEWA

BEMPEDOIC ACID

TABLET;ORAL  
 NEXLETOL

+! ESPERION THERAPS INC 180MG N211616 001 Feb 21, 2020 Feb NEWA

BEMPEDOIC ACID; EZETIMIBE

TABLET;ORAL  
 NEXLIZET

+! ESPERION THERAPS INC 180MG;10MG N211617 001 Feb 26, 2020 Feb NEWA

BENZAEPRIIL HYDROCHLORIDE

TABLET;ORAL

BENZAEPRIIL HYDROCHLORIDE

AB COREPHARMA 5MG A077128 001 Mar 08, 2006 Feb CAHN  
 AB A077128 002 Mar 08, 2006 Feb CAHN  
 AB 20MG A077128 003 Mar 08, 2006 Feb CAHN  
 AB 40MG A077128 004 Mar 08, 2006 Feb CAHN

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC  
 FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE

+! BAUSCH 0.4%;0.3% N211039 001 Mar 09, 2020 Mar NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL  
 BENZPHETAMINE HYDROCHLORIDE

>D> AA @ EMCURE PHARMS LTD 50MG A202061 001 Jan 27, 2012 Mar DISC  
 >A> SPECGX LLC 50MG A040773 001 Apr 25, 2007 Apr DISC  
 >A> @ 50MG A040773 001 Apr 25, 2007 Apr DISC  
 >D> AA TWI PHARMS 50MG A040578 001 Apr 17, 2006 Apr DISC  
 >A> @ 50MG A040578 001 Apr 17, 2006 Apr DISC

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC  
 BEPOTASTINE BESILATE

@ MYLAN 1.5% A206220 001 Mar 18, 2019 Feb DISC  
 BEPREVE  
 +! BAUSCH AND LOMB INC 1.5% N022288 001 Sep 08, 2009 Feb CTEC

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL  
 BETAMETHASONE DIPROPIONATE

AB ! GLENMARK GENERICS EQ 0.05% BASE A078930 001 Sep 23, 2008 Feb CHRS  
 DIPROLENE AF  
 + @ MERCK SHARP DOHME EQ 0.05% BASE N019555 001 Apr 27, 1987 Feb DISC  
 LOTION;TOPICAL  
 BETAMETHASONE DIPROPIONATE  
 >D> AB ACTAVIS MID ATLANTIC EQ 0.05% BASE A070281 001 Jul 31, 1985 Apr DISC  
 >A> @ EQ 0.05% BASE A070281 001 Jul 31, 1985 Apr DISC

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION;TOPICAL

>A> CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE  
 >A> AB TOLMAR 0.064%;0.005% A210765 001 May 11, 2020 Apr NFTG  
 TACLONEX  
 >D> +! LEO PHARMA AS 0.064%;0.005% N022185 001 May 09, 2008 Apr CFTG  
 >A> AB +! 0.064%;0.005% N022185 001 May 09, 2008 Apr CFTG

BETHANECHOL CHLORIDE

TABLET;ORAL  
 BETHANECHOL CHLORIDE

AA ! AMNEAL PHARM 5MG A040855 001 Nov 21, 2007 Jan CHRS  
 AA ! 10MG A040855 002 Nov 21, 2007 Jan CHRS  
 AA ! 25MG A040855 003 Nov 21, 2007 Jan CHRS  
 @ IMPAX LABS 25MG A040721 003 Nov 01, 2006 Jan CMS1  
 URECHOLINE  
 @ ODYSSEY PHARMS 5MG A089095 001 Dec 19, 1985 Jan DISC  
 @ 10MG A088440 001 May 29, 1984 Jan DISC  
 @ 25MG A088441 001 May 29, 1984 Jan DISC

BEXAROTENE

CAPSULE;ORAL  
 BEXAROTENE

AB ANI PHARMS INC 75MG A209861 001 May 08, 2018 Jan CAHN

BICALUTAMIDE

TABLET;ORAL  
 BICALUTAMIDE

@ MYLAN 50MG A079185 001 Jul 06, 2009 Jan DISC

BIMATOPROST

IMPLANT;OPHTHALMIC  
 DURYSTA

+! ALLERGAN INC 10MCG N211911 001 Mar 04, 2020 Mar NEWA  
 SOLUTION/DROPS;TOPICAL  
 BIMATOPROST  
 AT ALEMBIC PHARMS LTD 0.03% A210515 001 Jan 21, 2020 Jan NEWA

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

>D>	AB	TEVA PHARMS	5MG	A075644	001	Jun 26, 2001	Apr	DISC
>A>		@	5MG	A075644	001	Jun 26, 2001	Apr	DISC
>D>	AB		10MG	A075644	002	Jun 26, 2001	Apr	DISC
>A>		@	10MG	A075644	002	Jun 26, 2001	Apr	DISC

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

BIVALIRUDIN

	@	APOTEX	250MG/VIAL	A204876	001	Jul 06, 2017	Feb	DISC
--	---	--------	------------	---------	-----	--------------	-----	------

BOSENTAN

TABLET; ORAL

BOSENTAN

AB		ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020	Jan	NEWA
AB			125MG	A211461	002	Jan 23, 2020	Jan	NEWA
	@	MYLAN	62.5MG	A205173	001	Jan 15, 2020	Jan	DISC
	@		125MG	A205173	002	Jan 15, 2020	Jan	DISC

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

AT2		GLAND PHARMA LTD	EQ 0.09% ACID	A211029	001	Mar 17, 2020	Mar	NEWA
-----	--	------------------	---------------	---------	-----	--------------	-----	------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

>A>	AA	LANNETT CO INC	2MG/5ML; 10MG/5ML; 30MG/5ML	A213125	001	Apr 17, 2020	Apr	NEWA
-----	----	----------------	-----------------------------	---------	-----	--------------	-----	------

BUDESONIDE

AEROSOL, FOAM; RECTAL

UCERIS

	+!	SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Feb	CAHN
--	----	-------	---------------	---------	-----	--------------	-----	------

BUMETANIDE

TABLET; ORAL

BUMETANIDE

AB		RISING	0.5MG	A212019	001	Dec 12, 2019	Jan	CAHN
AB			1MG	A212019	002	Dec 12, 2019	Jan	CAHN
AB			2MG	A212019	003	Dec 12, 2019	Jan	CAHN

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

AB		AMNEAL PHARMS LLC	5MCG/HR	A211586	001	Apr 14, 2020	Mar	NEWA
AB			7.5MCG/HR	A211586	002	Apr 14, 2020	Mar	NFTG
AB			10MCG/HR	A211586	003	Apr 14, 2020	Mar	NEWA
AB			15MCG/HR	A211586	004	Apr 14, 2020	Mar	NEWA
AB			20MCG/HR	A211586	005	Apr 14, 2020	Mar	NEWA

BUTRANS

AB	+	PURDUE PHARMA LP	7.5MCG/HR	N021306	005	Jun 30, 2014	Mar	CFTG
----	---	------------------	-----------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

>A>	AB	MYLAN TECHNOLOGIES	EQ 2MG BASE; EQ 0.5MG BASE	A211785	001	Apr 17, 2020	Apr	NEWA
>A>	AB		EQ 4MG BASE; EQ 1MG BASE	A211785	002	Apr 17, 2020	Apr	NEWA

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		RHODES PHARMS	EQ 2MG BASE; EQ 0.5MG BASE	A205601	001	Mar 30, 2020	Mar	NEWA
AB			EQ 8MG BASE; EQ 2MG BASE	A205601	002	Mar 30, 2020	Mar	NEWA

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB		CADILA PHARMS LTD	75MG	A208606	001	Jan 16, 2020	Jan	NEWA
AB			100MG	A208606	002	Jan 16, 2020	Jan	NEWA
>A>	AB	MICRO LABS	75MG	A207403	001	Apr 17, 2020	Apr	NEWA
>A>	AB		100MG	A207403	002	Apr 17, 2020	Apr	NEWA

## TABLET, EXTENDED RELEASE;ORAL

## BUPROPION HYDROCHLORIDE

	@ JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013	Feb	DISC
	@	150MG	A202774	002	Oct 11, 2013	Feb	DISC
	@	150MG	A202775	001	Oct 11, 2013	Feb	DISC
	@	150MG	A207459	001	Jun 30, 2017	Feb	DISC
	@	200MG	A202774	003	Oct 11, 2013	Feb	DISC
	@	300MG	A207459	002	Jun 30, 2017	Feb	DISC
>D>	AB1 WATSON LABS INC	100MG	A077455	001	Jul 19, 2010	Apr	DISC
>A>	@	100MG	A077455	001	Jul 19, 2010	Apr	DISC
>D>	AB1	150MG	A077455	002	Mar 12, 2008	Apr	DISC
>A>	@	150MG	A077455	002	Mar 12, 2008	Apr	DISC
>D>	AB1	200MG	A077455	003	Jul 19, 2010	Apr	DISC
>A>	@	200MG	A077455	003	Jul 19, 2010	Apr	DISC

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE;ORAL

## CONTRAVE

+!	NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014	Jan	CAHN
----	------------	----------	---------	-----	--------------	-----	------

BUSULFAN

## INJECTABLE; INJECTION

>A>	BUSULFAN						
>A>	AP MYLAN INSTITUTIONAL	6MG/ML	A208536	001	Nov 20, 2017	Apr	CTNA
	@ MYLAN LABS LTD	6MG/ML	A205184	001	Jul 13, 2018	Feb	DISC
>D>	MYLERAN						
>D>	AP MYLAN INSTITUTIONAL	6MG/ML	A208536	001	Nov 20, 2017	Apr	CTNA

CABERGOLINE

## TABLET; ORAL

## CABERGOLINE

	@ MYLAN	0.5MG	A202947	001	Dec 02, 2013	Jan	DISC
--	---------	-------	---------	-----	--------------	-----	------

CALCITRIOL

## CAPSULE; ORAL

## CALCITRIOL

AB	SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Mar	CMFD
AB		0.5MCG	A204556	002	Feb 21, 2019	Mar	CMFD

## INJECTABLE; INJECTION

## CALCITRIOL

AP	! AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Jan	CTEC
AP	GLAND PHARMA LTD	0.001MG/ML	A211030	001	Feb 03, 2020	Jan	NEWA

CALCIUM ACETATE

## CAPSULE; ORAL

## CALCIUM ACETATE

	@ LOTUS PHARM CO LTD	667MG	A203298	001	Jul 26, 2016	Jan	DISC
AB	SUVEN LIFE	667MG	A211038	001	Feb 21, 2020	Feb	NEWA

CAPECITABINE

## TABLET; ORAL

## CAPECITABINE

>A>	AB RELIANCE LIFE	150MG	A211724	001	Apr 27, 2020	Apr	NEWA
>A>	AB	500MG	A211724	002	Apr 27, 2020	Apr	NEWA

CAPREOMYCIN SULFATE

## INJECTABLE; INJECTION

## CAPREOMYCIN SULFATE

	@ HISUN PHARM HANGZHOU	EQ 1GM BASE/VIAL	A204796	001	Oct 18, 2018	Mar	DISC
--	------------------------	------------------	---------	-----	--------------	-----	------

CAPTOPRIL

## TABLET; ORAL

## CAPTOPRIL

	@ COREPHARMA	12.5MG	A074737	001	Oct 28, 1998	Feb	CAHN
	@	25MG	A074737	002	Oct 28, 1998	Feb	CAHN
	@	50MG	A074737	003	Oct 28, 1998	Feb	CAHN
	@	100MG	A074737	004	Oct 28, 1998	Feb	CAHN
>D>	AB TEVA	12.5MG	A074322	001	Feb 13, 1996	Apr	DISC
>A>	@	12.5MG	A074322	001	Feb 13, 1996	Apr	DISC
>D>	AB	25MG	A074322	002	Feb 13, 1996	Apr	DISC
>A>	@	25MG	A074322	002	Feb 13, 1996	Apr	DISC
>D>	AB	50MG	A074322	003	Feb 13, 1996	Apr	DISC

## TABLET; ORAL

## CAPTOPRIL

>A>	@	50MG	A074322	003	Feb 13, 1996	Apr	DISC
>D>	AB	100MG	A074322	004	Feb 13, 1996	Apr	DISC
>A>	@	100MG	A074322	004	Feb 13, 1996	Apr	DISC
>D>	AB	WATSON LABS 12.5MG	A074386	001	May 23, 1996	Apr	DISC
>A>	@	12.5MG	A074386	001	May 23, 1996	Apr	DISC
>D>	AB	25MG	A074386	002	May 23, 1996	Apr	DISC
>A>	@	25MG	A074386	002	May 23, 1996	Apr	DISC
>D>	AB	50MG	A074386	003	May 23, 1996	Apr	DISC
>A>	@	50MG	A074386	003	May 23, 1996	Apr	DISC
>D>	AB	100MG	A074386	004	May 23, 1996	Apr	DISC
>A>	@	100MG	A074386	004	May 23, 1996	Apr	DISC

CARBAMAZEPINE

## TABLET; ORAL

## CARBAMAZEPINE

AB	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005	Mar	CTEC
AB	UMEDICA LABS PVT LTD	100MG	A207798	001	Apr 15, 2020	Mar	NEWA
AB		200MG	A207798	002	Apr 15, 2020	Mar	NEWA

## TABLET, EXTENDED RELEASE; ORAL

## CARBAMAZEPINE

>A>	AB	UNIQUE PHARM	100MG	A211623	001	Apr 24, 2020	Apr	NEWA
>A>	AB		200MG	A211623	002	Apr 24, 2020	Apr	NEWA
>A>	AB		400MG	A211623	003	Apr 24, 2020	Apr	NEWA

CARBIDOPA

## TABLET; ORAL

## CARBIDOPA

AB	ANI PHARMS INC	25MG	A203261	001	Mar 10, 2014	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

CARBIDOPA; LEVODOPA

## TABLET, EXTENDED RELEASE; ORAL

## SINEMET CR

+	@	MERCK SHARP DOHME	25MG;100MG	N019856	002	Dec 24, 1992	Jan	DISC
---	---	-------------------	------------	---------	-----	--------------	-----	------

CARBOPLATIN

## INJECTABLE; INTRAVENOUS

## CARBOPLATIN

	@	EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar	DISC
	@		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar	DISC
	@		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar	DISC
>D>	AP	PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008	Apr	DISC
>A>	@		50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008	Apr	DISC
>D>	AP		150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008	Apr	DISC
>A>	@		150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008	Apr	DISC
>D>	AP		450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008	Apr	DISC
>A>	@		450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008	Apr	DISC
>D>	AP		600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008	Apr	DISC
>A>	@		600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008	Apr	DISC

CARFILZOMIB

## POWDER; INTRAVENOUS

## CARFILZOMIB

AP	APOTEX	30MG/VIAL	A211185	001	Mar 20, 2020	Mar	NFTG	
AP		60MG/VIAL	A209425	001	Mar 16, 2020	Mar	NEWA	
AP	+	ONYX THERAP	30MG/VIAL	N202714	002	Jun 03, 2016	Mar	CFTG

CARISOPRODOL

## TABLET; ORAL

## CARISOPRODOL

>D>	@	HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Feb	DISC
>A>	AA	OXFORD PHARMS	350MG	A040188	001	Mar 07, 1997	Apr	CMFD
>A>	AA		350MG	A040188	001	Mar 07, 1997	Apr	CMFD

CEFIXIME

## FOR SUSPENSION; ORAL

## SUPRAX

@	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Jan	DISC
---	--------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL  
SUPRAX

@ LUPIN PHARMS 400MG A065130 001 Feb 12, 2004 Jan DISC

CEFOXITIN SODIUM

INJECTABLE;INJECTION

MEFOXIN IN PLASTIC CONTAINER

@ MYLAN INSTITUTIONAL EQ 20MG BASE/ML A063182 001 Jan 25, 1993 Mar DISC  
@ EQ 40MG BASE/ML A063182 002 Jan 25, 1993 Mar DISC

CEFPROZIL

FOR SUSPENSION;ORAL

CEFPROZIL

>D> AB TEVA PHARMS 125MG/5ML A065236 001 Dec 08, 2005 Apr DISC  
>A> @ 125MG/5ML A065236 001 Dec 08, 2005 Apr DISC  
>D> AB 250MG/5ML A065236 002 Dec 08, 2005 Apr DISC  
>A> @ 250MG/5ML A065236 002 Dec 08, 2005 Apr DISC

CEFTRIAZONE SODIUM

INJECTABLE;INJECTION

CEFTRIAZONE

@ HOSPIRA INC EQ 10GM BASE/VIAL A065232 001 Aug 02, 2005 Jan DISC

CELECOXIB

CAPSULE;ORAL

CELECOXIB

>A> AB NANJING 200MG A213598 001 May 13, 2020 Apr NEWA  
AB TIANJIN TIANYAO 50MG A207872 001 Feb 25, 2020 Feb NEWA  
AB 100MG A207872 002 Feb 25, 2020 Feb NEWA  
AB 200MG A207872 003 Feb 25, 2020 Feb NEWA  
AB 400MG A207872 004 Feb 25, 2020 Feb NEWA  
AB UMEDICA LABS PVT LTD 50MG A210628 001 Nov 27, 2019 Jan CDFR  
AB 100MG A210628 002 Nov 27, 2019 Jan CDFR  
AB 200MG A210628 003 Nov 27, 2019 Jan CDFR  
AB 400MG A210628 004 Nov 27, 2019 Jan CDFR  
AB YILING PHARM LTD 50MG A211412 001 Mar 06, 2020 Feb NEWA  
AB 100MG A211412 002 Mar 06, 2020 Feb NEWA  
AB 200MG A211412 003 Mar 06, 2020 Feb NEWA  
AB 400MG A211412 004 Mar 06, 2020 Feb NEWA

CENOBAAMATE

TABLET;ORAL

XCOPRI

+ SK LIFE 12.5MG N212839 001 Mar 10, 2020 Mar NEWA  
+ 25MG N212839 002 Mar 10, 2020 Mar NEWA  
+ 50MG N212839 003 Mar 10, 2020 Mar NEWA  
+ 100MG N212839 004 Mar 10, 2020 Mar NEWA  
+ 150MG N212839 005 Mar 10, 2020 Mar NEWA  
+! 200MG N212839 006 Mar 10, 2020 Mar NEWA

CHLOROQUINE PHOSPHATE

TABLET;ORAL

ARALEN

>D> + @ SANOFI AVENTIS US EQ 300MG BASE N006002 001 Apr CPOT  
>A> + @ 500MG N006002 001 Apr CPOT  
CHLOROQUINE PHOSPHATE  
>D> @ HIKMA PHARMS EQ 150MG BASE A083082 001 Apr CPOT  
@ EQ 150MG BASE A083082 001 Feb DISC  
>A> @ 250MG A083082 001 Apr CPOT  
>D> AA EQ 300MG BASE A083082 002 Sep 17, 1999 Apr CPOT  
>A> AA 500MG A083082 002 Sep 17, 1999 Apr CPOT  
>D> @ IMPAX LABS EQ 150MG BASE A080880 001 Apr CPOT  
>A> @ 250MG A080880 001 Apr CPOT  
>D> @ EQ 300MG BASE A040516 001 Aug 29, 2003 Apr CPOT  
>A> @ 500MG A040516 001 Aug 29, 2003 Apr CPOT  
>D> AA IPCA LABS LTD EQ 150MG BASE A090610 001 Dec 03, 2009 Apr CPOT  
>A> AA 250MG A090610 001 Dec 03, 2009 Apr CPOT  
>D> AA EQ 300MG BASE A090249 001 Dec 03, 2009 Apr CPOT  
>A> AA 500MG A090249 001 Dec 03, 2009 Apr CPOT  
>D> @ MD PHARM EQ 150MG BASE A087228 001 Apr CPOT  
>A> @ 250MG A087228 001 Apr CPOT  
>D> AA ! NATCO PHARMA LTD EQ 150MG BASE A091621 001 Jan 21, 2011 Apr CPOT  
AA ! EQ 150MG BASE A091621 001 Jan 21, 2011 Feb CHRS



## TABLET;ORAL

## CHLOROQUINE PHOSPHATE

>A>	AA	!	250MG	A091621	001	Jan 21, 2011	Apr	CPOT
>D>	AA	!	EQ 300MG BASE	A090612	001	Jan 21, 2011	Apr	CPOT
>A>	AA	!	500MG	A090612	001	Jan 21, 2011	Apr	CPOT
>D>		@	PUREPAC PHARM EQ 150MG BASE	A080886	001		Apr	CPOT
>A>		@	250MG	A080886	001		Apr	CPOT
>D>		@	TEVA EQ 150MG BASE	A087504	001	Jan 13, 1982	Apr	CPOT
>A>		@	250MG	A087504	001	Jan 13, 1982	Apr	CPOT
>D>		@	WATSON LABS EQ 150MG BASE	A087979	001	Dec 21, 1982	Apr	CPOT
>A>		@	250MG	A087979	001	Dec 21, 1982	Apr	CPOT
>D>		@	EQ 300MG BASE	A088030	001	Dec 21, 1982	Apr	CPOT
>A>		@	500MG	A088030	001	Dec 21, 1982	Apr	CPOT

CHLORPROMAZINE HYDROCHLORIDE

## TABLET;ORAL

## CHLORPROMAZINE HYDROCHLORIDE

AB		ZYDUS	10MG	A213368	001	Jan 17, 2020	Jan	NEWA
AB			25MG	A213368	002	Jan 17, 2020	Jan	NEWA
AB			50MG	A213368	003	Jan 17, 2020	Jan	NEWA
AB			100MG	A213368	004	Jan 17, 2020	Jan	NEWA
AB			200MG	A213368	005	Jan 17, 2020	Jan	NEWA

CHLORTHALIDONE

## TABLET;ORAL

## CHLORTHALIDONE

AB		ALKEM LABS LTD	25MG	A213412	001	Feb 11, 2020	Jan	NEWA
AB			50MG	A213412	002	Feb 11, 2020	Jan	NEWA
AB		VISTAPHARM	25MG	A211063	001	Feb 26, 2019	Feb	CAHN
AB			50MG	A211063	002	Feb 26, 2019	Feb	CAHN

CHOLESTYRAMINE

## POWDER;ORAL

## CHOLESTYRAMINE

AB		AJANTA PHARMA LTD	EQ 4GM RESIN/PACKET	A211119	001	Apr 06, 2020	Mar	NEWA
AB			EQ 4GM RESIN/SCOOPFUL	A211119	002	Apr 06, 2020	Mar	NEWA
		LOCHOLEST						
		@ ALLIED	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Feb	CAHN
		@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Feb	CAHN
		@ INVATECH	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Jan	CAHN
		@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Jan	CAHN
		LOCHOLEST LIGHT						
		@ ALLIED	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Feb	CAHN
		@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Feb	CAHN

CHOLINE FENOFIBRATE

## CAPSULE, DELAYED RELEASE;ORAL

## FENOFIBRIC ACID

AB		TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Mar	CMFD
AB			EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Mar	CMFD

CINACALCET HYDROCHLORIDE

## TABLET;ORAL

## CINACALCET HYDROCHLORIDE

		@ LUPIN LTD	EQ 30MG BASE	A210548	001	Jun 28, 2019	Jan	DISC
		@	EQ 60MG BASE	A210548	002	Jun 28, 2019	Jan	DISC
		@	EQ 90MG BASE	A210548	003	Jun 28, 2019	Jan	DISC

CISATRACURIUM BESYLATE

## INJECTABLE;INJECTION

## CISATRACURIUM BESYLATE

>A>	AP	AUROBINDO PHARMA LTD	EQ 2MG BASE/ML	A209144	001	May 08, 2020	Apr	NEWA
>A>	AP	HOSPIRA INC	EQ 2MG BASE/ML	A203238	001	Mar 30, 2018	Jan	CMFD
>A>	AP	PIRAMAL HLTHCARE UK	EQ 2MG BASE/ML	A212190	001	May 04, 2020	Apr	NEWA

CITALOPRAM HYDROBROMIDE

## TABLET;ORAL

## CITALOPRAM HYDROBROMIDE

		@ JUBILANT GENERICS	EQ 10MG BASE	A205407	001	Dec 23, 2015	Mar	DISC
		@	EQ 20MG BASE	A205407	002	Dec 23, 2015	Mar	DISC
		@	EQ 40MG BASE	A205407	003	Dec 23, 2015	Mar	DISC

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

AB	HETERO LABS LTD III	2.5MG/ML	A209796	001	Feb 24, 2020	Feb	NEWA	
>A>	AB	LANNETT CO INC	2.5MG/ML	A213110	001	Apr 24, 2020	Apr	NEWA
>D>	AB	TEVA PHARMS USA	2.5MG/ML	A211032	001	Jan 31, 2020	Apr	DISC
>A>	@		2.5MG/ML	A211032	001	Jan 31, 2020	Apr	DISC
AB		2.5MG/ML	A211032	001	Jan 31, 2020	Jan	NEWA	

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1	ALEOR DERMACEUTICALS	0.05%	A213291	001	Jan 27, 2020	Jan	NEWA
	SPRAY;TOPICAL						
	CLOBETASOL PROPIONATE						
	@ ALEOR DERMACEUTICALS	0.05%	A211191	001	Oct 02, 2019	Jan	DISC

CLOCORTOLONE PIVALATE

CREAM;TOPICAL

CLOCORTOLONE PIVALATE

>A>								
>A>	AB	TARO	0.1%	A206370	001	Apr 21, 2020	Apr	NFTG
		CLODERM						
>D>	+!	EPI HLTH	0.1%	N017765	001		Apr	CFTG
>A>	AB	+!	0.1%	N017765	001		Apr	CFTG

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	LEADING PHARMA LLC	25MG	A211364	001	Feb 07, 2020	Jan	NEWA
AB		50MG	A211364	002	Feb 07, 2020	Jan	NEWA
AB		75MG	A211364	003	Feb 07, 2020	Jan	NEWA
AB	MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Jan	CMFD
AB		50MG	A211767	002	Apr 08, 2019	Jan	CMFD
AB		75MG	A211767	003	Apr 08, 2019	Jan	CMFD
	@ TEVA	25MG	A074958	001	Aug 26, 1997	Feb	DISC
	@	50MG	A074958	002	Aug 26, 1997	Feb	DISC
	@	75MG	A074958	003	Aug 26, 1997	Feb	DISC
AB	TULEX PHARMS INC	25MG	A210653	001	Apr 03, 2020	Mar	NEWA
AB		50MG	A210653	002	Apr 03, 2020	Mar	NEWA
AB		75MG	A210653	003	Apr 03, 2020	Mar	NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP	XGEN PHARMS	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	Feb	CAHN
AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	Feb	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	CLONIDINE HYDROCHLORIDE						
AB1	UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018	Feb	CMFD

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

>D>	AB	CSPC OUYI	EQ 75MG BASE	A204359	001	Feb 02, 2017	Apr	CAHN
>A>	AB	GRAVITI PHARMS	EQ 75MG BASE	A204359	001	Feb 02, 2017	Apr	CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG  
@ 7.5MG

A072112	002	Aug 26, 1988	Feb	CMS1
A072112	003	Aug 26, 1988	Feb	CMS1

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

NUMBRINO

CODY LABS INC 4%

N209575	001	Jan 10, 2020	Jan	NEWA
---------	-----	--------------	-----	------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

>D>	PROMETHAZINE WITH CODEINE							
>D> AA	VINTAGE	10MG/5ML; 6.25MG/5ML	A 040650	001	Jan 31, 2006	Apr	DISC	
>A>	@	10MG/5ML; 6.25MG/5ML	A 040650	001	Jan 31, 2006	Apr	DISC	

COLCHICINE

TABLET; ORAL

COLCHICINE

AB	AMNEAL PHARMS	0.6MG	A 204711	001	Sep 28, 2016	Jan	CMFD	
AB	GRANULES PHARMS	0.6MG	A 210425	001	Feb 05, 2020	Jan	NEWA	

COLESEVELAM HYDROCHLORIDE

TABLET; ORAL

COLESEVELAM HYDROCHLORIDE

>A> AB	INVAGEN PHARMS	625MG	A 212602	001	Apr 20, 2020	Apr	NEWA	
--------	----------------	-------	----------	-----	--------------	-----	------	--

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP	XGEN PHARMS	EQ 150MG BASE/VIAL	A 064216	001	Feb 26, 1999	Feb	CAHN	
----	-------------	--------------------	----------	-----	--------------	-----	------	--

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

AB	ANI PHARMS INC	25MG	A 207014	001	Mar 19, 2018	Jan	CAHN	
AB		50MG	A 207014	002	Mar 19, 2018	Jan	CAHN	

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	APPCO	4MG	A 206553	001	Nov 29, 2016	Mar	CAHN	
----	-------	-----	----------	-----	--------------	-----	------	--

CYSTEAMINE BITARTRATE

GRANULE; ORAL

PROCYSBI

+	HORIZON PHARMA USA	EQ 75MG BASE/PACKET	N 213491	001	Feb 14, 2020	Feb	NEWA	
+	!	EQ 300MG BASE/PACKET	N 213491	002	Feb 14, 2020	Feb	NEWA	

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

DABIGATRAN ETEXILATE MESYLATE

AB	ALKEM LABS LTD	EQ 75MG BASE	A 208040	001	Mar 11, 2020	Feb	NFTG	
AB		EQ 150MG BASE	A 208040	002	Mar 11, 2020	Feb	NFTG	
>A> AB	HETERO LABS LTD III	EQ 75MG BASE	A 207961	001	May 06, 2020	Apr	NEWA	
>A> AB		EQ 150MG BASE	A 207961	002	May 06, 2020	Apr	NEWA	
AB	+	BOEHRINGER INGELHEIM	EQ 75MG BASE	N 022512	001	Oct 19, 2010	Feb	CFTG
AB	+	!	EQ 150MG BASE	N 022512	002	Oct 19, 2010	Feb	CFTG

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

AP	XGEN PHARMS	0.5MG/VIAL	A 203999	001	May 20, 2019	Feb	CAHN	
----	-------------	------------	----------	-----	--------------	-----	------	--

DAPSONE

GEL; TOPICAL

DAPSONE

AB	TARO PHARMS	7.5%	A 210191	001	Jun 26, 2019	Feb	NEWA	
----	-------------	------	----------	-----	--------------	-----	------	--

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN HYDROBROMIDE

>D> AB	ALAN LABS INC	EQ 7.5MG BASE	A 209571	002	Oct 22, 2019	Apr	DISC	
>A>	@	EQ 7.5MG BASE	A 209571	002	Oct 22, 2019	Apr	DISC	
>D> AB		EQ 15MG BASE	A 209571	001	Oct 22, 2019	Apr	DISC	
>A>	@	EQ 15MG BASE	A 209571	001	Oct 22, 2019	Apr	DISC	
	@ ANCHEN PHARMS	EQ 7.5MG BASE	A 091190	001	Mar 13, 2015	Feb	DISC	
	@	EQ 15MG BASE	A 091190	002	Mar 13, 2015	Feb	DISC	

DEFERASIROX

TABLET; ORAL

DEFERASIROX

AB	ALKEM LABS LTD	90MG	A210555	001	Mar 30, 2020	Mar	NEWA	
AB		360MG	A210555	002	Mar 30, 2020	Mar	NEWA	
AB	AMNEAL	90MG	A210727	001	Dec 27, 2019	Feb	CAHN	
AB		360MG	A210727	002	Dec 27, 2019	Feb	CAHN	
AB	CIPLA	90MG	A211852	001	Feb 11, 2020	Jan	NEWA	
AB		360MG	A211852	002	Feb 11, 2020	Jan	NEWA	
>A>	AB	TEVA PHARMS USA	180MG	A209223	003	Apr 24, 2020	Apr	NEWA
		TABLET, FOR SUSPENSION; ORAL						
		DEFERASIROX						
>A>	AB	ZYDUS PHARMS	125MG	A208882	001	May 05, 2020	Apr	NEWA
>A>	AB		250MG	A208882	002	May 05, 2020	Apr	NEWA
>A>	AB		500MG	A208882	003	May 05, 2020	Apr	NEWA

DEFERIPRONE

SOLUTION; ORAL

FERRIPROX

+	CHIESI	80MG/ML	N208030	002	Apr 20, 2018	Mar	CAHN
+	!	100MG/ML	N208030	001	Sep 09, 2015	Mar	CAHN

TABLET; ORAL

FERRIPROX

+	!	CHIESI	500MG	N021825	001	Oct 14, 2011	Mar	CAHN
+			1GM	N021825	002	Jul 25, 2019	Mar	CAHN

DELAVIRDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

+	@	VIIIV HLTHCARE	200MG	N020705	002	Jul 14, 1999	Mar	DISC
---	---	----------------	-------	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

AP	UBI	0.004MG/ML	A210218	001	Feb 14, 2020	Feb	NEWA
----	-----	------------	---------	-----	--------------	-----	------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

>D>	AB	VINTAGE PHARMS LLC	0.15MG; 0.03MG	A076675	001	Feb 25, 2011	Apr	DISC
>A>		@	0.15MG; 0.03MG	A076675	001	Feb 25, 2011	Apr	DISC
		SIMLIYA						
AB		AUROBINDO PHARMA LTD	0.15MG, N/A; 0.02MG, 0.01MG	A206853	001	Mar 22, 2017	Mar	CTNA

DESONIDE

GEL; TOPICAL

DESONATE

>D>		+	!	LEO PHARMA AS	0.05%	N021844	001	Oct 20, 2006	Apr	CFTG
>A>	AB		+		0.05%	N021844	001	Oct 20, 2006	Apr	CFTG
>A>				DESONIDE						
>A>	AB			TERESINA	0.05%	A202470	001	May 11, 2020	Apr	NFTG

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	CADILA	0.25%	A205620	001	Sep 28, 2018	Mar	CMFD
AB	COSETTE	0.25%	A209595	001	Mar 04, 2020	Feb	NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

	@	MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015	Feb	DISC
--	---	-------	--------------	---------	-----	--------------	-----	------

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX ST

		+	!	EYEVANCE	0.05%; 0.3%	N050818	001	Feb 13, 2009	Feb	CAHN
--	--	---	---	----------	-------------	---------	-----	--------------	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

	INJECTABLE; INJECTION							
	DEXMEDETOMIDINE							
AP	JIANGSU HENGRUI MED	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jan	CTNA	
	DEXMEDETOMIDINE HYDROCHLORIDE							
AP	HIKMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	Jan	NEWA	
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	Jan	NEWA	

DEXMETHYLPHENIDATE HYDROCHLORIDE

	TABLET; ORAL							
	DEXMETHYLPHENIDATE HYDROCHLORIDE							
AB	BIONPHARMA INC	5MG	A209754	001	Mar 24, 2020	Mar	NEWA	
AB		10MG	A209754	002	Mar 24, 2020	Mar	NEWA	

DEXTROAMPHETAMINE SULFATE

	CAPSULE, EXTENDED RELEASE; ORAL							
	DEXTROAMPHETAMINE SULFATE							
	@ PII	5MG	A205077	001	Jun 21, 2019	Jan	DISC	
	@	10MG	A205077	002	Jun 21, 2019	Jan	DISC	
	@	15MG	A205077	003	Jun 21, 2019	Jan	DISC	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

	SYRUP; ORAL							
	PROMETHAZINE DM							
AA	! SLATE	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Mar	CMFD	
	@	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Feb	CAHN	
	PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE							
AA	AMNEAL PHARMS	15MG/5ML; 6.25MG/5ML	A090575	001	Feb 08, 2011	Mar	CMFD	
	@ HI TECH PHARMA	15MG/5ML; 6.25MG/5ML	A040027	001	Jul 31, 1996	Mar	DISC	

DIAZEPAM

	SPRAY; NASAL							
	VALTOCO							
	+ NEURELIS INC	5MG/SPRAY	N211635	001	Jan 10, 2020	Jan	NEWA	
	+	7.5MG/SPRAY	N211635	002	Jan 10, 2020	Jan	NEWA	
	+!	10MG/SPRAY	N211635	003	Jan 10, 2020	Jan	NEWA	

DICLOFENAC EPOLAMINE

	SYSTEM; TOPICAL							
	FLECTOR							
	+! INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007	Feb	CDFR	
	LICART							
>D>	+ @ IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Apr	CMFD	
>A>	+!	1.3%	N206976	001	Dec 19, 2018	Apr	CHRS	
>A>	+	1.3%	N206976	001	Dec 19, 2018	Apr	CMFD	

DICLOFENAC POTASSIUM

	TABLET; ORAL							
	CATAFLAM							
	+ @ NOVARTIS	50MG	N020142	002	Nov 24, 1993	Jan	CRLD	

DICLOFENAC SODIUM

	GEL; TOPICAL							
	DICLOFENAC SODIUM							
AB	ENCUBE	1%	A210986	001	Jan 27, 2020	Jan	NEWA	
>D> AB	PERRIGO UK FINCO	1%	A211253	001	May 16, 2019	Apr	CMS1	
	TABLET, DELAYED RELEASE; ORAL							
	DICLOFENAC SODIUM							
	@ MICRO LABS USA	50MG	A074986	001	Feb 26, 1999	Mar	CAHN	
	@	75MG	A074986	002	Feb 26, 1999	Mar	CAHN	

DICLOFENAC SODIUM; MISOPROSTOL

	TABLET, DELAYED RELEASE; ORAL							
	DICLOFENAC SODIUM AND MISOPROSTOL							
AB	YUNG SHIN PHARM	50MG; 0.2MG	A205143	001	Feb 19, 2020	Feb	NEWA	
AB		75MG; 0.2MG	A205143	002	Feb 19, 2020	Feb	NEWA	

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

TENUATE

+ @ NOSTRUM LABS INC 25MG N011722 002 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

TENUATE DOSPAN

+ @ NOSTRUM LABS INC 75MG N012546 001 Mar CAHN

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED; NASAL

DIHYDROERGOTAMINE MESYLATE

AB CUSTOPHARM INC 0.5MG/SPRAY A211393 001 Feb 28, 2020 Feb NFTG

MIGRANAL

AB +! BAUSCH 0.5MG/SPRAY N020148 001 Dec 08, 1997 Feb CFTG

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

>A> AB2 ACCORD HLTHCARE 120MG A206997 001 Apr 28, 2020 Apr NEWA

>A> AB2 180MG A206997 002 Apr 28, 2020 Apr NEWA

>A> AB2 240MG A206997 003 Apr 28, 2020 Apr NEWA

>D> APOTEX 120MG A074943 003 Dec 19, 2000 Apr CTEC

>A> AB2 120MG A074943 003 Dec 19, 2000 Apr CTEC

DILTZAC

>A> @ APOTEX 120MG A076395 001 Feb 01, 2006 Apr DISC

>A> @ 180MG A076395 002 Feb 01, 2006 Apr DISC

>A> @ 240MG A076395 003 Feb 01, 2006 Apr DISC

>A> @ 300MG A076395 004 Feb 01, 2006 Apr DISC

>A> @ 360MG A076395 005 Feb 01, 2006 Apr DISC

>D> AB4 APOTEX INC 120MG A076395 001 Feb 01, 2006 Apr DISC

>D> AB4 180MG A076395 002 Feb 01, 2006 Apr DISC

>D> AB4 240MG A076395 003 Feb 01, 2006 Apr DISC

>D> AB4 300MG A076395 004 Feb 01, 2006 Apr DISC

>D> AB4 360MG A076395 005 Feb 01, 2006 Apr DISC

DISULFIRAM

TABLET; ORAL

DISULFIRAM

@ HIKMA 250MG A202652 001 Feb 05, 2014 Feb DISC

@ 500MG A202652 002 Feb 05, 2014 Feb DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DIVALPROEX SODIUM

AB AJANTA PHARMA LTD EQ 125MG VALPROIC ACID A213181 001 Mar 02, 2020 Feb NEWA

@ MYLAN EQ 125MG VALPROIC ACID A090407 001 Mar 28, 2011 Jan DISC

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

@ MYLAN EQ 125MG VALPROIC ACID A090062 001 Mar 17, 2009 Jan DISC

@ EQ 250MG VALPROIC ACID A090062 002 Mar 17, 2009 Jan DISC

@ EQ 500MG VALPROIC ACID A090062 003 Mar 17, 2009 Jan DISC

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

>D> AB LUPIN LTD EQ 250MG VALPROIC ACID A209286 001 Oct 18, 2019 Apr DISC

>A> @ EQ 250MG VALPROIC ACID A209286 001 Oct 18, 2019 Apr DISC

>D> AB EQ 500MG VALPROIC ACID A209286 002 Oct 18, 2019 Apr DISC

>A> @ EQ 500MG VALPROIC ACID A209286 002 Oct 18, 2019 Apr DISC

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP SHILPA MEDICARE LTD 20MG/ML (20MG/ML) A210327 001 May 16, 2019 Jan CMFD

AP 80MG/4ML (20MG/ML) A210327 002 May 16, 2019 Jan CMFD

AP 160MG/8ML (20MG/ML) A210327 003 May 16, 2019 Jan CMFD

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

AB MSN 0.125MG A213220 001 Jan 29, 2020 Jan NEWA

AB 0.25MG A213220 002 Jan 29, 2020 Jan NEWA

AB 0.5MG A213220 003 Jan 29, 2020 Jan NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

>D>	AB	CSPC OUYI	5MG	A202114	001	Jul 05, 2013	Apr	CAHN
>D>	AB		10MG	A202114	002	Jul 05, 2013	Apr	CAHN
>A>	AB	GRAVITI PHARMS	5MG	A202114	001	Jul 05, 2013	Apr	CAHN
>A>	AB		10MG	A202114	002	Jul 05, 2013	Apr	CAHN
		@ MYLAN PHARMS INC	5MG	A090521	001	May 31, 2011	Mar	DISC
		@	10MG	A090521	002	May 31, 2011	Mar	DISC

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ ANI PHARMS INC

@

@

@

EQ 1MG BASE

EQ 2MG BASE

EQ 4MG BASE

EQ 8MG BASE

A075432	001	Oct 18, 2000	Jan	DISC
A075432	002	Oct 18, 2000	Jan	DISC
A075432	003	Oct 18, 2000	Jan	DISC
A075432	004	Oct 18, 2000	Jan	DISC

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

AP		MEITHEAL	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Feb	CAHN
AP		NANJING KING-FRIEND	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Jan	NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

@ MYLAN PHARMS INC

EQ 150MG BASE

A202778	001	Jun 08, 2012	Jan	DISC
---------	-----	--------------	-----	------

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB		ZHEJIANG YONGTAI	EQ 50MG BASE	A212610	001	Mar 31, 2020	Mar	NEWA
AB			EQ 100MG BASE	A212610	002	Mar 31, 2020	Mar	NEWA

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB		ALEMBIC PHARMS LTD	EQ 20MG BASE	A210537	001	Mar 03, 2020	Feb	NEWA
AB		ORALOCK LLC	EQ 100MG BASE	A210664	001	Mar 16, 2020	Mar	NEWA

TABLET, DELAYED RELEASE; ORAL

DORYX

+		MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Mar	CMFD
---	--	--------------	--------------	---------	-----	--------------	-----	------

DOXYCYCLINE HYCLATE

AB		PRINSTON INC	EQ 50MG BASE	A207494	003	Feb 19, 2019	Feb	NEWA
----	--	--------------	--------------	---------	-----	--------------	-----	------

DRONABINOL

CAPSULE; ORAL

DRONABINOL

AB		ASCENT PHARMS INC	2.5MG	A207421	001	Feb 07, 2020	Jan	NEWA
AB			5MG	A207421	002	Feb 07, 2020	Jan	NEWA
AB			10MG	A207421	003	Feb 07, 2020	Jan	NEWA

MARINOL

AB	+	ALKEM LABS LTD	2.5MG	N018651	001	May 31, 1985	Jan	CAHN
AB	+	!	5MG	N018651	002	May 31, 1985	Jan	CAHN
AB	+		10MG	N018651	003	May 31, 1985	Jan	CAHN

SOLUTION; ORAL

SYNDROS

+	!	BENUVIA	5MG/ML	N205525	001	Mar 23, 2017	Feb	CAHN
---	---	---------	--------	---------	-----	--------------	-----	------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		ALLIED	3MG;0.02MG	A203291	001	Jul 18, 2017	Jan	CAHN
----	--	--------	------------	---------	-----	--------------	-----	------

TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		HETERO LABS LTD	3MG;0.03MG	A213034	001	Jan 24, 2020	Jan	NEWA
----	--	-----------------	------------	---------	-----	--------------	-----	------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL  
DULOXETINE HYDROCHLORIDE

@	YAOPHARMA CO LTD	EQ 20MG BASE	A207219	001	Aug 16, 2019	Mar	DISC
@		EQ 30MG BASE	A207219	002	Aug 16, 2019	Mar	DISC
@		EQ 60MG BASE	A207219	003	Aug 16, 2019	Mar	DISC

DUTASTERIDE

CAPSULE;ORAL  
DUTASTERIDE

@	ACTAVIS LABS FL INC	0.5MG	A202808	001	Nov 20, 2015	Jan	DISC
@	APOTEX INC	0.5MG	A204292	001	Nov 24, 2015	Feb	DISC
@	HIKMA	0.5MG	A202204	001	Nov 23, 2015	Feb	DISC
@	STRIDES PHARMA	0.5MG	A208227	001	Jun 22, 2018	Mar	CAHN

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
TRIJARDY XR

+	BOEHRINGER INGELHEIM	5MG;2.5MG;1GM	N212614	001	Jan 27, 2020	Jan	NEWA
+		10MG;5MG;1GM	N212614	002	Jan 27, 2020	Jan	NEWA
+		12.5MG;2.5MG;1GM	N212614	003	Jan 27, 2020	Jan	NEWA
+	!	25MG;5MG;1GM	N212614	004	Jan 27, 2020	Jan	NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL  
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	MYLAN	200MG;300MG	A206436	001	Apr 09, 2018	Feb	DISC
	ZYDUS PHARMS	200MG;300MG	A212689	001	Feb 28, 2020	Feb	NEWA

ENTECAVIR

TABLET;ORAL  
ENTECAVIR

	MYLAN	0.5MG	A206226	001	Mar 26, 2019	Jan	DISC	
	@	1MG	A206226	002	Mar 26, 2019	Jan	DISC	
>D>	AB	YAOPHARMA CO LTD	0.5MG	A212201	001	Nov 04, 2019	Apr	DISC
>A>		@	0.5MG	A212201	001	Nov 04, 2019	Apr	DISC
>D>	AB		1MG	A212201	002	Nov 04, 2019	Apr	DISC
>A>		@	1MG	A212201	002	Nov 04, 2019	Apr	DISC

EPHEDRINE SULFATE

>A> SOLUTION;INTRAVENOUS  
>A> EMERPHED

>A>	+	NEXUS PHARMS	50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Apr	NEWA
-----	---	--------------	--------------------	---------	-----	--------------	-----	------

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
ADRENALIN

>D>	+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Apr	CFTG
>A>	AP	+	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Apr	CFTG
>A>		EPINEPHRINE						
>A>	AP	INTL MEDICATION SYS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	A211880	001	Apr 24, 2020	Apr	NFTG

EPLERENONE

TABLET;ORAL  
EPLERENONE

AB	COREPHARMA	25MG	A078482	001	Jul 30, 2008	Feb	CAHN
AB		50MG	A078482	002	Jul 30, 2008	Feb	CAHN

EPROSARTAN MESYLATE

TABLET;ORAL  
EPROSARTAN MESYLATE

>D>		MYLAN PHARMS INC	EQ 400MG BASE	A202012	001	Nov 16, 2011	Apr	DISC
>A>		@	EQ 400MG BASE	A202012	001	Nov 16, 2011	Apr	DISC
>D>	AB	!	EQ 600MG BASE	A202012	002	Nov 16, 2011	Apr	DISC
>A>		@	EQ 600MG BASE	A202012	002	Nov 16, 2011	Apr	DISC



EPTIFIBATIDEINJECTABLE; INJECTION  
EPTIFIBATIDE

AP	HYBIO	2MG/ML	A207864	001	Mar 20, 2020	Mar	NEWA
AP		75MG/100ML	A207864	002	Mar 20, 2020	Mar	NEWA

ERLOTINIB HYDROCHLORIDETABLET; ORAL  
ERLOTINIB HYDROCHLORIDE

>A>	AB	ZYDUS PHARMS	EQ 25MG BASE	A213065	001	Apr 16, 2020	Apr	NEWA
>A>	AB		EQ 100MG BASE	A213065	002	Apr 16, 2020	Apr	NEWA
>A>	AB		EQ 150MG BASE	A213065	003	Apr 16, 2020	Apr	NEWA

ESCITALOPRAM OXALATESOLUTION; ORAL  
ESCITALOPRAM OXALATE

AA	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Jan	CAHN	
>D>	AA	HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221	001	Jun 12, 2012	Apr	CHRS
>A>	AA	!	EQ 5MG BASE/5ML	A202221	001	Jun 12, 2012	Apr	CHRS
		LEXAPRO						
>D>	AA	+! ALLERGAN	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Apr	DISC
>A>		+ @	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Apr	DISC

ESOMEPRAZOLE MAGNESIUMFOR SUSPENSION, DELAYED RELEASE; ORAL  
ESOMEPRAZOLE MAGNESIUM

AB	CIPLA	EQ 10MG BASE/PACKET	A211752	001	Mar 23, 2020	Mar	NFTG
AB		EQ 20MG BASE/PACKET	A211751	001	Mar 23, 2020	Mar	NFTG
AB		EQ 40MG BASE/PACKET	A211751	002	Mar 23, 2020	Mar	NFTG
		NEXIUM					
AB	+ ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	Mar	CFTG
AB	+	EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006	Mar	CFTG
AB	+!	EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006	Mar	CFTG

ESOMEPRAZOLE MAGNESIUM; NAPROXENTABLET, DELAYED RELEASE; ORAL  
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB	DR REDDYS LABS LTD	EQ 20MG BASE;375MG	A204206	001	Feb 18, 2020	Feb	NEWA
AB		EQ 20MG BASE;500MG	A204206	002	Feb 18, 2020	Feb	NEWA
		VIMOVO					
AB	+ HORIZON	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Feb	CTEC
AB	+!	EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Feb	CTEC

ESOMEPRAZOLE SODIUMINJECTABLE; INTRAVENOUS  
ESOMEPRAZOLE SODIUM

AP	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	Mar	NEWA
AP		EQ 40MG BASE/VIAL	A203349	002	Apr 01, 2020	Mar	NEWA

ESOMEPRAZOLE STRONTIUMCAPSULE, DELAYED RELEASE; ORAL  
ESOMEPRAZOLE STRONTIUM

+ @	BELCHER	24.65MG	N202342	001	Aug 06, 2013	Mar	CAHN
+ @		49.3MG	N202342	002	Aug 06, 2013	Mar	CAHN

ESTRADIOL VALERATEINJECTABLE; INJECTION  
DELESTROGEN

>D>	+!	PAR STERILE PRODUCTS	10MG/ML	N009402	002		Apr	CTEC
>A>	AO	+!	10MG/ML	N009402	002		Apr	CTEC
		ESTRADIOL VALERATE						
>A>	AO	HIKMA	10MG/ML	A203723	001	Apr 21, 2020	Apr	NEWA
>A>	AO		20MG/ML	A203723	002	Apr 21, 2020	Apr	NEWA
>A>	AO		40MG/ML	A203723	003	Apr 21, 2020	Apr	NEWA

ESTRADIOL; NORETHINDRONE ACETATETABLET; ORAL  
ESTRADIOL AND NORETHINDRONE ACETATE  
@ TEVA PHARMS USA 0.5MG;0.1MG

A200747	001	Mar 08, 2012	Jan	DISC
---------	-----	--------------	-----	------

ESTROPIPATE

TABLET; ORAL  
ESTROPIPATE  
@ MYLAN  
@

0.75MG  
1.5MG

A040359 001 Aug 26, 1999 Jan DISC  
A040359 002 Aug 26, 1999 Jan DISC

ESZOPICLONE

TABLET; ORAL  
ESZOPICLONE  
@ HIKMA  
@  
@

1MG  
2MG  
3MG

A091153 001 Apr 15, 2014 Feb DISC  
A091153 002 Apr 15, 2014 Feb DISC  
A091153 003 Apr 15, 2014 Feb DISC

ETHACRYNIC ACID

TABLET; ORAL  
ETHACRYNIC ACID

AB UPSHER SMITH LABS 25MG

A212417 001 Feb 19, 2020 Feb NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

SYSTEM; TRANSDERMAL  
TWIRLA

+! AGILE 0.03MG/24HR; 0.12MG/24HR

N204017 001 Feb 14, 2020 Feb NEWA

TABLET; ORAL  
BALCOLTRA

+! AVION PHARMS 0.02MG; 0.1MG  
+ 0.02MG; 0.1MG

N208612 001 Jan 09, 2018 Jan CHRS  
N208612 001 Jan 09, 2018 Jan CRLD

FAYOSIM  
@ LUPIN LTD

0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A

A205943 001 Mar 29, 2016 Mar DISC

TABLET; ORAL-28  
ELIFEMME

@ XIROMED 0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG

A202507 001 Dec 04, 2015 Mar DISC

LEVONORGESTREL AND ETHINYL ESTRADIOL  
@ MYLAN LABS LTD

0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG

A202970 001 Mar 23, 2018 Feb DISC

TABLET, CHEWABLE; ORAL  
LEVONORGESTREL AND ETHINYL ESTRADIOL

+! EXELTIS USA INC 0.02MG; 0.1MG

N209405 001 Mar 30, 2020 Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL  
LOESTRIN 24 FE

AB + TEVA BRANDED PHARM 0.02MG; 1MG

N021871 001 Feb 17, 2006 Jan CAHN

TABLET; ORAL-21  
LOESTRIN 21 1.5/30

AB + TEVA BRANDED PHARM 0.03MG; 1.5MG

N017875 001 Jan CAHN

LOESTRIN 21 1/20

AB + TEVA BRANDED PHARM 0.02MG; 1MG

N017876 001 Jan CAHN

LOESTRIN FE 1.5/30

AB +! TEVA BRANDED PHARM 0.03MG; 1.5MG

N017355 001 Jan CAHN

TABLET; ORAL-28  
CHABELINA FE

AB NOVAST LABS 0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG

A202962 001 Apr 15, 2020 Mar NEWA

LOESTRIN FE 1/20

AB + TEVA BRANDED PHARM 0.02MG; 1MG

N017354 001 Jan CAHN

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL  
@ MYLAN LABS LTD

0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG

A205069 001 Jun 22, 2018 Feb DISC

TABLET, CHEWABLE; ORAL  
FINZALA

AB TEVA PHARMS USA INC 0.02MG; 1MG

A210087 001 Apr 07, 2020 Mar NEWA

ETHOSUXIMIDE

CAPSULE; ORAL  
ETHOSUXIMIDE

AB PURACAP PHARM LLC 250MG

A210654 001 Mar 16, 2020 Mar NEWA

<u>ETODOLAC</u>									
TABLET; ORAL									
ETODOLAC									
	@ TEVA	400MG		A075009	001	Nov 26, 1997	Feb	DISC	
	@	500MG		A075009	002	Dec 28, 1999	Feb	DISC	
<u>ETOMIDATE</u>									
INJECTABLE; INJECTION									
ETOMIDATE									
	@ MYLAN LABS LTD	2MG/ML		A078289	001	Jan 02, 2009	Feb	DISC	
<u>EXEMESTANE</u>									
TABLET; ORAL									
EXEMESTANE									
	@ MAYNE PHARMA INC	25MG		A208764	001	Aug 08, 2019	Jan	DISC	
AB	QILU	25MG		A213547	001	Apr 13, 2020	Mar	NEWA	
<u>EZETIMIBE</u>									
TABLET; ORAL									
EZETIMIBE									
	@ MYLAN	10MG		A201790	001	Apr 26, 2019	Feb	DISC	
	@ TEVA PHARMS USA	10MG		A078724	001	Jun 12, 2017	Mar	DISC	
<u>FAMOTIDINE</u>									
TABLET; ORAL									
FAMOTIDINE									
AB	!	AUROBINDO PHARMA LTD	40MG	A206530	002	Dec 22, 2015	Jan	CHRS	
	@ MYLAN		20MG	A075704	001	Apr 16, 2001	Feb	DISC	
	@ TEVA		20MG	A075311	001	Apr 16, 2001	Mar	DISC	
	@		40MG	A075311	002	Apr 16, 2001	Mar	DISC	
PEPCID									
	+ @ VALEANT PHARMS NORTH	20MG		N019462	001	Oct 15, 1986	Jan	DISC	
	+ @	40MG		N019462	002	Oct 15, 1986	Jan	DISC	
<u>FENOFIBRATE</u>									
CAPSULE; ORAL									
FENOFIBRATE (MICRONIZED)									
AB		ANI PHARMS INC	67MG	A209504	001	Apr 30, 2018	Jan	CAHN	
AB			134MG	A209504	002	Apr 30, 2018	Jan	CAHN	
AB			200MG	A209504	003	Apr 30, 2018	Jan	CAHN	
	@ MYLAN PHARMS INC		43MG	A202579	001	Jan 10, 2013	Mar	DISC	
	@		130MG	A202579	002	Jan 10, 2013	Mar	DISC	
TABLET; ORAL									
FENOFIBRATE									
AB		ALEMBIC PHARMS LTD	54MG	A213252	001	Jan 17, 2020	Jan	NEWA	
AB			160MG	A213252	002	Jan 17, 2020	Jan	NEWA	
AB		APPCO	54MG	A210670	001	Sep 06, 2019	Jan	CAHN	
AB			160MG	A210670	002	Sep 06, 2019	Jan	CAHN	
AB		GRAVITI PHARMS	48MG	A211122	001	Mar 18, 2020	Mar	NEWA	
AB			54MG	A210606	001	Aug 17, 2018	Jan	CMFD	
AB			145MG	A211122	002	Mar 18, 2020	Mar	NEWA	
AB			160MG	A210606	002	Aug 17, 2018	Jan	CMFD	
<u>FENTANYL CITRATE</u>									
INJECTABLE; INJECTION									
FENTANYL CITRATE PRESERVATIVE FREE									
AP	+	HIKMA	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb	CAHN	
<u>FERRIC DERISOMALTOSE</u>									
SOLUTION; INTRAVENOUS									
MONOFERRIC									
	+	PHARMACOSMOS AS	100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020	Jan	NEWA	
	+		500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020	Jan	NEWA	
	+		1GM/10ML (100MG/ML)	N208171	003	Jan 16, 2020	Jan	NEWA	
<u>FERRIC PYROPHOSPHATE CITRATE</u>									
SOLUTION; INTRAVENOUS									
TRIFERIC AVNU									
	+	ROCKWELL MEDICAL INC	6.75MG IRON/4.5ML (1.5MG IRON/ML)	N212860	001	Mar 27, 2020	Mar	NEWA	

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL  
FESOTERODINE FUMARATE

@ DR REDDYS LABS LTD	4MG	A204975	001	Aug 13, 2019	Feb	DISC
@	8MG	A204975	002	Aug 13, 2019	Feb	DISC

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL  
FEXOFENADINE HYDROCHLORIDE

@ BARR	30MG	A076191	001	Aug 31, 2005	Mar	DISC
@	60MG	A076191	002	Aug 31, 2005	Mar	DISC
@	180MG	A076191	003	Aug 31, 2005	Mar	DISC

FIDAXOMICIN

FOR SUSPENSION;ORAL  
DIFICID

+! CUBIST PHARMS LLC	40MG/ML	N213138	001	Jan 24, 2020	Jan	NEWA
----------------------	---------	---------	-----	--------------	-----	------

FINASTERIDE

TABLET;ORAL  
FINASTERIDE

@ TEVA	1MG	A076905	001	Nov 05, 2013	Mar	DISC
--------	-----	---------	-----	--------------	-----	------

FLUCONAZOLE

FOR SUSPENSION;ORAL  
FLUCONAZOLE

@ HIKMA	50MG/5ML	A076246	001	Jul 29, 2004	Feb	DISC
@	200MG/5ML	A076246	002	Jul 29, 2004	Feb	DISC

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764	001	Jan 30, 2012	Mar	DISC
@	400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012	Mar	DISC
@ HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004	Mar	DISC
@	400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004	Mar	DISC
@ WOODWARD	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Mar	DISC
@	400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Mar	DISC

TABLET;ORAL

FLUCONAZOLE

@ MYLAN	50MG	A076351	001	Jul 29, 2004	Jan	DISC
@	100MG	A076351	002	Jul 29, 2004	Jan	DISC
@	150MG	A076351	003	Jul 29, 2004	Jan	DISC
@	200MG	A076351	004	Jul 29, 2004	Jan	DISC
@ TEVA	50MG	A074681	001	Jul 29, 2004	Mar	DISC
@	100MG	A074681	002	Jul 29, 2004	Mar	DISC
@	150MG	A074681	003	Jul 29, 2004	Mar	DISC
@	200MG	A074681	004	Jul 29, 2004	Mar	DISC

FLUCYTOSINE

CAPSULE;ORAL

FLUCYTOSINE

>A> AB	AUROBINDO PHARMA LTD	250MG	A213665	001	May 01, 2020	Apr	NEWA
>A> AB		500MG	A213665	002	May 01, 2020	Apr	NEWA
>A> AB	STRIDES PHARMA	250MG	A212632	001	Apr 17, 2020	Apr	NEWA
>A> AB		500MG	A212632	002	Apr 17, 2020	Apr	NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS  
FLUDEOXYGLUCOSE F18

AP	UNIV TX SW MEDCTR	20-200mCi/ML	A210265	001	Feb 06, 2020	Jan	NEWA
----	-------------------	--------------	---------	-----	--------------	-----	------

FLUNISOLIDE

SPRAY, METERED;NASAL

FLUNISOLIDE

!	APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Mar	CHRS
		0.029MG/SPRAY	A077436	001	Aug 09, 2007	Mar	CMFD

FLUOCINONIDECREAM; TOPICAL  
FLUOCINONIDE

>D>	@	AMNEAL PHARMS LLC	0.05%	A210554	001	Aug 21, 2018	Apr	CMFD
>A>	AB1		0.05%	A210554	001	Aug 21, 2018	Apr	CMFD
	AB	CADILA	0.1%	A208989	001	Feb 10, 2020	Feb	CAHN
	AB	ZYDUS PHARMS	0.1%	A208989	001	Feb 10, 2020	Jan	NEWA
		SOLUTION; TOPICAL						
		FLUOCINONIDE						
	@	TEVA	0.05%	A072511	001	Feb 07, 1989	Mar	DISC

FLUOROURACILINJECTABLE; INJECTION  
FLUOROURACIL

>D>	AP	INGENUS PHARMS LLC	500MG/10ML (50MG/ML)	A209219	001	Dec 12, 2019	Apr	DISC
>A>	@		500MG/10ML (50MG/ML)	A209219	001	Dec 12, 2019	Apr	DISC
>D>	AP		500MG/10ML (50MG/ML)	A209271	001	Dec 11, 2019	Apr	DISC
>A>	@		500MG/10ML (50MG/ML)	A209271	001	Dec 11, 2019	Apr	DISC
>D>	AP		1GM/20ML (50MG/ML)	A209219	002	Dec 12, 2019	Apr	DISC
>A>	@		1GM/20ML (50MG/ML)	A209219	002	Dec 12, 2019	Apr	DISC
>D>	AP		2.5GM/50ML (50MG/ML)	A209271	002	Dec 11, 2019	Apr	DISC
>A>	@		2.5GM/50ML (50MG/ML)	A209271	002	Dec 11, 2019	Apr	DISC
		SOLUTION; TOPICAL						
		FLUOROURACIL						
AT	!	TARO	5%	A076526	002	Nov 05, 2003	Mar	CHRS

FLUOXETINE HYDROCHLORIDECAPSULE; ORAL  
FLUOXETINE HYDROCHLORIDE

	@	BARR	EQ 10MG BASE	A074803	002	Jan 30, 2002	Mar	DISC	
	@		EQ 20MG BASE	A074803	001	Aug 02, 2001	Mar	DISC	
		SOLUTION; ORAL							
		FLUOXETINE HYDROCHLORIDE							
AA		AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Mar	CMFD	
		TABLET; ORAL							
		FLUOXETINE HYDROCHLORIDE							
AB		AUROBINDO PHARMA LTD	EQ 10MG BASE	A213286	001	Apr 08, 2020	Mar	NEWA	
AB			EQ 20MG BASE	A213286	002	Apr 08, 2020	Mar	NEWA	
	@	G AND W LABS INC	EQ 60MG BASE	A212191	001	Jul 05, 2019	Mar	DISC	
		SARAFEM							
>D>	AB1	+	APIL	EQ 15MG BASE	N021860	002	May 19, 2006	Apr	CTEC
>A>		+		EQ 15MG BASE	N021860	002	May 19, 2006	Apr	CTEC
>D>		SELFEMRA							
>D>	AB1		TEVA PHARMS USA	EQ 10MG BASE	A200151	001	Feb 03, 2014	Apr	DISC
>A>	@			EQ 10MG BASE	A200151	001	Feb 03, 2014	Apr	DISC
>D>	AB1			EQ 15MG BASE	A200151	002	Feb 03, 2014	Apr	DISC
>A>	@			EQ 15MG BASE	A200151	002	Feb 03, 2014	Apr	DISC
>D>	AB1			EQ 20MG BASE	A200151	003	Feb 03, 2014	Apr	DISC
>A>	@			EQ 20MG BASE	A200151	003	Feb 03, 2014	Apr	DISC

FLUPHENAZINE HYDROCHLORIDETABLET; ORAL  
FLUPHENAZINE HYDROCHLORIDE

@	SANDOZ	1MG	A089586	002	Oct 16, 1987	Mar	DISC
@		2.5MG	A089586	003	Oct 16, 1987	Mar	DISC
@		5MG	A089586	004	Oct 16, 1987	Mar	DISC
@		10MG	A089586	001	Oct 16, 1987	Mar	DISC

FLUTICASONE PROPIONATEPOWDER; INHALATION  
ARMONAIR DIGIHALER

+	TEVA PHARM	0.055MG/INH	N208798	004	Feb 20, 2020	Mar	NEWA
+		0.113MG/INH	N208798	005	Feb 20, 2020	Mar	NEWA
+	!	0.232MG/INH	N208798	006	Feb 20, 2020	Mar	NEWA

FLUVOXAMINE MALEATECAPSULE, EXTENDED RELEASE; ORAL  
FLUVOXAMINE MALEATE

>A>	AB	BIONPHARMA INC	150MG	A212182	001	May 11, 2020	Apr	NEWA
-----	----	----------------	-------	---------	-----	--------------	-----	------

## TABLET; ORAL

## FLUVOXAMINE MALEATE

@ TEVA	25MG	A 075893	001	Sep 10, 2002	Mar	DISC
@	50MG	A 075893	002	Sep 10, 2002	Mar	DISC
@	100MG	A 075893	003	Sep 10, 2002	Mar	DISC

FOLIC ACID

## INJECTABLE; INJECTION

## FOLIC ACID

AP	X-GEN PHARMS INC	5MG/ML	A 202522	001	Nov 06, 2019	Jan	CAHN
AP	XGEN PHARMS	5MG/ML	A 202522	001	Nov 06, 2019	Feb	CAHN

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

## TABLET; ORAL

## FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>D>	AB	AUROBINDO PHARMA	20MG;12.5MG	A 079245	002	Jul 09, 2009	Apr	CHRS
>A>	AB	!	20MG;12.5MG	A 079245	002	Jul 09, 2009	Apr	CHRS
>D>	AB	EMCURE PHARMS LTD	10MG;12.5MG	A 079025	001	Sep 17, 2010	Apr	DISC
>A>		@	10MG;12.5MG	A 079025	001	Sep 17, 2010	Apr	DISC
>D>	AB	!	20MG;12.5MG	A 079025	002	Sep 17, 2010	Apr	DISC
>A>		@	20MG;12.5MG	A 079025	002	Sep 17, 2010	Apr	DISC

FULVESTRANT

## INJECTABLE; INTRAMUSCULAR

## FULVESTRANT

AO	CHIA TAI TIANQING	50MG/ML	A 211422	001	Feb 07, 2020	Jan	NEWA
----	-------------------	---------	----------	-----	--------------	-----	------

FUROSEMIDE

## TABLET; ORAL

## FUROSEMIDE

@ AVET	20MG	N 018413	001	Nov 30, 1983	Jan	DISC
@	40MG	N 018413	002	Nov 30, 1983	Jan	DISC

GABAPENTIN

## CAPSULE; ORAL

## GABAPENTIN

AB	CSPC OUYI	100MG	A 075477	001	Mar 23, 2005	Jan	CMFD
AB		300MG	A 075477	002	Mar 23, 2005	Jan	CMFD
AB		400MG	A 075477	003	Mar 23, 2005	Jan	CMFD
	@ TEVA PHARMS	100MG	A 075435	001	Oct 08, 2004	Mar	DISC
	@	300MG	A 075435	002	Oct 08, 2004	Mar	DISC
	@	400MG	A 075435	003	Oct 08, 2004	Mar	DISC

## TABLET; ORAL

## GABAPENTIN

@ MYLAN PHARMS INC	600MG	A 090335	001	Jun 01, 2010	Mar	DISC
@	800MG	A 090335	002	Jun 01, 2010	Mar	DISC
@ TEVA PHARMS USA	600MG	A 205807	001	Mar 10, 2017	Mar	DISC
@	800MG	A 205807	002	Mar 10, 2017	Mar	DISC

## GRALISE

BX	+!	ALMATICA	300MG	N 022544	001	Jan 28, 2011	Jan	CAHN
BX	+!		600MG	N 022544	002	Jan 28, 2011	Jan	CAHN

GALANTAMINE HYDROBROMIDE

## TABLET; ORAL

## GALANTAMINE HYDROBROMIDE

@ HIKMA	EQ 4MG BASE	A 077608	001	Feb 11, 2009	Feb	DISC
@	EQ 8MG BASE	A 077608	002	Feb 11, 2009	Feb	DISC
@	EQ 12MG BASE	A 077608	003	Feb 11, 2009	Feb	DISC

GEMCITABINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## GEMCITABINE HYDROCHLORIDE

@ APOTEX	200MG/5.26ML (38MG/ML)	A 206776	001	May 23, 2017	Feb	DISC	
@	1GM/26.3ML (38MG/ML)	A 206776	002	May 23, 2017	Feb	DISC	
@	2GM/52.6ML (38MG/ML)	A 206776	003	May 23, 2017	Feb	DISC	
@ MYLAN LABS LTD	EQ 2GM BASE/VIAL	A 200145	003	Jul 25, 2011	Mar	DISC	
AP	SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A 207575	001	Feb 22, 2019	Jan	CMFD
AP		EQ 1GM BASE/VIAL	A 207575	002	Feb 22, 2019	Jan	CMFD
@ TEVA PHARMS	EQ 200MG BASE/VIAL	A 077983	002	Jan 25, 2011	Mar	DISC	
@	EQ 1GM BASE/VIAL	A 077983	001	Jan 25, 2011	Mar	DISC	

GEMFIBROZILTABLET; ORAL  
GEMFIBROZIL

AB	CADILA	600MG	A204189	001	Aug 28, 2018	Feb	CAHN
	@ TEVA	600MG	A074256	001	Oct 31, 1993	Feb	DISC

GENTAMICIN SULFATEINJECTABLE; INJECTION  
GENTAMICIN SULFATE  
@ HOSPIRA

EQ 10MG BASE/ML A062612 004 Feb 20, 1986 Mar DISC

GLIMEPIRIDETABLET; ORAL  
GLIMEPIRIDE

>D>	AB	MYLAN	1MG	A077624	001	Nov 28, 2005	Apr	DISC
>A>		@	1MG	A077624	001	Nov 28, 2005	Apr	DISC
>D>	AB		2MG	A077624	002	Nov 28, 2005	Apr	DISC
>A>		@	2MG	A077624	002	Nov 28, 2005	Apr	DISC
>D>	AB		4MG	A077624	003	Nov 28, 2005	Apr	DISC
>A>		@	4MG	A077624	003	Nov 28, 2005	Apr	DISC

GLYBURIDETABLET; ORAL  
GLYBURIDE (MICRONIZED)

	@ MYLAN	1.5MG	A074792	001	Jun 26, 1998	Jan	DISC
	@	3MG	A074792	002	Jun 26, 1998	Jan	DISC
	@	6MG	A074792	003	Aug 17, 1999	Jan	DISC

GLYCOPYRROLATEINJECTABLE; INJECTION  
GLYCOPYRROLATE

AP	RICONPHARMA LLC	0.2MG/ML	A210083	001	Feb 21, 2020	Feb	NEWA
	POWDER; INHALATION						
	SEEBRI						
	+ @ NOVARTIS	15.6MCG/INH	N207923	001	Oct 29, 2015	Mar	CAHN
	+ @ SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015	Mar	DISC
	SOLUTION; INTRAMUSCULAR, INTRAVENOUS						
	GLYRX-PF						
>A>	EXELA PHARMA SCS LLC	1MG/5ML (0.2MG/ML)	N210997	003	Apr 09, 2020	Apr	NEWA

GLYCOPYRROLATE; INDACATEROL MALEATEPOWDER; INHALATION  
UTIBRON

	+ @ NOVARTIS	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Mar	CAHN
	+ @ SUNOVION PHARMS INC	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Mar	DISC

GRANISETRON HYDROCHLORIDEINJECTABLE; INJECTION  
GRANISETRON HYDROCHLORIDE

>D>	AP	MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454	001	Apr 04, 2017	Apr	DISC
>A>		@	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454	001	Apr 04, 2017	Apr	DISC
>D>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454	002	Apr 04, 2017	Apr	DISC
>A>		@	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454	002	Apr 04, 2017	Apr	DISC
		@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017	Mar	DISC
>D>	AP	YUNG SHIN PHARM	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647	001	Mar 06, 2020	Apr	DISC
>A>		@	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647	001	Mar 06, 2020	Apr	DISC
AP			EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647	001	Mar 06, 2020	Feb	NEWA

TABLET; ORAL

GRANISETRON HYDROCHLORIDE  
@ MYLAN

EQ 1MG BASE A078725 001 Jan 30, 2008 Jan DISC

HALCINONIDESOLUTION; TOPICAL  
HALOG

! SUN PHARM INDS INC 0.1% N017823 001 Mar CMFD

HALOPERIDOL LACTATEINJECTABLE; INJECTION  
HALOPERIDOL

@	TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001	Mar	DISC
---	-----------------	----------------	---------	-----	--------------	-----	------

HEPARIN SODIUMINJECTABLE; INJECTION  
HEPARIN SODIUM

>A>	AP	GLAND PHARMA LTD	1,000 UNITS/ML	A205323	002	Nov 18, 2019	Apr	NEWA
	AP	NANJING KING-FRIEND	20,000 UNITS/ML	A211004	001	Feb 24, 2020	Feb	NEWA
		HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
>A>		BAXTER HLTHCARE	2,000 UNITS/1000ML	N018609	004	Apr 23, 2020	Apr	NEWA
		HEPARIN SODIUM PRESERVATIVE FREE						
	AP	+! FRESINIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar	CTEC
	AP	NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Mar	NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

>D>		@ BRECKENRIDGE	1.5MG/5ML; 5MG/5ML	A210663	001	Jun 11, 2019	Apr	CAHN
>A>		@ NOSTRUM LABS INC	1.5MG/5ML; 5MG/5ML	A210663	001	Jun 11, 2019	Apr	CAHN

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA	!	NOVEL LABS INC	1.5MG; 5MG	A091528	001	Apr 20, 2011	Jan	CHRS
		TUSSIGON						
		@ KING PHARMS	1.5MG; 5MG	A088508	001	Jul 30, 1985	Jan	DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP		XGEN PHARMS	20MG/ML	A203110	001	Jun 29, 2015	Feb	CAHN
----	--	-------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

		@ STRIDES PHARMA	10MG	A200770	004	Jun 25, 2019	Jan	DISC
--	--	------------------	------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

		@ IVAX SUB TEVA PHARMS	12.5MG	A077005	001	Jul 13, 2005	Mar	DISC
--	--	------------------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

		@ MYLAN PHARMS INC	25MG	A040735	002	Jan 23, 2007	Jan	DISC
		@	50MG	A040735	003	Jan 23, 2007	Jan	DISC

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

		@ COREPHARMA	12.5MG; 10MG	A076674	001	Oct 05, 2004	Feb	CAHN
		@	12.5MG; 20MG	A076674	002	Oct 05, 2004	Feb	CAHN
		@	25MG; 20MG	A076674	003	Oct 05, 2004	Feb	CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>	AB	HERITAGE PHARMS INC	12.5MG; 7.5MG	A202150	001	Mar 07, 2014	Apr	DISC
>A>		@	12.5MG; 7.5MG	A202150	001	Mar 07, 2014	Apr	DISC
>D>	AB		12.5MG; 15MG	A202150	002	Mar 07, 2014	Apr	DISC
>A>		@	12.5MG; 15MG	A202150	002	Mar 07, 2014	Apr	DISC
>D>	AB		25MG; 15MG	A202150	003	Mar 07, 2014	Apr	DISC
>A>		@	25MG; 15MG	A202150	003	Mar 07, 2014	Apr	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

		@ UMEDICA LABS PVT LTD	12.5MG; 20MG	A208847	001	Sep 17, 2019	Mar	DISC
		@	12.5MG; 40MG	A208847	003	Sep 17, 2019	Mar	DISC
		@	25MG; 40MG	A208847	002	Sep 17, 2019	Mar	DISC



HYDROCHLOROTHIAZIDE; TELMISARTAN

## TABLET; ORAL

## TELMISARTAN AND HYDROCHLOROTHIAZIDE

>D>	AB	MYLAN	12.5MG;40MG	A091648	001	Feb 25, 2014	Apr	DISC
>A>		@	12.5MG;40MG	A091648	001	Feb 25, 2014	Apr	DISC
>D>	AB		12.5MG;80MG	A091648	002	Feb 25, 2014	Apr	DISC
>A>		@	12.5MG;80MG	A091648	002	Feb 25, 2014	Apr	DISC
>D>	AB		25MG;80MG	A091648	003	Feb 25, 2014	Apr	DISC
>A>		@	25MG;80MG	A091648	003	Feb 25, 2014	Apr	DISC

HYDROCHLOROTHIAZIDE; TRIAMTERENE

## CAPSULE; ORAL

## TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		CADILA	25MG;37.5MG	A208358	001	Feb 11, 2019	Feb	CAHN
		@ DURAMED PHARMS BARR	25MG;37.5MG	A075052	001	Jun 18, 1999	Mar	DISC

## TABLET; ORAL

## TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@ PLIVA 25MG;37.5MG

A074026 001 Apr 26, 1996 Mar DISC

HYDROCODONE BITARTRATE

## CAPSULE, EXTENDED RELEASE; ORAL

## HYDROCODONE BITARTRATE

AB		ALVOGEN	10MG	A206986	001	Jan 21, 2020	Jan	NFTG
AB			15MG	A206986	002	Jan 21, 2020	Jan	NFTG
AB			20MG	A206986	003	Jan 21, 2020	Jan	NFTG
AB			30MG	A206986	004	Jan 21, 2020	Jan	NFTG
AB			40MG	A206986	005	Jan 21, 2020	Jan	NFTG
AB			50MG	A206986	006	Jan 21, 2020	Jan	NFTG
		ZOHYDRO ER						
AB	+!	PERSION	10MG	N202880	001	Oct 25, 2013	Jan	CFTG
AB	+		15MG	N202880	002	Oct 25, 2013	Jan	CFTG
AB	+		20MG	N202880	003	Oct 25, 2013	Jan	CFTG
AB	+		30MG	N202880	004	Oct 25, 2013	Jan	CFTG
AB	+		40MG	N202880	005	Oct 25, 2013	Jan	CFTG
AB	+		50MG	N202880	006	Oct 25, 2013	Jan	CFTG

HYDROCORTISONE

## ENEMA; RECTAL

## HYDROCORTISONE

@ TEVA PHARMS 100MG/60ML

A074171 001 May 27, 1994 Mar DISC

## LOTION; TOPICAL

## HYDROCORTISONE

>D>	AT	!	FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000	Apr	DISC
>A>			@	2.5%	A040351	001	Jul 25, 2000	Apr	DISC
			STIE-CORT						
>D>	AT		PERRIGO CO	2.5%	A089074	001	Nov 26, 1985	Apr	CHRS
>A>	AT	!		2.5%	A089074	001	Nov 26, 1985	Apr	CHRS

## OINTMENT; TOPICAL

## HYDROCORTISONE

@ ACTAVIS MID ATLANTIC 1%

A087796 001 Oct 13, 1982 Mar DISC

## TABLET; ORAL

## HYDROCORTISONE

AB		STRIDES PHARMA	5MG	A207029	001	Apr 27, 2017	Feb	CAHN
AB			10MG	A207029	002	Apr 27, 2017	Feb	CAHN
AB			20MG	A207029	003	Apr 27, 2017	Feb	CAHN

HYDROCORTISONE VALERATE

## OINTMENT; TOPICAL

## HYDROCORTISONE VALERATE

AB		COSETTE	0.2%	A211764	001	Mar 04, 2020	Feb	NEWA
----	--	---------	------	---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

## INJECTABLE; INJECTION

## DILAUDID

+! FRESENIUS KABI USA 0.2MG/ML

N019034 006 Jan 16, 2020 Jan NEWA

## HYDROMORPHONE HYDROCHLORIDE

@ BARR 10MG/ML

A076444 001 Apr 25, 2003 Mar DISC

## SOLUTION; ORAL

## HYDROMORPHONE HYDROCHLORIDE

>A>	AA	LANNETT CO INC	5MG/5ML	A207108	001	Apr 22, 2020	Apr	NEWA
-----	----	----------------	---------	---------	-----	--------------	-----	------

## TABLET;ORAL

	HYDROMORPHONE HYDROCHLORIDE						
AB	NOSTRUM LABS INC	8MG	A076723	001	Oct 18, 2005	Feb	CAHN

HYDROXYCHLOROQUINE SULFATE

## TABLET;ORAL

	HYDROXYCHLOROQUINE SULFATE						
AB	ACCORD HLTHCARE	200MG	A213342	001	Apr 07, 2020	Mar	NEWA
AB	APPCO	200MG	A210441	001	May 01, 2018	Mar	CAHN
AB	LAURUS LABS LTD	200MG	A210959	001	Jan 15, 2019	Mar	CMFD
AB	LUPIN LTD	200MG	A210543	001	Jul 06, 2018	Mar	CMFD

HYDROXYPROGESTERONE CAPROATE

## SOLUTION;INTRAMUSCULAR

	HYDROXYPROGESTERONE CAPROATE						
	@ AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Feb	DISC
AP1		1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Jan	CMS1

HYDROXYUREA

## CAPSULE;ORAL

	HYDROXYUREA						
AB	LEADING PHARMA LLC	500MG	A213438	001	Apr 08, 2020	Mar	NEWA

IBUPROFEN

## TABLET;ORAL

	IBUPROFEN							
>A>	AB	AUROBINDO PHARMA LTD	400MG	A213794	001	May 08, 2020	Apr	NEWA
>A>	AB		600MG	A213794	002	May 08, 2020	Apr	NEWA
>A>	AB		800MG	A213794	003	May 08, 2020	Apr	NEWA

IBUPROFEN LYSINE

## INJECTABLE;INTRAVENOUS

	IBUPROFEN LYSINE						
AP	XGEN PHARMS	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Feb	CAHN

IBUPROFEN; OXYCODONE HYDROCHLORIDE

## TABLET;ORAL

	COMBUNOX							
>D>	@	FOREST LABS	400MG;5MG	N021378	001	Nov 26, 2004	Apr	CRLD
>A>	+ @		400MG;5MG	N021378	001	Nov 26, 2004	Apr	CRLD
	OXYCODONE HYDROCHLORIDE AND IBUPROFEN							
>D>	AB	ACTAVIS ELIZABETH	400MG;5MG	A078769	001	Jan 04, 2008	Apr	CTEC
>A>			400MG;5MG	A078769	001	Jan 04, 2008	Apr	CTEC
>D>	AB	! BARR LABS INC	400MG;5MG	A078316	001	Nov 29, 2007	Apr	DISC
>A>	@		400MG;5MG	A078316	001	Nov 29, 2007	Apr	DISC

ICATIBANT ACETATE

## INJECTABLE;SUBCUTANEOUS

	ICATIBANT ACETATE						
AP	JIANGSU HANSOH PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A211021	001	Mar 09, 2020	Feb	NEWA

IMATINIB MESYLATE

## TABLET;ORAL

	IMATINIB MESYLATE						
AB	ZYDUS PHARMS	EQ 100MG BASE	A210658	001	Apr 08, 2020	Mar	NEWA
AB		EQ 400MG BASE	A210658	002	Apr 08, 2020	Mar	NEWA

IMIPRAMINE HYDROCHLORIDE

## TABLET;ORAL

	IMIPRAMINE HYDROCHLORIDE							
>D>	@	OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	Apr	CMFD
>A>	AB		10MG	A040751	003	Feb 28, 2008	Apr	CMFD
>D>	@		25MG	A040751	002	Feb 28, 2008	Apr	CMFD
>A>	AB		25MG	A040751	002	Feb 28, 2008	Apr	CMFD
>D>	@		50MG	A040751	001	Feb 28, 2008	Apr	CMFD
>A>	AB		50MG	A040751	001	Feb 28, 2008	Apr	CMFD

INDACATEROL MALEATEPOWDER; INHALATION  
ARCAPTA NEOHALER

	+ @ NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Mar	CAHN
	+ @ SUNOVION PHARMS INC	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Mar	DISC

INDAPAMIDETABLET; ORAL  
INDAPAMIDE

AB	ANI PHARMS INC	1.25MG	A075201	001	Dec 04, 1998	Jan	CAHN
AB		2.5MG	A075201	002	Dec 04, 1998	Jan	CAHN

INDINAVIR SULFATECAPSULE; ORAL  
CRIXIVAN

	+ @ MERCK SHARP DOHME	EQ 200MG BASE	N020685	003	Mar 13, 1996	Mar	DISC
--	-----------------------	---------------	---------	-----	--------------	-----	------

INDOMETHACINCAPSULE; ORAL  
INDOMETHACIN

AB	HERITAGE	25MG	N018851	001	May 18, 1984	Jan	CAHN
AB		50MG	N018851	002	May 18, 1984	Jan	CAHN
>D>	AB	HERITAGE PHARMA	A070719	001	Feb 12, 1986	Apr	DISC
>A>	@	25MG	A070719	001	Feb 12, 1986	Apr	DISC
	@	50MG	A070756	001	Feb 12, 1986	Mar	DISC

IPRATROPIUM BROMIDESOLUTION; INHALATION  
IPRATROPIUM BROMIDE

>D>	AN	WATSON LABS	0.02%	A076291	001	May 09, 2005	Apr	DISC
>A>	@		0.02%	A076291	001	May 09, 2005	Apr	DISC

SPRAY, METERED; NASAL  
IPRATROPIUM BROMIDE

AB	APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003	Jan	CMFD
----	------------	---------------	---------	-----	--------------	-----	------

IRBESARTANTABLET; ORAL  
IRBESARTAN

	@ HIKMA	75MG	A090201	001	Oct 15, 2012	Feb	DISC
	@	150MG	A090201	002	Oct 15, 2012	Feb	DISC
	@	300MG	A090201	003	Oct 15, 2012	Feb	DISC

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION  
IRINOTECAN HYDROCHLORIDE

>D>	AP	CIPLA LTD	40MG/2ML (20MG/ML)	A077219	001	Feb 20, 2008	Apr	DISC
>A>	@		40MG/2ML (20MG/ML)	A077219	001	Feb 20, 2008	Apr	DISC
>D>	AP		100MG/5ML (20MG/ML)	A077219	002	Feb 20, 2008	Apr	DISC
>A>	@		100MG/5ML (20MG/ML)	A077219	002	Feb 20, 2008	Apr	DISC
>D>	AP	PLIVA LACHEMA	40MG/2ML (20MG/ML)	A078122	001	Oct 31, 2008	Apr	DISC
>A>	@		40MG/2ML (20MG/ML)	A078122	001	Oct 31, 2008	Apr	DISC
>D>	AP		100MG/5ML (20MG/ML)	A078122	002	Oct 31, 2008	Apr	DISC
>A>	@		100MG/5ML (20MG/ML)	A078122	002	Oct 31, 2008	Apr	DISC

ISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE; ORAL  
ISOSORBIDE MONONITRATE

	@ HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006	Feb	DISC
	@	60MG	A076813	001	Jan 07, 2005	Feb	DISC

ITRACONAZOLESOLUTION; ORAL  
ITRACONAZOLE

	@ APOTEX	10MG/ML	A208481	001	Aug 02, 2019	Feb	DISC
--	----------	---------	---------	-----	--------------	-----	------

IVERMECTINCREAM; TOPICAL  
IVERMECTIN

AB	PERRIGO UK FINCO	1%	A210225	001	Apr 13, 2020	Mar	NEWA
----	------------------	----	---------	-----	--------------	-----	------

	LOTION; TOPICAL							
>A>	IVERMECTIN							
>A>	AB	TARO	0.5%	A210720	001	May 06, 2020	Apr	NFTG
		SKLICE						
>D>	+	ARBOR PHARMS LLC	0.5%	N202736	001	Feb 07, 2012	Apr	CFTG
>A>	AB	+	0.5%	N202736	001	Feb 07, 2012	Apr	CFTG
	<u>KETOCONAZOLE</u>							
	TABLET; ORAL							
	KETOCONAZOLE							
>D>		@ HAVIX	200MG	A075912	001	Jan 10, 2002	Apr	CMFD
>A>	AB		200MG	A075912	001	Jan 10, 2002	Apr	CMFD
	<u>KETOROLAC TROMETHAMINE</u>							
	TABLET; ORAL							
	KETOROLAC TROMETHAMINE							
	AB	MYLAN	10MG	A074761	001	May 16, 1997	Feb	CHRS
>D>	AB	PLIVA	10MG	A075284	001	Jun 23, 1999	Apr	DISC
>A>		@	10MG	A075284	001	Jun 23, 1999	Apr	DISC
	AB	! TEVA	10MG	A074754	001	May 16, 1997	Feb	CHRS
	<u>LABETALOL HYDROCHLORIDE</u>							
	INJECTABLE; INJECTION							
	NORMODYNE							
	+	@ SCHERING	5MG/ML	N018686	001	Aug 01, 1984	Jan	CRLD
	TABLET; ORAL							
	LABETALOL HYDROCHLORIDE							
	AB	HERITAGE PHARMA	100MG	A074787	001	Aug 03, 1998	Feb	CMFD
	AB		200MG	A074787	002	Aug 03, 1998	Feb	CMFD
	<u>LACTITOL</u>							
	FOR SOLUTION; ORAL							
	PIZENSY							
	+	! BRAINTREE LABS	10GM	N211281	001	Feb 12, 2020	Feb	NEWA
	+		10GM/PACKET	N211281	001	Feb 12, 2020	Feb	NEWA
	<u>LAMIVUDINE; ZIDOVUDINE</u>							
	TABLET; ORAL							
	LAMIVUDINE AND ZIDOVUDINE							
>D>		@ MYLAN	150MG; 300MG	A079079	001	Aug 12, 2019	Apr	CAHN
>A>		@ MYLAN LABS LTD	150MG; 300MG	A079079	001	Aug 12, 2019	Apr	CAHN
	<u>LAMOTRIGINE</u>							
	TABLET; ORAL							
	LAMOTRIGINE							
		@ MYLAN	25MG	A077420	001	Jan 27, 2009	Mar	DISC
		@	100MG	A077420	002	Jan 27, 2009	Mar	DISC
		@	150MG	A077420	003	Jan 27, 2009	Mar	DISC
		@	200MG	A077420	004	Jan 27, 2009	Mar	DISC
	TABLET, EXTENDED RELEASE; ORAL							
	LAMOTRIGINE							
	AB	DR REDDYS LABS LTD	250MG	A202383	006	Sep 06, 2018	Mar	NEWA
	AB	ZYDUS PHARMS	25MG	A207763	001	Apr 01, 2020	Mar	NEWA
	AB		50MG	A207763	002	Apr 01, 2020	Mar	NEWA
	AB		100MG	A207763	003	Apr 01, 2020	Mar	NEWA
	AB		200MG	A207763	004	Apr 01, 2020	Mar	NEWA
	AB		250MG	A207763	005	Apr 01, 2020	Mar	NEWA
	AB		300MG	A207763	006	Apr 01, 2020	Mar	NEWA
	<u>LASMIDITAN SUCCINATE</u>							
	TABLET; ORAL							
	REYVOW							
	+	ELI LILLY AND CO	50MG	N211280	001	Jan 31, 2020	Jan	NEWA
	+	!	100MG	N211280	002	Jan 31, 2020	Jan	NEWA
	<u>LATANOPROST</u>							
	SOLUTION/DROPS; OPHTHALMIC							
	LATANOPROST							
		@ AUROBINDO PHARMA LTD	0.005%	A206519	001	Sep 03, 2019	Mar	DISC

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

>D>	AB	BARR	10MG	A077083	001	Sep 13, 2005	Apr	DISC
>A>		@	10MG	A077083	001	Sep 13, 2005	Apr	DISC
>D>	AB		20MG	A077083	002	Sep 13, 2005	Apr	DISC
>A>		@	20MG	A077083	002	Sep 13, 2005	Apr	DISC
	AB	LUPIN LTD	10MG	A211863	001	Feb 04, 2020	Jan	NEWA
	AB		20MG	A211863	002	Feb 04, 2020	Jan	NEWA
>D>	AB	TEVA PHARMS	10MG	A077084	001	Sep 13, 2005	Apr	DISC
>A>		@	10MG	A077084	001	Sep 13, 2005	Apr	DISC
>D>	AB		20MG	A077084	002	Sep 13, 2005	Apr	DISC
>A>		@	20MG	A077084	002	Sep 13, 2005	Apr	DISC

>A> LEMBOREXANT

&gt;A&gt; TABLET; ORAL

&gt;A&gt; DAYVIGO

>A>	+	EISAI INC	5MG	N212028	001	Apr 07, 2020	Apr	NEWA
>A>		+	10MG	N212028	002	Apr 07, 2020	Apr	NEWA

LEUCOVORIN CALCIUM

TABLET; ORAL

LEUCOVORIN CALCIUM

AB		EPIC PHARMA LLC	EQ 5MG BASE	A074544	001	Aug 28, 1997	Mar	CMFD
AB			EQ 25MG BASE	A074544	002	Aug 28, 1997	Mar	CMFD

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM

AP		XGEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
----	--	-------------	----------------------	---------	-----	--------------	-----	------

TABLET; ORAL

LEVETIRACETAM

>D>	AB	TEVA PHARMS	250MG	A078101	001	Jan 15, 2009	Apr	DISC
>A>		@	250MG	A078101	001	Jan 15, 2009	Apr	DISC
>D>	AB		500MG	A078101	002	Jan 15, 2009	Apr	DISC
>A>		@	500MG	A078101	002	Jan 15, 2009	Apr	DISC
>D>	AB		750MG	A078101	003	Jan 15, 2009	Apr	DISC
>A>		@	750MG	A078101	003	Jan 15, 2009	Apr	DISC
>D>	AB		1GM	A078101	004	Jan 15, 2009	Apr	DISC
>A>		@	1GM	A078101	004	Jan 15, 2009	Apr	DISC
	AB	VIWIT PHARM	250MG	A078869	001	Mar 13, 2009	Mar	CAHN
	AB		250MG	A078869	001	Mar 13, 2009	Mar	CAHN
	AB		500MG	A078869	002	Mar 13, 2009	Mar	CAHN
	AB		500MG	A078869	002	Mar 13, 2009	Mar	CAHN
	AB		750MG	A078869	003	Mar 13, 2009	Mar	CAHN
	AB		750MG	A078869	003	Mar 13, 2009	Mar	CAHN
	AB		1GM	A078869	004	Mar 13, 2009	Mar	CAHN
	AB		1GM	A078869	004	Mar 13, 2009	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

>D>	AB	ACTAVIS ELIZABETH	500MG	A091557	001	Sep 12, 2011	Apr	DISC
>A>		@	500MG	A091557	001	Sep 12, 2011	Apr	DISC
>D>	AB		750MG	A091557	002	Sep 12, 2011	Apr	DISC
>A>		@	750MG	A091557	002	Sep 12, 2011	Apr	DISC
>D>	AB	TEVA PHARMS	500MG	A091430	001	Sep 12, 2011	Apr	DISC
>A>		@	500MG	A091430	001	Sep 12, 2011	Apr	DISC
>D>	AB		750MG	A091430	002	Sep 12, 2011	Apr	DISC
>A>		@	750MG	A091430	002	Sep 12, 2011	Apr	DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

@ APOTEX 2.5MG/5ML

A202915 001 Aug 21, 2014 Feb DISC

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

@ APOTEX 5MG

A203027 001 Feb 13, 2015 Feb DISC

LEVOFLOXACININJECTABLE; INJECTION  
LEVOFLOXACIN

>A>	AP	GLAND PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A205540	001	Apr 22, 2020	Apr	NEWA
>A>	AP		EQ 750MG/30ML (EQ 25MG/ML)	A205540	002	Apr 22, 2020	Apr	NEWA

LEVOLEUCOVORIN CALCIUMSOLUTION; INTRAVENOUS  
LEVOLEUCOVORIN CALCIUM

>D>	AP	INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	Apr	CHRS
>A>	AP	!	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	Apr	CHRS
>D>	AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	Apr	CHRS
>A>	AP	!	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	Apr	CHRS
>D>	AP	! SANDOZ INC	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Apr	DISC
>A>		@	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Apr	DISC

LEVOTHYROXINE SODIUMPOWDER; INTRAVENOUS  
LEVOTHYROXINE SODIUM

AP		DR REDDYS	100MCG/VIAL	A208837	001	Mar 27, 2020	Mar	NEWA
----	--	-----------	-------------	---------	-----	--------------	-----	------

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL  
THYRO-TABS

AB2,	+	ALVOGEN	0.3MG	N021116	009	Oct 24, 2002	Jan	CHRS
AB4								

LIDOCAINEOINTMENT; TOPICAL  
LIDOCAINE

AT		MACLEODS PHARMS LTD	5%	A211697	001	Mar 16, 2020	Mar	NEWA
		@ SUNGEN PHARMA	5%	A212486	001	Oct 17, 2019	Mar	DISC
AT			5%	A212486	001	Oct 17, 2019	Mar	CPOT
>D>	AT	TEVA PHARMS USA	5%	A210256	001	Jan 16, 2018	Apr	DISC
>A>		@	5%	A210256	001	Jan 16, 2018	Apr	DISC

PATCH; TOPICAL  
LIDOCAINE

>A>	AB	RHODES PHARMS	5%	A209190	001	Apr 30, 2020	Apr	NEWA
-----	----	---------------	----	---------	-----	--------------	-----	------

LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION  
LIDOCAINE HYDROCHLORIDE

>A>	AP	HUONS	1%	A212821	001	May 07, 2020	Apr	NEWA
	AP	WEST-WARD PHARMS INT	1%	A080407	001		Mar	CMFD
	AP		2%	A080407	002		Mar	CMFD
		LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
	AP	WEST-WARD PHARMS INT	1%	A084625	001		Mar	CMFD
	AP		2%	A084625	002		Mar	CMFD

LINCOMYCIN HYDROCHLORIDEINJECTABLE; INJECTION  
LINCOMYCIN

AP		XGEN PHARMS	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	Feb	CAHN
----	--	-------------	------------------	---------	-----	--------------	-----	------

LINEZOLIDTABLET; ORAL  
LINEZOLID

>D>	AB	GATE PHARMS	600MG	A091210	001	Feb 05, 2016	Apr	DISC
>A>		@	600MG	A091210	001	Feb 05, 2016	Apr	DISC

LIOETHYRONINE SODIUM

	INJECTABLE; INJECTION						
	LIOETHYRONINE SODIUM						
AP	XGEN PHARMS	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Feb	CAHN
	TABLET; ORAL						
	LIOETHYRONINE SODIUM						
AB	SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jan	CMFD
AB		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jan	CMFD
AB		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jan	CMFD

LISINAPRIL

	TABLET; ORAL						
	LISINAPRIL						
AB	COREPHARMA	2.5MG	A076102	001	Sep 30, 2002	Feb	CAHN
AB		5MG	A076102	002	Sep 30, 2002	Feb	CAHN
AB		10MG	A076102	003	Sep 30, 2002	Feb	CAHN
AB		20MG	A076102	004	Sep 30, 2002	Feb	CAHN
AB		30MG	A076102	005	Sep 30, 2002	Feb	CAHN
AB		40MG	A076102	006	Sep 30, 2002	Feb	CAHN

LITHIUM CARBONATE

	CAPSULE; ORAL						
	LITHIUM CARBONATE						
AB	+ HIKMA	150MG	N017812	002	Jan 28, 1987	Jan	CAHN
AB	+	300MG	N017812	001		Jan	CAHN
AB	+!	600MG	N017812	003	Jan 28, 1987	Jan	CAHN
	@ MYLAN	150MG	A076243	002	Feb 24, 2003	Jan	DISC
	@	300MG	A076243	001	Jun 27, 2002	Jan	DISC

LITHIUM CITRATE

	SYRUP; ORAL						
	LITHIUM CITRATE						
AA	+! HIKMA	EQ 300MG CARBONATE/5ML	N018421	001		Jan	CAHN

LORAZEPAM

	TABLET; ORAL						
	LORAZEPAM						
	@ MYLAN	0.5MG	A077657	001	Mar 16, 2006	Mar	DISC
	@	1MG	A077657	002	Mar 16, 2006	Mar	DISC
	@	2MG	A077657	003	Mar 16, 2006	Mar	DISC

LORCASERIN HYDROCHLORIDE

	TABLET; ORAL						
	BELVIQ						
	+ @ EISAI INC	10MG	N022529	001	Jun 27, 2012	Feb	DISC
	TABLET, EXTENDED RELEASE; ORAL						
	BELVIQ XR						
	+ @ EISAI INC	20MG	N208524	001	Jul 15, 2016	Feb	DISC

LOSARTAN POTASSIUM

	TABLET; ORAL						
	LOSARTAN POTASSIUM						
	@ HIKMA	25MG	A077459	001	Oct 06, 2010	Feb	DISC
	@	50MG	A077459	002	Oct 06, 2010	Feb	DISC
	@	100MG	A077459	003	Oct 06, 2010	Feb	DISC

LOVASTATIN

	TABLET; ORAL						
	LOVASTATIN						
AB	COREPHARMA	10MG	A077748	001	Feb 28, 2007	Feb	CAHN
AB		20MG	A077748	002	Feb 28, 2007	Feb	CAHN
AB		40MG	A077748	003	Feb 28, 2007	Feb	CAHN

MAZINDOL

	TABLET; ORAL						
	SANOREX						
	+ @ NOVARTIS	1MG	N017247	001		Jan	CAHN
	+ @	2MG	N017247	002		Jan	CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

@ MYLAN PHARMS INC	12.5MG	A202640	001	Sep 17, 2012	Jan	DISC
@	25MG	A202640	002	Sep 17, 2012	Jan	DISC

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

! BARR	250MG	A076392	001	Dec 29, 2003	Feb	CTEC
@ HIKMA	250MG	A076523	001	Oct 01, 2004	Feb	DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

	@ HIKMA	40MG/ML	A075997	001	Feb 15, 2002	Feb	DISC
AB	! PAR PHARM	40MG/ML	A075671	001	Jul 25, 2001	Feb	CHRS
>D>	AB TEVA PHARMS	40MG/ML	A075681	001	May 05, 2003	Apr	DISC
>A>	@	40MG/ML	A075681	001	May 05, 2003	Apr	DISC

MELOXICAM

SOLUTION; INTRAVENOUS

ANJESO

>D>	+!	BAUDAX	30MG/ML (30MG/ML)	N210583	001	Feb 20, 2020	Feb	NEWA
>D>		TABLET, ORALLY DISINTEGRATING; ORAL						
>D>		QMIIZ ODT						
>D>	+	TERSERA THERAPS LLC	7.5MG	N211210	001	Oct 19, 2018	Apr	DISC
>A>	+	@	7.5MG	N211210	001	Oct 19, 2018	Apr	DISC
>D>	+	!	15MG	N211210	002	Oct 19, 2018	Apr	DISC
>A>	+	@	15MG	N211210	002	Oct 19, 2018	Apr	DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

>A>	AP	BPI LABS LLC	EQ 50MG BASE/VIAL	A209197	001	May 08, 2020	Apr	NEWA	
	AP	INGENUS PHARMS LLC	EQ 50MG BASE/VIAL	A210947	001	Feb 18, 2020	Feb	NEWA	
		@ PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016	Feb	DISC	
		@ TWI PHARMS	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Jan	DISC	
		POWDER; INTRAVENOUS							
		EVOMELA							
		+!	ACROTECH	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar	CTEC
AP		+!		EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Feb	CFTG
		MELPHALAN HYDROCHLORIDE							
		@ ACTAVIS LLC	EQ 50MG BASE/VIAL	A209323	001	Mar 06, 2020	Mar	DISC	
AP			EQ 50MG BASE/VIAL	A209323	001	Mar 06, 2020	Feb	NFTG	

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

AB		ANI PHARMS INC	7MG	A205365	001	Feb 28, 2020	Feb	NEWA
AB			14MG	A205365	002	Feb 28, 2020	Feb	NEWA
AB			21MG	A205365	003	Feb 28, 2020	Feb	NEWA
AB			28MG	A205365	004	Feb 28, 2020	Feb	NEWA
		TABLET; ORAL						
		MEMANTINE HYDROCHLORIDE						
		@ CHARTWELL	5MG	A090244	001	Jul 11, 2018	Mar	CAHN
		@	10MG	A090244	002	Jul 11, 2018	Mar	CAHN
	AB	HIKMA PHARMS	5MG	A208173	001	Feb 28, 2020	Feb	NEWA
	AB		10MG	A208173	002	Feb 28, 2020	Feb	NEWA
>D>	AB	NINGBO	5MG	A212947	001	Apr 03, 2020	Apr	CAHN
>A>	AB		5MG	A212947	001	Apr 03, 2020	Apr	CAHN
	AB		5MG	A212947	001	Apr 03, 2020	Mar	NEWA
>D>	AB		10MG	A212947	002	Apr 03, 2020	Apr	CAHN
>A>	AB		10MG	A212947	002	Apr 03, 2020	Apr	CAHN
	AB		10MG	A212947	002	Apr 03, 2020	Mar	NEWA
>D>	AB	TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	Apr	DISC
>A>		@	5MG	A090052	001	Oct 25, 2011	Apr	DISC
>D>	AB		10MG	A090052	002	Oct 25, 2011	Apr	DISC
>A>		@	10MG	A090052	002	Oct 25, 2011	Apr	DISC



MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

AA	!	EPIC PHARMA	50MG	A 040331	001	May 28, 1999	Feb	CHRS
AA	!		100MG	A 040331	002	May 28, 1999	Feb	CHRS
	@	HIKMA	50MG	A 040110	001	Mar 12, 1997	Feb	DISC
	@		100MG	A 040110	002	Mar 12, 1997	Feb	DISC

MESALAMINE

SUPPOSITORY; RECTAL

MESALAMINE

AB		ANNORA PHARMA	1GM	A 213377	001	Mar 19, 2020	Mar	NEWA
AB		ZYDUS PHARMS	1GM	A 208953	001	Feb 12, 2020	Jan	NEWA

METAXALONE

TABLET; ORAL

METAXALONE

AB		MOUNTAIN	400MG	A 040486	001	Feb 27, 2015	Mar	CTEC
AB		SCIEGEN PHARMS INC	400MG	A 207466	002	Mar 13, 2020	Mar	NEWA

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

METFORMIN HYDROCHLORIDE

AB		SAPTALIS PHARMS	500MG/5ML	A 211309	001	Mar 03, 2020	Feb	NFTG
		RIOMET						
AB	+	RANBAXY	500MG/5ML	N 021591	001	Sep 11, 2003	Feb	CFTG
	+		500MG/5ML	N 021591	001	Sep 11, 2003	Jan	CAHN

TABLET; ORAL

METFORMIN HYDROCHLORIDE

@	HERITAGE PHARMA	500MG
@		850MG
@		1GM
@	MYLAN	500MG
@		850MG
@		1GM

A 075978	001	Jan 25, 2002	Mar	DISC
A 075978	002	Jan 25, 2002	Mar	DISC
A 075978	003	Nov 05, 2002	Mar	DISC
A 075976	001	Jan 24, 2002	Jan	DISC
A 075976	002	Jan 24, 2002	Jan	DISC
A 075976	003	Jan 24, 2002	Jan	DISC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB2		AJANTA PHARMA LTD	500MG	A 213651	001	Apr 09, 2020	Mar	NEWA
AB2			1GM	A 213651	002	Apr 09, 2020	Mar	NEWA
>D>	AB	BARR	750MG	A 076863	001	Oct 14, 2004	Apr	DISC
>A>		@	750MG	A 076863	001	Oct 14, 2004	Apr	DISC

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE HYDROCHLORIDE

AA		NOSTRUM LABS INC	5MG	A 210484	001	Aug 02, 2018	Mar	CAHN
AA			5MG	A 210484	001	Aug 02, 2018	Mar	CAHN
AA			10MG	A 210484	002	Aug 02, 2018	Mar	CAHN
AA			10MG	A 210484	002	Aug 02, 2018	Mar	CAHN
AA		VISTAPHARM	10MG	A 204166	001	Mar 16, 2020	Mar	NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

@	HIKMA INTL PHARMS	500MG
@		750MG

A 085159	001		Feb	DISC
A 085123	001		Feb	DISC

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

@	MYLAN LABS LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)
@		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)
@		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)
	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)

A 201529	001	Mar 29, 2012	Jan	DISC
A 201529	002	Mar 29, 2012	Jan	DISC
A 201529	003	Mar 29, 2012	Jan	DISC
A 040843	003	Feb 27, 2012	Jan	CTEC

TABLET; ORAL

METHOTREXATE SODIUM

AB		ACCORD HLTHCARE	EQ 2.5MG BASE	A 213343	001	Jan 24, 2020	Jan	NEWA
	+	@ DAVA PHARMS INC	EQ 2.5MG BASE	N 008085	002		Mar	DISC
AB		EUGIA PHARMA	EQ 2.5MG BASE	A 210454	001	Jan 30, 2020	Jan	NEWA

## TABLET;ORAL

## METHOTREXATE SODIUM

AB	!	HIKMA	EQ 2.5MG BASE	A040054	001	Aug 01, 1994	Mar	CHRS
----	---	-------	---------------	---------	-----	--------------	-----	------

METHSCOPOLAMINE BROMIDE

## TABLET;ORAL

## METHSCOPOLAMINE BROMIDE

>D>		BAYSHORE PHARMS LLC	2.5MG	A200602	001	Sep 24, 2012	Apr	CTEC
>A>	AA		2.5MG	A200602	001	Sep 24, 2012	Apr	CTEC
>D>	!		5MG	A200602	002	Sep 24, 2012	Apr	CTEC
>A>	AA	!	5MG	A200602	002	Sep 24, 2012	Apr	CTEC
>D>	@	BRECKENRIDGE PHARM	2.5MG	A040642	001	Dec 06, 2011	Apr	CMFD
>A>	AA		2.5MG	A040642	001	Dec 06, 2011	Apr	CMFD
>D>	@		5MG	A040642	002	Dec 06, 2011	Apr	CMFD
>A>	AA		5MG	A040642	002	Dec 06, 2011	Apr	CMFD

METHYLDOPA

## TABLET;ORAL

## METHYLDOPA

>D>	AB	HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986	Apr	DISC
>A>	@		250MG	A070098	001	Feb 20, 1986	Apr	DISC
>D>	AB		500MG	A070343	001	Feb 20, 1986	Apr	DISC
>A>	@		500MG	A070343	001	Feb 20, 1986	Apr	DISC
>D>	AB	WATSON LABS	500MG	A070625	001	Jun 06, 1986	Apr	DISC
>A>	@		500MG	A070625	001	Jun 06, 1986	Apr	DISC

METHYLERGONOVINE MALEATE

## TABLET;ORAL

## METHYLERGONOVINE MALEATE

>A>	AB	TULEX PHARMS INC	0.2MG	A212233	001	May 01, 2020	Apr	NEWA
-----	----	------------------	-------	---------	-----	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE;ORAL

## METHYLPHENIDATE HYDROCHLORIDE

>D>	AB1	BARR LABS INC	10MG	A079031	004	Oct 15, 2014	Apr	DISC
>A>	@		10MG	A079031	004	Oct 15, 2014	Apr	DISC
>D>	AB1		20MG	A079031	001	Jul 13, 2012	Apr	DISC
>A>	@		20MG	A079031	001	Jul 13, 2012	Apr	DISC
>D>	AB1		30MG	A079031	002	Jul 13, 2012	Apr	DISC
>A>	@		30MG	A079031	002	Jul 13, 2012	Apr	DISC
>D>	AB1		40MG	A079031	003	Jul 13, 2012	Apr	DISC
>A>	@		40MG	A079031	003	Jul 13, 2012	Apr	DISC

## SOLUTION;ORAL

## METHYLPHENIDATE HYDROCHLORIDE

AA		ALKEM LABS LTD	5MG/5ML	A211647	001	Mar 30, 2020	Mar	NEWA
AA			10MG/5ML	A211647	002	Mar 30, 2020	Mar	NEWA
AA		PATRIN PHARMA INC	5MG/5ML	A210764	001	Apr 10, 2020	Mar	NEWA
AA			10MG/5ML	A210764	002	Apr 10, 2020	Mar	NEWA

## TABLET;ORAL

## METHYLPHENIDATE HYDROCHLORIDE

>D>	AB	ACTAVIS LABS FL INC	5MG	A040220	001	Aug 29, 1997	Apr	DISC
>D>	AB		10MG	A040220	002	Aug 29, 1997	Apr	DISC
>D>	AB		20MG	A040220	003	Aug 29, 1997	Apr	DISC
>A>	@	WATSON LABS	5MG	A040220	001	Aug 29, 1997	Apr	DISC
>A>	@		10MG	A040220	002	Aug 29, 1997	Apr	DISC
>A>	@		20MG	A040220	003	Aug 29, 1997	Apr	DISC

## TABLET, EXTENDED RELEASE;ORAL

## METHYLPHENIDATE HYDROCHLORIDE

@	ACTAVIS LABS FL	18MG	A076772	001	Mar 22, 2018	Mar	DISC
@		27MG	A076772	002	Mar 22, 2018	Mar	DISC
@		36MG	A076772	003	Mar 22, 2018	Mar	DISC
@		54MG	A076655	001	Mar 21, 2018	Mar	DISC

METHYLPREDNISOLONE

## TABLET;ORAL

## METHYLPREDNISOLONE

@	DURAMED PHARMS BARR	4MG	A088497	001	Feb 21, 1984	Mar	DISC
---	---------------------	-----	---------	-----	--------------	-----	------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL		METOPROLOL SUCCINATE					
	@ ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	Mar	DISC
	@	EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	Mar	DISC
	@	EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	Mar	DISC
	@	EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	Mar	DISC
	@ ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Jan	DISC
	@	EQ 100MG TARTRATE	A077298	001	Apr 15, 2010	Jan	DISC
	@	EQ 200MG TARTRATE	A077298	002	Apr 15, 2010	Jan	DISC
AB	PHARMADAX INC	EQ 25MG TARTRATE	A203028	001	Mar 31, 2020	Mar	NEWA
AB		EQ 50MG TARTRATE	A203028	002	Mar 31, 2020	Mar	NEWA
AB		EQ 100MG TARTRATE	A203699	001	Mar 30, 2020	Mar	NEWA
AB		EQ 200MG TARTRATE	A203699	002	Mar 30, 2020	Mar	NEWA

METOPROLOL TARTRATE

TABLET;ORAL		METOPROLOL TARTRATE					
	@ HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995	Feb	DISC
	@	100MG	A074141	002	Jan 31, 1995	Feb	DISC
AB	YOUNGTECH PHARMS INC	25MG	A208955	001	Feb 05, 2020	Jan	NEWA
AB		50MG	A208955	002	Feb 05, 2020	Jan	NEWA
AB		100MG	A208955	003	Feb 05, 2020	Jan	NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION		MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE					
	@ MYLAN ASI	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Jan	DISC
	@	EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Jan	DISC

MILRINONE LACTATE

INJECTABLE;INJECTION		MILRINONE LACTATE						
>A>	AP	MEITHEAL	EQ 1MG BASE/ML	A211671	001	Mar 24, 2020	Apr	CAHN
>D>	AP	NANJING KING-FRIEND	EQ 1MG BASE/ML	A211671	001	Mar 24, 2020	Apr	CAHN
	AP		EQ 1MG BASE/ML	A211671	001	Mar 24, 2020	Mar	NEWA

MINOCYCLINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL		XIMINO						
		JOURNEY	EQ 45MG BASE	N201922	001	Jul 11, 2012	Feb	CAHN
	@		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Feb	CAHN
			EQ 90MG BASE	N201922	003	Jul 11, 2012	Feb	CAHN
	@		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Feb	CAHN
			EQ 135MG BASE	N201922	005	Jul 11, 2012	Feb	CAHN
TABLET;ORAL		MINOCYCLINE HYDROCHLORIDE						
>A>	AB	AUROBINDO PHARMA LTD	EQ 50MG BASE	A213662	001	May 01, 2020	Apr	NEWA
>A>	AB		EQ 75MG BASE	A213662	002	May 01, 2020	Apr	NEWA
>A>	AB		EQ 100MG BASE	A213662	003	May 01, 2020	Apr	NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL		MIRABEGRON					
	@ SAWAI USA	25MG	A209446	001	Dec 27, 2019	Jan	DISC
	MYRBETRIQ						
	+! APGDI	25MG	N202611	001	Jun 28, 2012	Jan	CTEC

MITOMYCIN

>A>		POWDER;PYELOALYCEAL						
>A>		JELMYTO						
>A>	+!	UROGEN PHARMA	40MG/VIAL	N211728	001	Apr 15, 2020	Apr	NEWA

MOMETASONE FUROATE

SPRAY, METERED;NASAL		MOMETASONE FUROATE					
AB	AMNEAL PHARMS	0.05MG/SPRAY	A207989	001	Apr 03, 2017	Mar	CPOT
AB	APOTEX INC	0.05MG/SPRAY	A091161	001	Mar 22, 2016	Mar	CPOT
	NASONEX						
AB	+! MERCK SHARP DOHME	0.05MG/SPRAY	N020762	001	Oct 01, 1997	Mar	CPOT

>A> MONOMETHYL FUMARATE  
 >A> CAPSULE, DELAYED RELEASE;ORAL  
 >A> BAFIERTAM  
 >A> +! BANNER LIFE SCIENCES 95MG N210296 001 Apr 28, 2020 Apr NEWA

MONTELUKAST SODIUM

GRANULE;ORAL  
 MONTELUKAST SODIUM  
 AB AUROBINDO PHARMA LTD EQ 4MG BASE/PACKET A213471 001 Feb 18, 2020 Feb NEWA  
 TABLET;ORAL  
 MONTELUKAST SODIUM  
 @ HIKMA EQ 10MG BASE A090655 001 Aug 03, 2012 Feb DISC  
 TABLET, CHEWABLE;ORAL  
 MONTELUKAST SODIUM  
 >D> AB CSPEC OUYI EQ 4MG BASE A209011 001 Apr 18, 2017 Apr CAHN  
 >D> AB EQ 5MG BASE A209011 002 Apr 18, 2017 Apr CAHN  
 >A> AB GRAVITI PHARMS EQ 4MG BASE A209011 001 Apr 18, 2017 Apr CAHN  
 >A> AB EQ 5MG BASE A209011 002 Apr 18, 2017 Apr CAHN  
 @ JUBILANT GENERICS EQ 4MG BASE A203795 001 Feb 27, 2015 Jan DISC  
 @ EQ 5MG BASE A203795 002 Feb 27, 2015 Jan DISC

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL  
 KADIAN  
 >D> AB + ALLERGAN 70MG N020616 010 Jul 09, 2012 Apr CTEC  
 >A> + 70MG N020616 010 Jul 09, 2012 Apr CTEC  
 MORPHINE SULFATE  
 >D> AB TEVA PHARMS USA 20MG A202718 001 Dec 29, 2014 Apr DISC  
 >A> @ 20MG A202718 001 Dec 29, 2014 Apr DISC  
 >D> AB 30MG A202718 002 Dec 29, 2014 Apr DISC  
 >A> @ 30MG A202718 002 Dec 29, 2014 Apr DISC  
 >D> AB 40MG A202718 007 Jun 03, 2015 Apr DISC  
 >A> @ 40MG A202718 007 Jun 03, 2015 Apr DISC  
 >D> AB 50MG A202718 003 Dec 29, 2014 Apr DISC  
 >A> @ 50MG A202718 003 Dec 29, 2014 Apr DISC  
 >D> AB 60MG A202718 004 Dec 29, 2014 Apr DISC  
 >A> @ 60MG A202718 004 Dec 29, 2014 Apr DISC  
 >D> AB 70MG A202718 008 Jun 03, 2015 Apr DISC  
 >A> @ 70MG A202718 008 Jun 03, 2015 Apr DISC  
 >D> AB 80MG A202718 005 Dec 29, 2014 Apr DISC  
 >A> @ 80MG A202718 005 Dec 29, 2014 Apr DISC  
 >D> AB 100MG A202718 006 Dec 29, 2014 Apr DISC  
 >A> @ 100MG A202718 006 Dec 29, 2014 Apr DISC

INJECTABLE; INJECTION  
 DURAMORPH PF

AP +! HIKMA 0.5MG/ML N018565 001 Sep 18, 1984 Feb CAHN  
 AP +! 1MG/ML N018565 002 Sep 18, 1984 Feb CAHN  
 INFUMORPH  
 AP +! HIKMA 10MG/ML N018565 003 Jul 19, 1991 Feb CAHN  
 AP +! 25MG/ML N018565 004 Jul 19, 1991 Feb CAHN  
 MORPHINE SULFATE  
 AP HIKMA 4MG/ML A205758 001 May 21, 2015 Feb CAHN  
 AP 8MG/ML A205758 002 May 21, 2015 Feb CAHN  
 AP 10MG/ML A205758 003 May 21, 2015 Feb CAHN

TABLET, EXTENDED RELEASE;ORAL  
 MORPHINE SULFATE

@ NESHER PHARMS 15MG A076733 001 May 19, 2004 Mar DISC  
 @ 100MG A077855 001 Sep 27, 2007 Mar DISC  
 @ 200MG A077855 002 Sep 27, 2007 Mar DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
 MOXIFLOXACIN HYDROCHLORIDE

AT1 GLAND PHARMA LTD EQ 0.5% BASE A208778 001 Mar 30, 2020 Mar NEWA  
 AT1 MYLAN EQ 0.5% BASE A206447 001 Mar 30, 2020 Mar NEWA

TABLET;ORAL  
 AVELOX

>D> AB +! BAYER HLTHCARE EQ 400MG BASE N021085 001 Dec 10, 1999 Apr DISC  
 >A> + @ EQ 400MG BASE N021085 001 Dec 10, 1999 Apr DISC

## TABLET;ORAL

## MOXIFLOXACIN HYDROCHLORIDE

>D>	AB	DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Apr CHRS
>A>	AB	!	EQ 400MG BASE	A076938	001	Mar 04, 2014	Apr CHRS

MUPIROCIN CALCIUM

## CREAM;TOPICAL

## MUPIROCIN

>D>	!	GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	Apr CTEC
>A>	AB	!	EQ 2% BASE	A201587	001	Jan 24, 2013	Apr CTEC
>A>	AB	TARO	EQ 2% BASE	A207116	001	Apr 27, 2020	Apr NEWA

MYCOPHENOLIC ACID

## TABLET, DELAYED RELEASE;ORAL

## MYCOPHENOLIC ACID

@	TEVA PHARMS USA	180MG
@		360MG

A202720	001	Oct 30, 2014	Mar DISC
A202720	002	Oct 30, 2014	Mar DISC

NABILONE

## CAPSULE;ORAL

## CESAMET

+	!	BAUSCH	1MG
---	---	--------	-----

N018677	001	Dec 26, 1985	Mar CAHN
---------	-----	--------------	----------

NADOLOL

## TABLET;ORAL

## NADOLOL

@	VGYAAN	20MG
@		40MG
@		80MG

A212856	001	Sep 13, 2019	Mar DISC
A212856	002	Sep 13, 2019	Mar DISC
A212856	003	Sep 13, 2019	Mar DISC

NALBUPHINE HYDROCHLORIDE

## INJECTABLE;INJECTION

## NALBUPHINE HYDROCHLORIDE

@	MYLAN LABS LTD	10MG/ML
@		10MG/ML
@		20MG/ML
@		20MG/ML

A206506	001	Feb 06, 2019	Feb DISC
A207595	001	Jan 11, 2019	Feb DISC
A206506	002	Feb 06, 2019	Feb DISC
A207595	002	Jan 11, 2019	Feb DISC

NALOXONE HYDROCHLORIDE

## INJECTABLE;INJECTION

## NALOXONE HYDROCHLORIDE

AP		DR REDDYS	1MG/ML
AP	!	INTL MEDICATION	1MG/ML
AP		PAR STERILE PRODUCTS	0.4MG/ML

A213209	001	Mar 16, 2020	Mar NEWA
A072076	001	Mar 24, 1988	Mar CTEC
A211286	001	Jan 17, 2020	Jan NEWA

NAPROXEN

## TABLET;ORAL

## NAPROXEN

	@	MYLAN	250MG
	@		375MG
	@		500MG
AB		SCIEGEN PHARMS INC	250MG
AB			375MG
AB			500MG

A074121	001	Dec 21, 1993	Jan DISC
A074121	002	Dec 21, 1993	Jan DISC
A074121	003	Dec 21, 1993	Jan DISC
A212517	001	Feb 21, 2020	Feb NEWA
A212517	002	Feb 21, 2020	Feb NEWA
A212517	003	Feb 21, 2020	Feb NEWA

## TABLET, DELAYED RELEASE;ORAL

## NAPROXEN

@	PLIVA	375MG
@		500MG

A075337	001	May 26, 1999	Mar DISC
A075337	002	May 26, 1999	Mar DISC

NAPROXEN SODIUM

## TABLET;ORAL

## NAPROXEN SODIUM

@	TEVA	EQ 250MG BASE
@		EQ 500MG BASE

A074198	001	Dec 21, 1993	Mar DISC
A074198	002	Dec 21, 1993	Mar DISC

NATEGLINIDE

## TABLET;ORAL

## NATEGLINIDE

@	ALVOGEN	60MG
@		120MG

A205055	001	Dec 11, 2015	Mar DISC
A205055	002	Dec 11, 2015	Mar DISC

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

>D>	AA	BRECKENRIDGE	500MG	A065468	001	Mar 29, 2010	Apr	DISC
>A>	@		500MG	A065468	001	Mar 29, 2010	Apr	DISC
	AA	XGEN PHARMS	500MG	A065220	001	Jul 28, 2006	Feb	CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT		WATSON LABS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A062664	001	Apr 08, 1986	Mar	CMFD
AT		XGEN PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A065106	001	Jan 31, 2006	Feb	CAHN
AT			EQ 40MG BASE/ML; 200,000 UNITS/ML	A065108	001	Jan 31, 2006	Feb	CAHN

NETARSUDIL MESYLATE

SOLUTION/DROPS; OPHTHALMIC

RHOPRESSA

+!		AERIE PHARMS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	Feb	CAIN
----	--	------------------	---------------	---------	-----	--------------	-----	------

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

@ MYLAN

500MG

A203742 001 Feb 22, 2019 Jan DISC

@

750MG

A203742 002 Feb 22, 2019 Jan DISC

@

1GM

A203742 003 Feb 22, 2019 Jan DISC

NIMODIPINE

SOLUTION; ORAL

NYMALIZE

>A>	+	@ ARBOR PHARMS LLC	3MG/ML	N203340	001	May 10, 2013	Apr	DISC
>A>	+	!	3MG/ML	N203340	001	May 10, 2013	Apr	CPOT
>A>	+	!	6MG/ML	N203340	002	Apr 08, 2020	Apr	NEWA
>D>	+	!	60MG/20ML	N203340	001	May 10, 2013	Apr	CPOT

NIRAPARIB TOSYLATE

CAPSULE; ORAL

ZEJULA

+!		GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Jan	CAHN
----	--	-----------------	---------------	---------	-----	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITRO-DUR

BX	+	!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Mar	CTEC
BX	+	!		0.2MG/HR	N020145	002	Apr 04, 1995	Mar	CTEC
BX	+	!		0.4MG/HR	N020145	004	Apr 04, 1995	Mar	CTEC
BX	+	!		0.6MG/HR	N020145	005	Apr 04, 1995	Mar	CTEC

TABLET; SUBLINGUAL

NITROGLYCERIN

@ ACTAVIS LABS FL INC

0.3MG

A203693 001 Oct 16, 2017 Mar DISC

@

0.4MG

A203693 002 Oct 16, 2017 Mar DISC

@

0.6MG

A203693 003 Oct 16, 2017 Mar DISC

NORETHINDRONE

TABLET; ORAL-28

NOR-QD

AB1	+	!	TEVA BRANDED PHARM	0.35MG	N017060	001		Jan	CAHN
-----	---	---	--------------------	--------	---------	-----	--	-----	------

NYSTATIN

POWDER; TOPICAL

NYSTATIN

AT		XGEN PHARMS	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Feb	CAHN
----	--	-------------	------------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		ZYDUS PHARMS	100,000 UNITS/GM; 0.1%	A207764	001	Nov 08, 2018	Mar	CMFD
----	--	--------------	------------------------	---------	-----	--------------	-----	------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

@	HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Feb	DISC
@		EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Feb	DISC
@		EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Feb	DISC

SOLUTION; SUBCUTANEOUS

BYNFEZIA PEN

+!	SUN PHARM	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N213224	001	Jan 28, 2020	Jan	NEWA
----	-----------	-------------------------------------	---------	-----	--------------	-----	------

OLANZAPINE

TABLET; ORAL

OLANZAPINE

@	IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Mar	DISC
@	TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011	Jan	DISC
@		5MG	A076000	002	Oct 24, 2011	Jan	DISC
@		7.5MG	A076000	003	Oct 24, 2011	Jan	DISC
@		10MG	A076000	004	Oct 24, 2011	Jan	DISC
@		15MG	A076000	005	Oct 24, 2011	Jan	DISC

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

@	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Feb	DISC
@		20MG	A205482	002	Apr 24, 2017	Feb	DISC
@		40MG	A205482	003	Apr 24, 2017	Feb	DISC
AB	SANDOZ INC	5MG	A090237	001	Apr 13, 2020	Mar	NEWA
AB		20MG	A090237	002	Apr 13, 2020	Mar	NEWA
AB		40MG	A090237	003	Apr 13, 2020	Mar	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

@	CIPLA	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Mar	DISC
@		EQ 0.2% BASE	A206087	001	Dec 05, 2017	Mar	DISC
@	WATSON LABS INC	EQ 0.7% BASE	A208637	001	Feb 19, 2020	Mar	DISC
AT		EQ 0.7% BASE	A208637	001	Feb 19, 2020	Feb	NFTG
	PAZEO						
+!	NOVARTIS	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Mar	CTEC
AT	+!	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Feb	CFTG

SPRAY, METERED; NASAL

OLOPATADINE HYDROCHLORIDE

AB	AMNEAL PHARMS LLC	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan	NEWA
----	-------------------	---------------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

OMEGA-3-ACID ETHYL ESTERS

>A>	AB	CSPC NBP PHARM CO	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211979	001	May 12, 2020	Apr	NEWA
	AB	SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Feb	CMFD

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

@	MYLAN	10MG	A205070	001	Jun 29, 2018	Feb	DISC
@		20MG	A075876	002	May 29, 2003	Jan	DISC
@		20MG	A205070	002	Jun 29, 2018	Feb	DISC
@		40MG	A205070	003	Jun 29, 2018	Feb	DISC

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

>A>	AB	GUARDIAN DRUG	20MG;1.1GM	A212587	001	Apr 30, 2020	Apr	NEWA
>A>	AB		40MG;1.1GM	A212587	002	Apr 30, 2020	Apr	NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL  
ONDANSETRON

@ BARR	4MG	A076693	001	Jun 25, 2007	Mar	DISC
@	8MG	A076693	002	Jun 25, 2007	Mar	DISC
@ TEVA	4MG	A076810	001	Jun 25, 2007	Mar	DISC
@	8MG	A076810	002	Jun 25, 2007	Mar	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION  
ONDANSETRON HYDROCHLORIDE

AP	@ BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Mar	DISC
	! QILU	EQ 2MG BASE/ML	A203711	001	Sep 08, 2014	Mar	CHRS

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

@ MYLAN	EQ 4MG BASE	A076930	001	Jun 25, 2007	Jan	DISC
@	EQ 8MG BASE	A076930	002	Jun 25, 2007	Jan	DISC
@ PLIVA HRVATSKA DOO	EQ 4MG BASE	A077112	001	Jun 25, 2007	Mar	DISC
@	EQ 8MG BASE	A077112	002	Jun 25, 2007	Mar	DISC
@	EQ 24MG BASE	A077112	003	Jun 25, 2007	Mar	DISC

>A> OPICAPONE

>A> CAPSULE;ORAL

>A> ONGENTYS

>A>	+ NEUROCRINE	25MG	N212489	001	Apr 24, 2020	Apr	NEWA
>A>	+!	50MG	N212489	002	Apr 24, 2020	Apr	NEWA

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	SUNSHINE LAKE	EQ 30MG BASE	A212739	001	Mar 04, 2020	Feb	NEWA
AB		EQ 45MG BASE	A212739	002	Mar 04, 2020	Feb	NEWA
AB		EQ 75MG BASE	A212739	003	Mar 04, 2020	Feb	NEWA

OSILODROSTAT PHOSPHATE

TABLET;ORAL

ISTURISA

+ RECORDATI RARE	EQ 1MG BASE	N212801	001	Mar 06, 2020	Mar	NEWA
+	EQ 5MG BASE	N212801	002	Mar 06, 2020	Mar	NEWA
+!	EQ 10MG BASE	N212801	003	Mar 06, 2020	Mar	NEWA

OXAPROZIN

TABLET;ORAL

OXAPROZIN

AB	CHARTWELL	600MG	A075987	001	Sep 02, 2004	Mar	CAHN
	@ IVAX SUB TEVA PHARMS	600MG	A075846	001	May 13, 2002	Mar	DISC

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB	FRONTIDA BIOPHARM	10MG	A071026	002	Aug 10, 1987	Mar	CMFD
AB		15MG	A071026	003	Aug 10, 1987	Mar	CMFD
AB		30MG	A071026	001	Aug 10, 1987	Mar	CMFD

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

@ HIKMA	150MG	A077795	001	Oct 09, 2007	Feb	DISC
@	300MG	A077795	002	Oct 09, 2007	Feb	DISC
@	600MG	A077795	003	Oct 09, 2007	Feb	DISC

OXYBUTYNIN CHLORIDE

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB	LEADING PHARMA LLC	5MG	A212798	001	Apr 06, 2020	Mar	NEWA
----	--------------------	-----	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

@ MYLAN PHARMS INC	10MG	A076644	001	Nov 09, 2006	Jan	DISC
@	15MG	A076644	002	May 10, 2007	Jan	DISC



OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

	@ ANI PHARMS INC	100MG/5ML	A203447	001	Aug 30, 2017	Jan	DISC
AA	AUROLIFE PHARMA LLC	5MG/5ML	A212429	001	Jan 27, 2020	Jan	NEWA
AA		100MG/5ML	A212429	002	Jan 27, 2020	Jan	NEWA
	@ HIKMA	100MG/5ML	A203208	001	Jul 12, 2013	Feb	DISC
>A> AA	RHODES PHARMS	100MG/5ML	A205853	001	Apr 29, 2020	Apr	NEWA

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

	@ NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Mar	DISC
	@	10MG	A077290	002	Dec 08, 2005	Mar	DISC
	@	15MG	A077290	003	Dec 08, 2005	Mar	DISC
	@	20MG	A077290	004	Dec 08, 2005	Mar	DISC
	@	30MG	A077290	005	Dec 08, 2005	Mar	DISC

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

	@ ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Mar	DISC
	@	7.5MG	A079046	001	Dec 13, 2010	Mar	DISC
	@	10MG	A079046	004	Jul 11, 2013	Mar	DISC
	@	15MG	A079046	002	Dec 13, 2010	Mar	DISC
	@	20MG	A079046	005	Jul 11, 2013	Mar	DISC
	@	30MG	A079046	006	Jul 11, 2013	Mar	DISC
	@	40MG	A079046	007	Jul 11, 2013	Mar	DISC

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA

+	CELGENE INTL	0.23MG	N209899	001	Mar 25, 2020	Mar	NEWA
+		0.46MG	N209899	002	Mar 25, 2020	Mar	NEWA
+	!	0.92MG	N209899	003	Mar 25, 2020	Mar	NEWA

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

	@ TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002	Mar	DISC
	@	90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002	Mar	DISC

PAROXETINE HYDROCHLORIDE

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

	@ JUBILANT GENERICS	EQ 10MG BASE	A205528	001	Nov 27, 2015	Jan	DISC
	@	EQ 20MG BASE	A205528	002	Nov 27, 2015	Jan	DISC
	@	EQ 30MG BASE	A205528	003	Nov 27, 2015	Jan	DISC
	@	EQ 40MG BASE	A205528	004	Nov 27, 2015	Jan	DISC

PASIREOTIDE DIASPARTATE

SOLUTION;SUBCUTANEOUS

SIGNIFOR

+	RECORDATI RARE	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012	Feb	CAHN
+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012	Feb	CAHN
+	!	EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012	Feb	CAHN

PASIREOTIDE PAMOATE

FOR SUSPENSION;INTRAMUSCULAR

SIGNIFOR LAR KIT

+	RECORDATI RARE	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018	Feb	CAHN
+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Feb	CAHN
+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018	Feb	CAHN
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Feb	CAHN
+	!	EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Feb	CAHN

PAZOPANIB HYDROCHLORIDETABLET; ORAL  
VOTRIENT

+ @ NOVARTIS EQ 400MG BASE N022465 002 Oct 19, 2009 Jan CRLD

PEMETREXEDSOLUTION; INTRAVENOUS  
PEMFEXY

+! EAGLE PHARMS 500MG/20ML (25MG/ML) N209472 001 Feb 08, 2020 Feb NEWA

>A> PEMIGATINIB>A> TABLET; ORAL  
>A> PEMAZYRE

&gt;A&gt; + INCYTE CORP 4.5MG N213736 001 Apr 17, 2020 Apr NEWA

&gt;A&gt; + 9MG N213736 002 Apr 17, 2020 Apr NEWA

&gt;A&gt; +! 13.5MG N213736 003 Apr 17, 2020 Apr NEWA

PENICILLAMINECAPSULE; ORAL  
PENICILLAMINE

AB ANI PHARMS INC 250MG A209921 001 May 07, 2019 Jan CAHN

&gt;A&gt; AB APOTEX 250MG A213310 001 Apr 28, 2020 Apr NEWA

TABLET; ORAL  
PENICILLAMINE

AB TEVA PHARMS USA 250MG A211497 001 Feb 13, 2020 Feb NEWA

PERMETHRINCREAM; TOPICAL  
ELIMITE

+ @ MYLAN 5% N019855 001 Aug 25, 1989 Feb DISC

PERMETHRIN

AB ! PERRIGO ISRAEL 5% A076369 001 Apr 21, 2003 Feb CHRS

PERPHENAZINETABLET; ORAL  
PERPHENAZINE

AB ZYDUS PHARMS 2MG A205232 001 Apr 06, 2020 Mar NEWA

AB 4MG A205232 002 Apr 06, 2020 Mar NEWA

AB 8MG A205232 003 Apr 06, 2020 Mar NEWA

AB 16MG A205232 004 Apr 06, 2020 Mar NEWA

PHENDIMETRAZINE TARTRATETABLET; ORAL  
PHENDIMETRAZINE TARTRATE

AA NOSTRUM LABS INC 35MG A203600 001 Dec 27, 2017 Mar CAHN

AA 35MG A203600 001 Dec 27, 2017 Mar CAHN

PHENTERMINE HYDROCHLORIDECAPSULE; ORAL  
PHENTERMINE HYDROCHLORIDE

@ BARR 15MG A090591 001 Mar 18, 2010 Mar DISC

@ 30MG A090591 002 Mar 18, 2010 Mar DISC

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

@ BARR 37.5MG A090470 001 Aug 31, 2009 Mar DISC

PHENYLEPHRINE HYDROCHLORIDESOLUTION; INTRAVENOUS  
PHENYLEPHRINE HYDROCHLORIDE

AP1 RICONPHARMA LLC 10MG/ML (10MG/ML) A209967 001 Jan 16, 2020 Jan NEWA

AP1 50MG/5ML (10MG/ML) A209967 002 Jan 16, 2020 Jan NEWA

AP1 100MG/10ML (10MG/ML) A209967 003 Jan 16, 2020 Jan NEWA

PHENYTOIN SODIUMCAPSULE; ORAL  
EXTENDED PHENYTOIN SODIUM

&gt;D&gt; AB LUPIN LTD 100MG EXTENDED A211633 001 Sep 30, 2019 Apr DISC

&gt;A&gt; @ 100MG EXTENDED A211633 001 Sep 30, 2019 Apr DISC

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

		PILOCARPINE HYDROCHLORIDE					
AB	AUROBINDO PHARMA LTD	5MG		A212377	001	Aug 13, 2019	Mar CMFD
	@	5MG		A212377	001	Aug 13, 2019	Feb DISC
AB		7.5MG		A212377	002	Aug 13, 2019	Mar CMFD
	@	7.5MG		A212377	002	Aug 13, 2019	Feb DISC

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

	@ MYLAN PHARMS INC	EQ 15MG BASE		A076801	001	Aug 17, 2012	Jan DISC
	@	EQ 30MG BASE		A076801	002	Aug 17, 2012	Jan DISC
	@	EQ 45MG BASE		A076801	003	Aug 17, 2012	Jan DISC

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

>D>	@ ASTRAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL		A212287	001	Jul 29, 2019	Apr CMFD
>A>	AP	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL		A212287	001	Jul 29, 2019	Apr CMFD
>D>	@	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL		A212287	002	Jul 29, 2019	Apr CMFD
>A>	AP	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL		A212287	002	Jul 29, 2019	Apr CMFD
>D>	@	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL		A212287	003	Jul 29, 2019	Apr CMFD
>A>	AP	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL		A212287	003	Jul 29, 2019	Apr CMFD

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB	STRIDES PHARMA	10MG		A206136	001	Jun 20, 2017	Mar CAHN
AB		20MG		A206136	002	Jun 20, 2017	Mar CAHN

PODOFILOX

SOLUTION; TOPICAL

CONDYLOX

AT	+! TEVA BRANDED PHARM	0.5%		N019795	001	Dec 13, 1990	Jan CAHN
----	-----------------------	------	--	---------	-----	--------------	----------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN

	@ GLAXOSMITHKLINE	EQ 500,000 UNITS BASE/VIAL		A062036	001		Jan CMS1
AP	XGEN PHARMS	EQ 500,000 UNITS BASE/VIAL		A063000	001	Sep 30, 1994	Feb CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB	STRIDES PHARMA	8MEQ		A205549	001	Dec 08, 2015	Mar CAHN
AB		10MEQ		A205549	002	Dec 08, 2015	Mar CAHN

FOR SUSPENSION, EXTENDED RELEASE; ORAL

MICRO-K LS

	+ @ KV PHARM	20MEQ/PACKET		N019561	003	Aug 26, 1988	Feb CRLD
--	--------------	--------------	--	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

>A>	AB1	AMNEAL	10MEQ	A212861	001	May 08, 2020	Apr NEWA
>A>	AB1		15MEQ	A212861	002	May 08, 2020	Apr NEWA
>A>	AB1		20MEQ	A212861	003	May 08, 2020	Apr NEWA
	AB2	GRANULES PHARMS	8MEQ	A211797	001	Mar 04, 2020	Feb NEWA
	AB2		10MEQ	A211797	002	Mar 04, 2020	Feb NEWA
	@ STRIDES PHARMA	8MEQ		A206881	001	Jan 22, 2019	Feb CAHN
	@	10MEQ		A206881	002	Jan 22, 2019	Feb CAHN
	@	10MEQ		A210097	001	Jun 17, 2019	Feb CAHN
	@	20MEQ		A210098	001	Apr 26, 2019	Feb CAHN

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL  
POTASSIUM CITRATE

>D>	AB	MOUNTAIN	5MEQ	A 077440	001	Jun 09, 2006	Apr	CAHN
>D>	AB		10MEQ	A 077440	002	Jun 09, 2006	Apr	CAHN
>A>	AB	RISING	5MEQ	A 077440	001	Jun 09, 2006	Apr	CAHN
>A>	AB		10MEQ	A 077440	002	Jun 09, 2006	Apr	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL  
PRAMIPEXOLE DIHYDROCHLORIDE

>D>	AB	HERITAGE PHARMA	0.125MG	A 077724	001	Feb 19, 2008	Apr	DISC
>A>		@	0.125MG	A 077724	001	Feb 19, 2008	Apr	DISC
>D>	AB		0.25MG	A 077724	002	Feb 19, 2008	Apr	DISC
>A>		@	0.25MG	A 077724	002	Feb 19, 2008	Apr	DISC
>D>	AB		0.5MG	A 077724	003	Feb 19, 2008	Apr	DISC
>A>		@	0.5MG	A 077724	003	Feb 19, 2008	Apr	DISC
>D>	AB		1MG	A 077724	004	Feb 19, 2008	Apr	DISC
>A>		@	1MG	A 077724	004	Feb 19, 2008	Apr	DISC
>D>	AB		1.5MG	A 077724	005	Feb 19, 2008	Apr	DISC
>A>		@	1.5MG	A 077724	005	Feb 19, 2008	Apr	DISC
		@ MYLAN	0.125MG	A 077854	001	Oct 08, 2010	Jan	DISC
		@	0.25MG	A 077854	002	Oct 08, 2010	Jan	DISC
		@	0.5MG	A 077854	003	Oct 08, 2010	Jan	DISC
		@	0.75MG	A 090764	001	Apr 09, 2010	Jan	DISC
		@	1MG	A 077854	004	Oct 08, 2010	Jan	DISC
		@	1.5MG	A 077854	005	Oct 08, 2010	Jan	DISC
AB		ZENNOVA	0.125MG	A 090151	001	Apr 30, 2012	Feb	CAHN
AB			0.25MG	A 090151	002	Apr 30, 2012	Feb	CAHN
AB			0.5MG	A 090151	003	Apr 30, 2012	Feb	CAHN
AB			0.75MG	A 090151	006	Apr 30, 2012	Feb	CAHN
AB			1MG	A 090151	004	Apr 30, 2012	Feb	CAHN
AB			1.5MG	A 090151	005	Apr 30, 2012	Feb	CAHN

PREDNICARBATE

CREAM;TOPICAL

>D>		DERMATOP E EMOLLIENT						
>D>	AB	+! VALEANT BERMUDA	0.1%	N 020279	001	Oct 29, 1993	Apr	DISC
>A>		+ @	0.1%	N 020279	001	Oct 29, 1993	Apr	DISC
		PREDNICARBATE						
>D>	AB	FOUGERA PHARMS	0.1%	A 077287	001	Sep 19, 2006	Apr	DISC
>A>		@	0.1%	A 077287	001	Sep 19, 2006	Apr	DISC

OINTMENT;TOPICAL

DERMATOP

		+ @ VALEANT PHARMS NORTH	0.1%	N 019568	001	Sep 23, 1991	Feb	DISC
		PREDNICARBATE						
		! FOUGERA PHARMS	0.1%	A 077236	001	Mar 09, 2007	Feb	CTEC
AB		!	0.1%	A 077236	001	Mar 09, 2007	Feb	CHRS

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC  
OMNIPRED

AB		+! NOVARTIS	1%	N 017469	001		Jan	CHRS
AB		+	1%	N 017469	001		Jan	CRLD

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

		PHARM ASSOC	EQ 30MG BASE/5ML	A 204962	001	Mar 11, 2020	Feb	NEWA
--	--	-------------	------------------	----------	-----	--------------	-----	------

PREDNISON

TABLET, DELAYED RELEASE;ORAL

>D>		PREDNISON						
>D>	AB	ACTAVIS LABS FL INC	1MG	A 204867	001	Apr 25, 2017	Apr	DISC
>A>		@	1MG	A 204867	001	Apr 25, 2017	Apr	DISC
>D>	AB		2MG	A 204867	002	Apr 25, 2017	Apr	DISC
>A>		@	2MG	A 204867	002	Apr 25, 2017	Apr	DISC
>D>	AB		5MG	A 204867	003	Apr 25, 2017	Apr	DISC
>A>		@	5MG	A 204867	003	Apr 25, 2017	Apr	DISC
		RAYOS						
>D>	AB	+ HORIZON PHARMA USA	1MG	N 202020	001	Jul 26, 2012	Apr	CTEC

TABLET, DELAYED RELEASE;ORAL  
RAYOS

>A>	+	1MG	N202020	001	Jul 26, 2012	Apr	CTEC	
>D>	AB	+	2MG	N202020	002	Jul 26, 2012	Apr	CTEC
>A>	+	2MG	N202020	002	Jul 26, 2012	Apr	CTEC	
>D>	AB	+	5MG	N202020	003	Jul 26, 2012	Apr	CTEC
>A>	+	5MG	N202020	003	Jul 26, 2012	Apr	CTEC	

PREGABALIN

CAPSULE;ORAL  
PREGABALIN

AB	CELLTRION	50MG	A212865	001	Mar 20, 2020	Mar	NEWA
AB		75MG	A212865	002	Mar 20, 2020	Mar	NEWA
AB		100MG	A212865	003	Mar 20, 2020	Mar	NEWA
AB		150MG	A212865	004	Mar 20, 2020	Mar	NEWA
AB	HIKAL	25MG	A213423	001	Mar 23, 2020	Mar	NEWA
AB		50MG	A213423	002	Mar 23, 2020	Mar	NEWA
AB		75MG	A213423	003	Mar 23, 2020	Mar	NEWA
AB		100MG	A213423	004	Mar 23, 2020	Mar	NEWA
AB		150MG	A213423	005	Mar 23, 2020	Mar	NEWA
AB		200MG	A213423	006	Mar 23, 2020	Mar	NEWA
AB		225MG	A213423	007	Mar 23, 2020	Mar	NEWA
AB		300MG	A213423	008	Mar 23, 2020	Mar	NEWA
	@ MYLAN	25MG	A091228	001	Sep 20, 2019	Feb	DISC
	@	50MG	A091228	002	Sep 20, 2019	Feb	DISC
	@	75MG	A091228	003	Sep 20, 2019	Feb	DISC
	@	100MG	A091228	004	Sep 20, 2019	Feb	DISC
	@	150MG	A091228	005	Sep 20, 2019	Feb	DISC
	@	200MG	A091228	006	Sep 20, 2019	Feb	DISC
	@	225MG	A091228	007	Sep 20, 2019	Feb	DISC
	@	300MG	A091228	008	Sep 20, 2019	Feb	DISC

PROCHLORPERAZINE MALEATE

TABLET;ORAL  
COMPazine

+	@ GLAXOSMITHKLINE	EQ 5MG BASE	N010571	001		Mar	CRLD
+	@	EQ 10MG BASE	N010571	002		Mar	CRLD
+	@	EQ 25MG BASE	N010571	003		Mar	CRLD
		PROCHLORPERAZINE MALEATE					
	@ SANDOZ	EQ 5MG BASE	A040101	001	Jul 19, 1996	Mar	DISC
	@	EQ 10MG BASE	A040101	002	Jul 19, 1996	Mar	DISC
		PROCOMP					
AB	! JUBILANT CADISTA	EQ 10MG BASE	A040268	002	Feb 27, 1998	Mar	CHRS

PROGESTERONE

>A>	SYSTEM;VAGINAL							
>A>	MILPROSA							
>A>	+	FERRING PHARMS INC	1.78GM	N201110	001	Apr 29, 2020	Apr	NEWA

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

AP	XGEN PHARMS	25MG/ML	A040737	001	Apr 24, 2008	Feb	CAHN
AP		50MG/ML	A040737	002	Apr 24, 2008	Feb	CAHN

SUPPOSITORY;RECTAL

		PROMETHAZINE HYDROCHLORIDE					
	@ WATSON LABS INC	12.5MG	A040479	001	Jun 24, 2003	Mar	DISC
	@	25MG	A040479	002	Jun 24, 2003	Mar	DISC

PYRAZINAMIDE

TABLET;ORAL

		PYRAZINAMIDE						
	!	AKORN	500MG	A081319	001	Jun 30, 1992	Feb	CHRS
			500MG	A081319	001	Jun 30, 1992	Feb	CTEC
	@	DAVA PHARMS INC	500MG	A080157	001		Feb	DISC

PYRIMETHAMINE

TABLET;ORAL

		DARAPRIM						
AB	+	VYERA PHARMS LLC	25MG	N008578	001		Feb	CFTG
		PYRIMETHAMINE						
AB		CEROVENE INC	25MG	A207127	001	Feb 28, 2020	Feb	NFTG

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ZENNOVA	EQ 25MG BASE	A 090960	001	Mar 27, 2012	Feb	CAHN
AB		EQ 50MG BASE	A 090960	002	Mar 27, 2012	Feb	CAHN
AB		EQ 100MG BASE	A 090960	003	Mar 27, 2012	Feb	CAHN
AB		EQ 200MG BASE	A 090960	004	Mar 27, 2012	Feb	CAHN
AB		EQ 300MG BASE	A 090960	005	Mar 27, 2012	Feb	CAHN
AB		EQ 400MG BASE	A 090960	006	Mar 27, 2012	Feb	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@	MYLAN	EQ 5MG BASE	A 076694	001	Dec 23, 2004	Mar	DISC
@		EQ 10MG BASE	A 076694	002	Dec 23, 2004	Mar	DISC
@		EQ 20MG BASE	A 076694	003	Dec 23, 2004	Mar	DISC
@		EQ 40MG BASE	A 076694	004	Dec 23, 2004	Mar	DISC

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

>D>	AB	SANDOZ	300MG	A 088072	001	Sep 26, 1983	Apr	CTEC
>A>	!		300MG	A 088072	001	Sep 26, 1983	Apr	CHRS
>A>			300MG	A 088072	001	Sep 26, 1983	Apr	CTEC
>D>	AB	! WATSON LABS	200MG	A 083288	001		Apr	DISC
>A>	@		200MG	A 083288	001		Apr	DISC
>D>	AB	!	300MG	A 085583	001		Apr	DISC
>A>	@		300MG	A 085583	001		Apr	DISC

RAMELTEON

TABLET; ORAL

RAMELTEON

AB	I3 PHARMS	8MG	A 212650	001	Apr 10, 2020	Mar	NEWA
----	-----------	-----	----------	-----	--------------	-----	------

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

@	TEVA PHARMS	1.25MG	A 077470	001	Jun 18, 2008	Mar	DISC
@		2.5MG	A 077470	002	Jun 18, 2008	Mar	DISC
@		5MG	A 077470	003	Jun 18, 2008	Mar	DISC
@		10MG	A 077470	004	Jun 18, 2008	Mar	DISC

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

>D>	AA	AMNEAL PHARMS	EQ 15MG BASE/ML	A 078312	001	Sep 02, 2008	Apr	DISC
>A>	@		EQ 15MG BASE/ML	A 078312	001	Sep 02, 2008	Apr	DISC

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@	AMNEAL PHARMS NY	EQ 150MG BASE	A 077824	001	Oct 13, 2006	Jan	DISC	
@		EQ 300MG BASE	A 077824	002	Oct 13, 2006	Jan	DISC	
>D>	AB	HERITAGE PHARMA	EQ 150MG BASE	A 075165	001	Sep 30, 1998	Apr	DISC
>A>	@		EQ 150MG BASE	A 075165	001	Sep 30, 1998	Apr	DISC
>D>	AB		EQ 300MG BASE	A 075165	002	Sep 30, 1998	Apr	DISC
>A>	@		EQ 300MG BASE	A 075165	002	Sep 30, 1998	Apr	DISC
>D>	AB	STRIDES PHARMA	EQ 150MG BASE	A 205512	001	Aug 22, 2016	Apr	DISC
>A>	@		EQ 150MG BASE	A 205512	001	Aug 22, 2016	Apr	DISC
@		EQ 150MG BASE	A 210010	001	Aug 01, 2018	Jan	DISC	
>D>	AB	!	EQ 300MG BASE	A 205512	002	Aug 22, 2016	Apr	DISC
>A>	@		EQ 300MG BASE	A 205512	002	Aug 22, 2016	Apr	DISC
AB	!		EQ 300MG BASE	A 205512	002	Aug 22, 2016	Jan	CHRS
@		EQ 300MG BASE	A 210010	002	Aug 01, 2018	Jan	DISC	

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANOLAZINE

AB	ANI PHARMS INC	500MG	A 210482	001	Oct 29, 2019	Jan	CAHN
AB		1GM	A 210482	002	Oct 29, 2019	Jan	CAHN
AB	MANKIND PHARMA	500MG	A 212284	001	Feb 12, 2020	Jan	NEWA
AB		1GM	A 212284	002	Feb 12, 2020	Jan	NEWA
AB	MICRO LABS	500MG	A 211745	001	Feb 27, 2020	Feb	NEWA

TABLET, EXTENDED RELEASE;ORAL  
RANOLAZINE

AB		1GM	A211745	002	Feb 27, 2020	Feb	NEWA
AB	SUNGEN PHARMA	500MG	A212781	001	Mar 23, 2020	Mar	NEWA
AB		1GM	A212781	002	Mar 23, 2020	Mar	NEWA
AB	SUNSHINE LAKE	500MG	A211865	001	Mar 23, 2020	Mar	NEWA
AB		1GM	A211865	002	Mar 23, 2020	Mar	NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

@ WATSON LABS INC

EQ 0.5MG BASE

A201823 001 Jul 01, 2013 Mar DISC

@

EQ 1MG BASE

A201823 002 Jul 01, 2013 Mar DISC

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

@ ACTAVIS TOTOWA

0.5MG

A090008 001 Jan 22, 2014 Mar DISC

@

1MG

A090008 002 Jan 22, 2014 Mar DISC

@

2MG

A090008 003 Jan 22, 2014 Mar DISC

RIBAVIRIN

CAPSULE;ORAL

RIBASPHERE

@ KADMON PHARMS LLC

200MG

A076203 001 Apr 06, 2004 Feb DISC

RIBAVIRIN

@ TEVA

200MG

A076277 001 Oct 04, 2004 Mar DISC

TABLET;ORAL

RIBAVIRIN

@ BEXIMCO PHARMS USA

200MG

A202546 001 Aug 12, 2014 Feb DISC

@

400MG

A202546 002 Aug 12, 2014 Feb DISC

@

500MG

A202546 003 Aug 12, 2014 Feb DISC

@

600MG

A202546 004 Aug 12, 2014 Feb DISC

@ KADMON PHARMS LLC

200MG

A077456 001 Dec 05, 2005 Feb DISC

@

400MG

A077456 002 Dec 05, 2005 Feb DISC

@

600MG

A077456 003 Dec 05, 2005 Feb DISC

@ ZYDUS PHARMS USA

400MG

A077094 002 Mar 16, 2007 Feb DISC

@

500MG

A077094 004 Apr 18, 2008 Feb DISC

@

600MG

A077094 003 Mar 16, 2007 Feb DISC

RILUZOLE

TABLET;ORAL

RILUZOLE

AB KENTON 50MG

A206045 001 Dec 09, 2019 Mar CAHN

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

NURTEC ODT

+! BIOHAVEN PHARM

EQ 75MG BASE

N212728 001 Feb 27, 2020 Feb NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

@ ACTAVIS LABS FL INC

0.5MG

A076996 001 Apr 19, 2011 Mar DISC

@

1MG

A076996 002 Apr 19, 2011 Mar DISC

@

2MG

A076996 003 Apr 19, 2011 Mar DISC

@

3MG

A076996 004 Apr 19, 2011 Mar DISC

@

4MG

A076996 005 Apr 19, 2011 Mar DISC

>D> AB HERITAGE PHARMA

0.5MG

A076908 001 Mar 12, 2012 Apr DISC

>A>

@

0.5MG

A076908 001 Mar 12, 2012 Apr DISC

>D> AB

1MG

A076908 002 Mar 12, 2012 Apr DISC

>A>

@

1MG

A076908 002 Mar 12, 2012 Apr DISC

>D> AB

2MG

A076908 003 Mar 12, 2012 Apr DISC

>A>

@

2MG

A076908 003 Mar 12, 2012 Apr DISC

RITODRINE HYDROCHLORIDE

INJECTABLE;INJECTION

YUTOPAR

@ ASTRAZENECA

15MG/ML

N018580 002 Sep 27, 1984 Jan CMS1

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING; ORAL  
RIZATRIPTAN BENZOATE

@ MYLAN PHARMS INC	EQ 5MG BASE	A078173	001	Dec 31, 2012	Feb	DISC
@	EQ 10MG BASE	A078173	002	Dec 31, 2012	Feb	DISC

ROCURONIUM BROMIDE

INJECTABLE; INJECTION  
ROCURONIUM BROMIDE

@ TEVA PHARMS	50MG/5ML (10MG/ML)	A078717	001	Nov 26, 2008	Mar	DISC
@	100MG/10ML (10MG/ML)	A078717	002	Nov 26, 2008	Mar	DISC

ROFLUMILAST

TABLET; ORAL  
ROFLUMILAST

AB	STRIDES PHARMA	500MCG	A208247	001	Mar 30, 2020	Mar	NEWA
----	----------------	--------	---------	-----	--------------	-----	------

ROMIDEPSIN

SOLUTION; INTRAVENOUS  
ROMIDEPSIN

+	TEVA PHARMS USA INC	10MG/2ML (5MG/ML)	N208574	001	Mar 13, 2020	Mar	NEWA
+	!	27.5MG/5.5ML (5MG/ML)	N208574	002	Mar 13, 2020	Mar	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL  
ROPINIROLE HYDROCHLORIDE

@ HIKMA	EQ 0.25MG BASE	A077852	001	May 05, 2008	Feb	DISC
@	EQ 0.5MG BASE	A077852	002	May 05, 2008	Feb	DISC
@	EQ 1MG BASE	A077852	003	May 05, 2008	Feb	DISC
@	EQ 2MG BASE	A077852	004	May 05, 2008	Feb	DISC
@	EQ 3MG BASE	A077852	005	May 05, 2008	Feb	DISC
@	EQ 4MG BASE	A077852	006	May 05, 2008	Feb	DISC
@	EQ 5MG BASE	A077852	007	May 19, 2008	Feb	DISC

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

+	@ GLAXOSMITHKLINE LLC	EQ 8MG BASE	N022008	004	Jun 13, 2008	Mar	DISC
---	-----------------------	-------------	---------	-----	--------------	-----	------

ROPINIROLE HYDROCHLORIDE

@ WATSON LABS INC	EQ 2MG BASE	A200431	001	Jun 06, 2012	Mar	DISC
@	EQ 4MG BASE	A200431	002	Jun 06, 2012	Mar	DISC
@	EQ 6MG BASE	A200431	003	Jun 06, 2012	Mar	DISC
@	EQ 8MG BASE	A200431	004	Jun 06, 2012	Mar	DISC
@	EQ 12MG BASE	A200431	005	Jun 06, 2012	Mar	DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION  
ROPIVACAINE HYDROCHLORIDE

AP	CAPLIN	40MG/20ML (2MG/ML)	A212808	001	Apr 09, 2020	Mar	NEWA
AP		100MG/20ML (5MG/ML)	A212808	002	Apr 09, 2020	Mar	NEWA
AP		150MG/30ML (5MG/ML)	A212808	003	Apr 09, 2020	Mar	NEWA
AP		200MG/20ML (10MG/ML)	A212808	004	Apr 09, 2020	Mar	NEWA

ROSUVASTATIN CALCIUM

TABLET; ORAL  
ROSUVASTATIN CALCIUM

AB	SUNSHINE LAKE	5MG	A210667	001	Apr 01, 2020	Mar	NEWA	
AB		10MG	A210667	002	Apr 01, 2020	Mar	NEWA	
AB		20MG	A210667	003	Apr 01, 2020	Mar	NEWA	
AB		40MG	A210667	004	Apr 01, 2020	Mar	NEWA	
>D>	AB	ZHEJIANG YONGTAI	5MG	A212059	001	Nov 04, 2019	Apr	DISC
>A>	@	5MG	A212059	001	Nov 04, 2019	Apr	DISC	
>D>	AB	10MG	A212059	002	Nov 04, 2019	Apr	DISC	
>A>	@	10MG	A212059	002	Nov 04, 2019	Apr	DISC	
>D>	AB	20MG	A212059	003	Nov 04, 2019	Apr	DISC	
>A>	@	20MG	A212059	003	Nov 04, 2019	Apr	DISC	
>D>	AB	40MG	A212059	004	Nov 04, 2019	Apr	DISC	
>A>	@	40MG	A212059	004	Nov 04, 2019	Apr	DISC	



SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

SELEGILINE HYDROCHLORIDE

@ DAVA PHARMS INC 5MG

A075352 001 Nov 30, 1998 Feb DISC

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@ MLV 5MG

A074672 001 Apr 01, 1997 Mar CAHN

SELEXIPAG

TABLET;ORAL

UPTRAVI

+! ACTELION PHARMS LTD 0.4MG

N207947 002 Dec 21, 2015 Jan CHRS

+ 1.6MG

N207947 008 Dec 21, 2015 Jan CHRS

>A> SELUMETINIB SULFATE

&gt;A&gt; CAPSULE;ORAL

&gt;A&gt; KOSELUGO

&gt;A&gt; + ASTRAZENECA PHARMS EQ 10MG BASE

N213756 001 Apr 10, 2020 Apr NEWA

&gt;A&gt; +! EQ 25MG BASE

N213756 002 Apr 10, 2020 Apr NEWA

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS

OZEMPIC

+! NOVO 4MG/3ML (1.34MG/ML)

N209637 002 Apr 09, 2019 Jan NEWA

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB VIWIT PHARM EQ 25MG BASE

A076882 001 Feb 06, 2007 Mar CAHN

AB EQ 25MG BASE

A076882 001 Feb 06, 2007 Mar CAHN

AB EQ 50MG BASE

A076882 002 Feb 06, 2007 Mar CAHN

AB EQ 50MG BASE

A076882 002 Feb 06, 2007 Mar CAHN

AB EQ 100MG BASE

A076882 003 Feb 06, 2007 Mar CAHN

AB EQ 100MG BASE

A076882 003 Feb 06, 2007 Mar CAHN

SEVELAMER CARBONATE

TABLET;ORAL

SEVELAMER CARBONATE

AB ANXIN 800MG

A212970 001 Apr 09, 2020 Mar NEWA

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

&gt;D&gt; AB APPCO 25MG

A207178 001 Mar 02, 2020 Apr CPOT

&gt;A&gt; AB EQ 25MG BASE

A207178 001 Mar 02, 2020 Apr CPOT

AB 25MG

A207178 001 Mar 02, 2020 Feb NEWA

&gt;D&gt; AB 50MG

A207178 002 Mar 02, 2020 Apr CPOT

&gt;A&gt; AB EQ 50MG BASE

A207178 002 Mar 02, 2020 Apr CPOT

AB 50MG

A207178 002 Mar 02, 2020 Feb NEWA

&gt;D&gt; AB 100MG

A207178 003 Mar 02, 2020 Apr CPOT

&gt;A&gt; AB EQ 100MG BASE

A207178 003 Mar 02, 2020 Apr CPOT

AB 100MG

A207178 003 Mar 02, 2020 Feb NEWA

&gt;A&gt; AB PERRIGO R AND D EQ 25MG BASE

A205791 001 Apr 23, 2020 Apr NEWA

&gt;A&gt; AB EQ 50MG BASE

A205791 002 Apr 23, 2020 Apr NEWA

SILODOSIN

CAPSULE;ORAL

SILODOSIN

AB HETERO LABS LTD V 4MG

A204793 001 Feb 14, 2020 Feb NEWA

AB 8MG

A204793 002 Feb 14, 2020 Feb NEWA

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

&gt;A&gt; AP NEPHRON 9MG/ML

A211968 001 Apr 23, 2020 Apr NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL  
 SODIUM IODIDE I 123  
 AA CURIUM 100uCi A071909 001 Feb 28, 1989 Feb CAHN  
 AA 200uCi A071910 001 Feb 28, 1989 Feb CAHN

SODIUM IODIDE I-131

SOLUTION;ORAL  
 HICON  
 AA +! JUBILANT DRAXIMAGE 250-1000mCi N021305 007 Dec 05, 2011 Jan CFTG  
 SODIUM IODIDE I 131  
 AA INTL ISOTOPES 250-1000mCi A209166 001 Feb 05, 2020 Jan NFTG

SODIUM PHENYL BUTYRATE

TABLET;ORAL  
 SODIUM PHENYL BUTYRATE  
 @ ALVOGEN 500MG A090910 001 Nov 18, 2011 Jan DISC

SODIUM POLYSTYRENE SULFONATE

SUSPENSION;ORAL, RECTAL  
 SODIUM POLYSTYRENE SULFONATE  
 @ HIKMA 15GM/60ML A089049 001 Nov 17, 1986 Feb DISC

SOFOBUVIR; VELPATASVIR

TABLET;ORAL  
 EPCLUSA  
 + GILEAD SCIENCES INC 200MG;50MG N208341 002 Mar 19, 2020 Mar NEWA

SOLIFENACIN SUCCINATE

TABLET;ORAL  
 SOLIFENACIN SUCCINATE  
 AB SUNSHINE LAKE 5MG A213346 001 Apr 13, 2020 Mar NEWA  
 AB 10MG A213346 002 Apr 13, 2020 Mar NEWA

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL  
 SUNOSI  
 + JAZZ EQ 75MG BASE N211230 001 Jun 17, 2019 Jan CPOT  
 + 75MG N211230 001 Jun 17, 2019 Jan CAIN  
 >D> + EQ 150MG BASE N211230 002 Jun 17, 2019 Apr CHRS  
 >A> +! EQ 150MG BASE N211230 002 Jun 17, 2019 Apr CHRS  
 + EQ 150MG BASE N211230 002 Jun 17, 2019 Jan CPOT  
 + 150MG N211230 002 Jun 17, 2019 Jan CAIN

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION  
 STREPTOMYCIN SULFATE  
 ! XGEN PHARMS EQ 1GM BASE/VIAL A064210 001 Jun 30, 1998 Feb CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION  
 QUELICIN PRESERVATIVE FREE  
 >D> @ HOSPIRA 50MG/ML N008845 002 Apr CRLD  
 >A> + @ 50MG/ML N008845 002 Apr CRLD  
 >D> @ 100MG/ML N008845 004 Apr CRLD  
 >A> + @ 100MG/ML N008845 004 Apr CRLD  
 SUCCINYLCHOLINE CHLORIDE  
 >A> AP ASPIRO 20MG/ML A213810 001 May 04, 2020 Apr NEWA  
 SUCOSTRIN  
 >D> @ APOTHECON 20MG/ML N008847 001 Apr CRLD  
 >A> + @ 20MG/ML N008847 001 Apr CRLD  
 >D> @ 100MG/ML N008847 003 Apr CRLD  
 >A> + @ 100MG/ML N008847 003 Apr CRLD

SULFACETAMIDE SODIUM

LOTION;TOPICAL  
 KLARON  
 AB +! BAUSCH 10% N019931 001 Dec 23, 1996 Mar CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION  
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP TEVA PHARMS USA 80MG/ML;16MG/ML A073303 001 Oct 31, 1991 Mar CMFD

SUMATRIPTAN SUCCINATE

TABLET; ORAL  
SUMATRIPTAN SUCCINATE

AB COREPHARMA EQ 25MG BASE A200263 001 Jun 19, 2012 Feb CAHN  
AB EQ 50MG BASE A200263 002 Jun 19, 2012 Feb CAHN  
AB EQ 100MG BASE A200263 003 Jun 19, 2012 Feb CAHN

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL  
TAMSULOSIN HYDROCHLORIDE

>D> AB ANBISON LAB 0.4MG A211885 001 Oct 17, 2019 Apr DISC  
>A> @ 0.4MG A211885 001 Oct 17, 2019 Apr DISC

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL  
NUCYNTA

+ @ COLLEGIUM PHARM INC EQ 20MG BASE/ML N203794 001 Oct 15, 2012 Feb CAHN

TABLET; ORAL  
NUCYNTA

+ COLLEGIUM PHARM INC EQ 50MG BASE N022304 001 Nov 20, 2008 Feb CAHN  
+ EQ 75MG BASE N022304 002 Nov 20, 2008 Feb CAHN  
+! EQ 100MG BASE N022304 003 Nov 20, 2008 Feb CAHN

TABLET, EXTENDED RELEASE; ORAL  
NUCYNTA ER

+ COLLEGIUM PHARM INC EQ 50MG BASE N200533 001 Aug 25, 2011 Feb CAHN  
+ EQ 100MG BASE N200533 002 Aug 25, 2011 Feb CAHN  
+ EQ 150MG BASE N200533 003 Aug 25, 2011 Feb CAHN  
+ EQ 200MG BASE N200533 004 Aug 25, 2011 Feb CAHN  
+! EQ 250MG BASE N200533 005 Aug 25, 2011 Feb CAHN

TAZEMETOSTAT HYDROBROMIDE

TABLET; ORAL  
TAZVERIK

+! EPIZYME INC EQ 200MG BASE N211723 001 Jan 23, 2020 Jan NEWA

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION  
HEPATOLITE

>D> @ PHARMALUCENCE N/A N018467 001 Mar 16, 1982 Apr CAHN  
>A> @ SUN PHARM INDS INC N/A N018467 001 Mar 16, 1982 Apr CAHN

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION  
TECHNETIUM TC-99M MEBROFENIN

>D> AP PHARMALUCENCE N/A A078242 001 Jan 29, 2008 Apr CAHN  
>A> AP SUN PHARM INDS INC N/A A078242 001 Jan 29, 2008 Apr CAHN

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION  
CIS-MDP

>D> PHARMALUCENCE N/A N018124 001 Apr CAHN  
>A> SUN PHARM INDS INC N/A N018124 001 Apr CAHN

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION  
TECHNETIUM TC99M MERTIATIDE KIT

>D> AP PHARMALUCENCE N/A A208994 001 Jul 12, 2019 Apr CAHN  
AP SOMMER PHARMS II LLC N/A A206489 001 Feb 06, 2020 Jan NEWA  
>A> AP SUN PHARM INDS INC N/A A208994 001 Jul 12, 2019 Apr CAHN

TECHNETIUM TC-99M PYROPHOSPHATE KITINJECTABLE; INJECTION  
CIS-PYRO

>D>	AP	PHARMALUCENCE	N/A	N019039	001	Jun 30, 1987	Apr	CAHN
>A>	AP	SUN PHARM INDS INC	N/A	N019039	001	Jun 30, 1987	Apr	CAHN

TECHNETIUM TC-99M SESTAMIBI KITINJECTABLE; INJECTION  
TECHNETIUM TC 99M SESTAMIBI

	AP	CURIUM	N/A	A078098	001	Sep 22, 2008	Feb	CAHN
>D>	AP	PHARMALUCENCE	10-30mCi	A079157	001	Jul 10, 2009	Apr	CAHN
>A>	AP	SUN PHARM INDS INC	10-30mCi	A079157	001	Jul 10, 2009	Apr	CAHN

TECHNETIUM TC-99M SULFUR COLLOID KITSOLUTION; INJECTION, ORAL  
AN-SULFUR COLLOID

>D>	+!	PHARMALUCENCE	N/A	N017858	001		Apr	CAHN
>A>	+!	SUN PHARM INDS INC	N/A	N017858	001		Apr	CAHN

TELMISARTANTABLET; ORAL  
TELMISARTAN

		@ JUBILANT GENERICS	20MG	A204164	001	Aug 22, 2016	Jan	DISC
		@	40MG	A204164	002	Aug 22, 2016	Jan	DISC
		@	80MG	A204164	003	Aug 22, 2016	Jan	DISC
>D>		@ MICRO LABS	20MG	A207016	001	Oct 03, 2017	Apr	CMFD
>A>	AB		20MG	A207016	001	Oct 03, 2017	Apr	CMFD
>D>		@	40MG	A207016	002	Oct 03, 2017	Apr	CMFD
>A>	AB		40MG	A207016	002	Oct 03, 2017	Apr	CMFD
>D>		@	80MG	A207016	003	Oct 03, 2017	Apr	CMFD
>A>	AB		80MG	A207016	003	Oct 03, 2017	Apr	CMFD

TENAPANOR HYDROCHLORIDETABLET; ORAL  
IBSRELA

		+ @ ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019	Mar	DISC
--	--	-----------------	--------------	---------	-----	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL  
TENOFOVIR DISOPROXIL FUMARATE

		@ MYLAN	150MG	A206569	001	Nov 27, 2018	Feb	DISC
		@	200MG	A206569	002	Nov 27, 2018	Feb	DISC
		@	250MG	A206569	003	Nov 27, 2018	Feb	DISC
		@	300MG	A206569	004	Nov 27, 2018	Feb	DISC

TERAZOSIN HYDROCHLORIDECAPSULE; ORAL  
TERAZOSIN HYDROCHLORIDE

		@ HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Feb	DISC
		@	EQ 2MG BASE	A075614	001	Jan 30, 2001	Feb	DISC
		@	EQ 5MG BASE	A075614	003	Jan 30, 2001	Feb	DISC
		@	EQ 10MG BASE	A075614	004	Jan 30, 2001	Feb	DISC

TERIFLUNOMIDETABLET; ORAL  
TERIFLUNOMIDE

		@ MYLAN	7MG	A209702	001	Feb 28, 2020	Mar	DISC
AB			7MG	A209702	001	Feb 28, 2020	Feb	NEWA
		@	14MG	A209702	002	Feb 28, 2020	Mar	DISC
AB			14MG	A209702	002	Feb 28, 2020	Feb	NEWA

TERIPARATIDEINJECTABLE; SUBCUTANEOUS  
FORTEO

		+! LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Jan	CAIN
		@	0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002	Jan	CAIN

SOLUTION; SUBCUTANEOUS  
BONSITY

		ALVOGEN	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Jan	CAIN
		FORTEO						
		+! LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Jan	CDFR

SOLUTION;SUBCUTANEOUS  
FORTEO

@	0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002	Jan CDFR
---	------------------------	---------	-----	--------------	----------

TESTOSTERONEGEL, METERED;TRANSDERMAL  
ANDROGEL

+ @	ABBVIE	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Mar DISC
-----	--------	-------------------------	---------	-----	--------------	----------

## TESTOSTERONE

BX	!	ACTAVIS LABS UT INC	12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Mar CHRS
BX			12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Mar CTEC
>A>	AB	XIROMED	1.62% (20.25MG/1.25GM ACTUATION)	A210835	001	Apr 16, 2020	Apr NEWA

TETRABENAZINE

## TABLET;ORAL

## TETRABENAZINE

AB		APOTEX	12.5MG	A206093	001	Mar 17, 2020	Mar NEWA
AB			25MG	A206093	002	Mar 17, 2020	Mar NEWA
AB		PIRAMAL HLTHCARE UK	12.5MG	A213316	001	Jan 22, 2020	Jan NEWA
AB			25MG	A213316	002	Jan 22, 2020	Jan NEWA

TETRACYCLINE HYDROCHLORIDE

## CAPSULE;ORAL

## TETRACYCLINE HYDROCHLORIDE

AB		STRIDES PHARMA	250MG	A212635	001	Mar 03, 2020	Feb NEWA
AB			500MG	A212635	002	Mar 03, 2020	Feb NEWA

THALLOUS CHLORIDE TL-201

## INJECTABLE;INTRAVENOUS

## THALLOUS CHLORIDE TL 201

@	CURIUM	2mCi/ML	A077698	001	Nov 09, 2006	Feb CAHN
---	--------	---------	---------	-----	--------------	----------

THIORIDAZINE HYDROCHLORIDE

## TABLET;ORAL

## THIORIDAZINE HYDROCHLORIDE

AB		MYLAN	10MG	A088004	002	Mar 15, 1983	Mar CTEC
AB			25MG	A088004	003	Mar 15, 1983	Mar CTEC
AB			50MG	A088004	004	Mar 15, 1983	Mar CTEC
AB	!		100MG	A088004	001	Nov 18, 1983	Mar CTEC
AB		SUN PHARM INDUSTRIES	10MG	A089953	004	Aug 01, 1986	Mar CMFD
AB			25MG	A089953	003	Aug 01, 1986	Mar CMFD
AB			50MG	A089953	002	Aug 01, 1986	Mar CMFD
AB			100MG	A089953	001	Oct 07, 1988	Mar CMFD

THIOTEPA

## POWDER;INTRAVENOUS

## TEPADINA

AP	+	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Feb CFTG
AP	+		100MG/VIAL	N208264	002	Jan 26, 2017	Feb CFTG

## THIOTEPA

AP		MSN	15MG/VIAL	A213049	001	Mar 04, 2020	Feb NFTG
AP			100MG/VIAL	A213049	002	Mar 04, 2020	Feb NFTG

TICAGRELOR

## TABLET;ORAL

## TICAGRELOR

AB		HEC PHARM CO LTD	90MG	A208508	001	Apr 06, 2020	Mar NEWA
AB		SIGMAPHARM LABS LLC	90MG	A208596	001	Apr 07, 2020	Mar NEWA

TIZANIDINE HYDROCHLORIDE

## CAPSULE;ORAL

## TIZANIDINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 2MG BASE	A213544	001	Mar 24, 2020	Mar NEWA
AB			EQ 4MG BASE	A213544	002	Mar 24, 2020	Mar NEWA
AB			EQ 6MG BASE	A213544	003	Mar 24, 2020	Mar NEWA

TOBRAMYCIN

## SOLUTION;INHALATION

## TOBRAMYCIN

@	MYLAN	300MG/5ML	A209554	001	Oct 13, 2017	Feb DISC
---	-------	-----------	---------	-----	--------------	----------

<u>TOBRAMYCIN SULFATE</u>							
INJECTABLE; INJECTION							
TOBRAMYCIN SULFATE							
AP	!	XGEN PHARMS	EQ 1.2GM BASE/VIAL	A065013	001	Aug 17, 2001	Feb CAHN
<u>TOLAZAMIDE</u>							
TABLET; ORAL							
TOLAZAMIDE							
		@ MYLAN PHARMS INC	250MG	A070259	001	Jan 02, 1986	Mar DISC
		@	500MG	A070259	003	Mar 17, 1986	Mar DISC
<u>TOLTERODINE TARTRATE</u>							
TABLET; ORAL							
TOLTERODINE TARTRATE							
		@ MYLAN PHARMS INC	1MG	A202641	001	Nov 27, 2012	Jan DISC
		@	2MG	A202641	002	Nov 27, 2012	Jan DISC
AB		UNIQUE PHARM LABS	1MG	A204721	001	Jan 24, 2020	Jan NEWA
AB			2MG	A204721	002	Jan 24, 2020	Jan NEWA
<u>TOPIRAMATE</u>							
TABLET; ORAL							
TOPIRAMATE							
AB		VIWIT PHARM	25MG	A077733	001	Mar 27, 2009	Mar CAHN
AB			25MG	A077733	001	Mar 27, 2009	Mar CAHN
AB			50MG	A077733	002	Mar 27, 2009	Mar CAHN
AB			50MG	A077733	002	Mar 27, 2009	Mar CAHN
AB			100MG	A077733	003	Mar 27, 2009	Mar CAHN
AB			100MG	A077733	003	Mar 27, 2009	Mar CAHN
AB			200MG	A077733	004	Mar 27, 2009	Mar CAHN
AB			200MG	A077733	004	Mar 27, 2009	Mar CAHN
<u>TORSEMIDE</u>							
TABLET; ORAL							
TORSEMIDE							
AB		COREPHARMA	5MG	A076894	001	May 31, 2005	Feb CAHN
AB			10MG	A076894	002	May 31, 2005	Feb CAHN
AB			20MG	A076894	003	May 31, 2005	Feb CAHN
AB			100MG	A076894	004	May 31, 2005	Feb CAHN
<u>TRANEXAMIC ACID</u>							
INJECTABLE; INJECTION							
TRANEXAMIC ACID							
		@ CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jan DISC
AP		XGEN PHARMS	100MG/ML	A201580	001	Jun 14, 2013	Feb CAHN
TABLET; ORAL							
TRANEXAMIC ACID							
		@ ANI PHARMS INC	650MG	A203256	001	Jul 25, 2016	Jan CAHN
<u>TRAZODONE HYDROCHLORIDE</u>							
TABLET; ORAL							
TRAZODONE HYDROCHLORIDE							
AB		AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Jan NEWA
AB			100MG	A204852	002	Feb 05, 2020	Jan NEWA
AB			150MG	A204852	003	Feb 05, 2020	Jan NEWA
AB			300MG	A204852	004	Feb 05, 2020	Jan NEWA
<u>TRIAMCINOLONE ACETONIDE</u>							
LOTION; TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT		SAPTALIS PHARMS	0.1%	A040672	002	Dec 13, 2006	Mar CAHN
OINTMENT; TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT		MACLEODS PHARMS LTD	0.025%	A209828	001	Nov 23, 2018	Mar CTNA
AT			0.1%	A209828	002	Nov 23, 2018	Mar CTNA
AT			0.5%	A209828	003	Nov 23, 2018	Mar CTNA
AT		STRIDES PHARMA	0.1%	A211315	001	Mar 18, 2020	Mar NEWA
AT			0.5%	A211315	002	Mar 18, 2020	Mar NEWA

TRIAZOLAM

TABLET;ORAL

TRIAZOLAM

@	MYLAN PHARMS INC	0.125MG	A074031	001	Mar 25, 1994	Jan	DISC
@		0.25MG	A074031	002	Mar 25, 1994	Jan	DISC

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

AB	RISING	250MG	A212238	001	Feb 20, 2020	Feb	NEWA
----	--------	-------	---------	-----	--------------	-----	------

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIUM CHLORIDE

>A>	AB	GRANULES PHARMS	60MG	A213185	001	Apr 23, 2020	Apr	NEWA
-----	----	-----------------	------	---------	-----	--------------	-----	------

>A> TUCATINIB

&gt;A&gt; TABLET;ORAL

&gt;A&gt; TUKYSA

>A>	+	SEATTLE GENETICS	50MG	N213411	001	Apr 17, 2020	Apr	NEWA
-----	---	------------------	------	---------	-----	--------------	-----	------

>A>	+	!	150MG	N213411	002	Apr 17, 2020	Apr	NEWA
-----	---	---	-------	---------	-----	--------------	-----	------

URSODIOL

CAPSULE;ORAL

URSODIOL

>A>		NEXGEN PHARMA INC	200MG	A205789	001	May 08, 2020	Apr	NFTG
-----	--	-------------------	-------	---------	-----	--------------	-----	------

>A>			400MG	A205789	002	May 08, 2020	Apr	NFTG
-----	--	--	-------	---------	-----	--------------	-----	------

AB	RISING	300MG	A213200	001	Feb 12, 2020	Jan	NEWA
----	--------	-------	---------	-----	--------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

	@	TEVA PHARMS	EQ 500MG BASE	A077655	001	May 24, 2010	Jan	DISC
	@		EQ 1GM BASE	A077655	002	May 24, 2010	Jan	DISC
AB		YILING PHARM LTD	EQ 500MG BASE	A209553	001	Mar 18, 2020	Mar	NEWA
AB			EQ 1GM BASE	A209553	002	Mar 18, 2020	Mar	NEWA

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB	GRANULES PHARMS	50MG/ML	A213306	001	Jan 31, 2020	Jan	NEWA
----	-----------------	---------	---------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan	CAHN
----	-------------	--------------------	---------	-----	--------------	-----	------

AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan	CAHN
----	--	------------------	---------	-----	--------------	-----	------

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

VARDENAFIL HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	10MG	A205988	001	Mar 10, 2020	Feb	NEWA
----	---------------------	------	---------	-----	--------------	-----	------

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOSTRICT

>A>	+	PAR STERILE PRODUCTS	40UNITS/100ML (0.4UNITS/ML)	N204485	003	Apr 15, 2020	Apr	NEWA
-----	---	----------------------	-----------------------------	---------	-----	--------------	-----	------

>A>	+	!	60UNITS/100ML (0.6UNITS/ML)	N204485	004	Apr 15, 2020	Apr	NEWA
-----	---	---	-----------------------------	---------	-----	--------------	-----	------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	INVENTIA HLTHCARE	EQ 37.5MG BASE	A203332	001	Mar 12, 2020	Mar	NEWA
----	-------------------	----------------	---------	-----	--------------	-----	------

AB		EQ 75MG BASE	A203332	002	Mar 12, 2020	Mar	NEWA
----	--	--------------	---------	-----	--------------	-----	------

AB		EQ 150MG BASE	A203332	003	Mar 12, 2020	Mar	NEWA
----	--	---------------	---------	-----	--------------	-----	------

VERAPAMIL HYDROCHLORIDESOLUTION; INTRAVENOUS  
VERAPAMIL HYDROCHLORIDE

AP	AREVA PHARMS	10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020	Mar	NEWA
AP	CAPLIN	5MG/2ML (2.5MG/ML)	A213232	001	Mar 25, 2020	Mar	NEWA
AP		10MG/4ML (2.5MG/ML)	A213232	002	Mar 25, 2020	Mar	NEWA

VIGABATRINFOR SOLUTION; ORAL  
VIGABATRIN

>A>	AA	GRANULES PHARMS	500MG/PACKET	A213469	001	Apr 24, 2020	Apr	NEWA
-----	----	-----------------	--------------	---------	-----	--------------	-----	------

VILAZODONE HYDROCHLORIDETABLET; ORAL  
VILAZODONE HYDROCHLORIDE

	@	TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019	Mar	DISC
	@		20MG	A208212	002	Sep 30, 2019	Mar	DISC
	@		40MG	A208212	003	Sep 30, 2019	Mar	DISC

VINCRISTINE SULFATEINJECTABLE; INJECTION  
VINCRISTINE SULFATE PFS

AP	!	HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988	Feb	CTEC
AP		TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Feb	CMFD

VORICONAZOLEINJECTABLE; INTRAVENOUS  
VORICONAZOLE

AP		GLAND PHARMA LTD	200MG/VIAL	A211099	001	Mar 31, 2020	Mar	NEWA
----	--	------------------	------------	---------	-----	--------------	-----	------

ZALEPLONCAPSULE; ORAL  
ZALEPLON

	@	TEVA PHARMS	5MG	A077239	001	Jun 06, 2008	Mar	DISC
	@		10MG	A077239	002	Jun 06, 2008	Mar	DISC

ZIDOVUDINETABLET; ORAL  
ZIDOVUDINE

>D>		@	MATRIX LABS LTD	100MG	N200732	001	Feb 23, 2011	Apr	CAHN
>A>		@	MYLAN LABS LTD	100MG	N200732	001	Feb 23, 2011	Apr	CAHN

ZINC SULFATESOLUTION; INTRAVENOUS  
ZINC SULFATE

>A>		AM REGENT	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	N209377	003	Apr 15, 2020	Apr	NEWA
-----	--	-----------	------------------------------------	---------	-----	--------------	-----	------

ZIPRASIDONE HYDROCHLORIDECAPSULE; ORAL  
ZIPRASIDONE HYDROCHLORIDE

AB		CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Mar	CMFD
AB			EQ 40MG BASE	A208988	002	Aug 22, 2017	Mar	CMFD
AB			EQ 60MG BASE	A208988	003	Aug 22, 2017	Mar	CMFD
AB			EQ 80MG BASE	A208988	004	Aug 22, 2017	Mar	CMFD

ZOLEDRONIC ACIDINJECTABLE; INTRAVENOUS  
ZOLEDRONIC ACID

>D>	AP	EMCURE PHARMS LTD	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Apr	DISC
>A>		@	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Apr	DISC
	AP	INGENUS PHARMS LLC	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Feb	NEWA

ZOLMITRIPTANTABLET; ORAL  
ZOLMITRIPTAN

AB		APPCO	2.5MG	A206973	001	Jun 30, 2017	Mar	CAHN
AB			5MG	A206973	002	Jun 30, 2017	Mar	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL  
ZOLMITRIPTAN

	@	MYLAN	2.5MG	A202855	001	Sep 20, 2019	Feb	DISC
	@		5MG	A202855	002	Sep 20, 2019	Feb	DISC



ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

>D>	AB	YUNG SHIN PHARM	5MG	A077990	001	Apr 23, 2007	Apr	DISC
>A>		@	5MG	A077990	001	Apr 23, 2007	Apr	DISC
>D>	AB		10MG	A077990	002	Apr 23, 2007	Apr	DISC
>A>		@	10MG	A077990	002	Apr 23, 2007	Apr	DISC

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB	AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006	Mar	CMFD
AB		50MG	A077645	003	Sep 29, 2006	Mar	CMFD
AB		100MG	A077645	001	Dec 22, 2005	Mar	CMFD

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL

ADVIL DUAL ACTION WITH ACETAMINOPHEN

>A>	+	GLAXOSMITHKLINE	250MG;125MG	N211733	001	Feb 28, 2020	Apr CAHN
>D>	+	PFIZER INC	250MG;125MG	N211733	001	Feb 28, 2020	Apr CAHN
	+		250MG;125MG	N211733	001	Feb 28, 2020	Feb NEWA

ADAPALENE

GEL; TOPICAL

ADAPALENE

>A>		GLENMARK GENERICS	0.1%	A091314	001	Jul 01, 2010	Mar CMS1
		P AND L	0.1%	A090962	001	Jun 02, 2010	Apr CMS1

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO R AND D 5MG;120MG

A210719 001 Nov 16, 2018 Mar CMFD

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

>A>		PERRIGO UK FINCO	1%	A211253	001	May 16, 2019	Apr CMS1
		VOLTAREN ARTHRITIS PAIN					
	+	GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar CTNA
	+		1%	N022122	001	Oct 17, 2007	Mar CMS1

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

SUN PHARM EQ 20MG BASE

A212866 001 May 04, 2020 Apr NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

		DR REDDYS LABS LTD	10MG	A077367	002	Aug 17, 2001	Jan CMS1
		@ MYLAN	10MG	A075674	001	Dec 21, 2001	Jan DISC
		@ TEVA	10MG	A075312	001	May 31, 2001	Mar DISC

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

L PERRIGO CO 60MG  
180MGA212971 001 Feb 24, 2020 Feb NEWA  
A212971 002 Feb 24, 2020 Feb NEWAGUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

>A>		GRANULES INDIA LTD	600MG	A213420	001	May 08, 2020	Apr NEWA
>A>			1.2GM	A213420	002	May 08, 2020	Apr NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 600MG;60MG  
1.2GM;120MGA213203 001 Mar 25, 2020 Mar NEWA  
A213203 002 Mar 25, 2020 Mar NEWA

>A>		SUN PHARM INDS INC	600MG;60MG	A212542	001	Apr 28, 2020	Apr NEWA
>A>			1.2GM;120MG	A212542	002	Apr 28, 2020	Apr NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

>A>		HETERO LABS LTD III	5MG	A213513	001	Apr 29, 2020	Apr NEWA
		PERRIGO R AND D	5MG	A211983	001	Mar 28, 2019	Feb CMFD

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

APOTEX	1.5MG	A205329	001	Sep 18, 2018	Jan	CMFD
LABORATOIRE HRA	1.5MG	A204044	001	Jul 03, 2018	Jan	CAHN
XIROMED	1.5MG	A205329	001	Sep 18, 2018	Feb	CAHN

LORATADINE

SYRUP; ORAL

LORATADINE

>D>	TEVA	1MG/ML	A075505	001	Nov 07, 2003	Apr	DISC
>A>	@	1MG/ML	A075505	001	Nov 07, 2003	Apr	DISC

TABLET; ORAL

LORATADINE

@ MYLAN	10MG	A075790	001	Nov 07, 2008	Jan	DISC
@	10MG	A078447	001	Aug 12, 2011	Jan	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

LORATADINE

>D>	ACTAVIS LABS FL INC	10MG	A075990	001	Nov 03, 2003	Apr	DISC
>A>	@	10MG	A075990	001	Nov 03, 2003	Apr	DISC

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

@ YICHANG HUMANWELL	220MG	A212033	001	Aug 30, 2019	Mar	DISC
---------------------	-------	---------	-----	--------------	-----	------

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL

NICOTINE POLACRILEX

DR REDDYS LABS SA	EQ 2MG BASE	A212983	001	Feb 21, 2020	Feb	NEWA
	EQ 4MG BASE	A212983	002	Feb 21, 2020	Feb	NEWA

NONOXYNOL-9

SPONGE; VAGINAL

TODAY

+ @ MAYER LABS INC	1GM	N018683	001	Apr 01, 1983	Mar	DISC
--------------------	-----	---------	-----	--------------	-----	------

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PATADAY ONCE DAILY RELIEF

+! NOVARTIS	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Mar	CTNA
+!	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Mar	CMS1

PATADAY TWICE DAILY RELIEF

+! NOVARTIS	EQ 0.1% BASE	N020688	001	Dec 18, 1996	Mar	CTNA
+!	EQ 0.1% BASE	N020688	001	Dec 18, 1996	Mar	CMS1

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE; ORAL

OMEPRAZOLE MAGNESIUM

HETERO LABS LTD III	EQ 20MG BASE	A211732	001	Mar 25, 2020	Mar	NEWA
---------------------	--------------	---------	-----	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

@ ACTAVIS ELIZABETH	20MG;1.1GM	A204137	001	Jul 15, 2016	Mar	DISC
---------------------	------------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX

LANNETT CO INC	17GM/PACKET	A090600	001	Oct 06, 2009	Jan	CMFD
	17GM/SCOOPFUL	A090600	002	Oct 06, 2009	Jan	CMFD

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

>D>	APOTEX INC	EQ 150MG BASE	A200172	001	May 31, 2012	Apr	DISC
>A>	@	EQ 150MG BASE	A200172	001	May 31, 2012	Apr	DISC
>D>	STRIDES PHARMA	EQ 75MG BASE	A201745	001	Feb 29, 2012	Apr	DISC
>A>	@	EQ 75MG BASE	A201745	001	Feb 29, 2012	Apr	DISC
>D>		EQ 75MG BASE	A209160	001	Mar 05, 2018	Apr	DISC
>A>	@	EQ 75MG BASE	A209160	001	Mar 05, 2018	Apr	DISC

## TABLET; ORAL

## RANITIDINE HYDROCHLORIDE

>D>		EQ 150MG BASE	A200536	001	Jun 28, 2011	Apr	DISC
>A>	@	EQ 150MG BASE	A200536	001	Jun 28, 2011	Apr	DISC
>D>		EQ 150MG BASE	A209161	001	Feb 22, 2018	Apr	DISC
>A>	@	EQ 150MG BASE	A209161	001	Feb 22, 2018	Apr	DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2020**

NO APRIL 2020 APPROVALS

## **ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST**

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2020 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN; BUTALBITAL - BUTALBITAL AND ACETAMINOPHEN</u>						
A 213115	001				CGT	Jul 28, 2020
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733	001				NP	Feb 28, 2023
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450	001	10588895	Jul 07, 2020	U-2772	M-256	Mar 29, 2022
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595	001	10588895	Jan 14, 2022	U-2772		
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457	001	10561808	Jan 01, 2032	DP		
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636	001	10561808	Jan 01, 2032	DP		
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636	002	10561808	Jan 01, 2032	DP		
		10569034	Aug 16, 2036	DP		
<u>ALCAFTADINE - LASTACAFT</u>						
N 022134	001	>A> 10617695	Mar 19, 2027	DP U-1493		
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434	001	10350214	Apr 24, 2035	DP		
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510	001	10525033	Mar 10, 2031	DP	NCE	Feb 26, 2025
		9084765	Mar 10, 2031	U-1744		
		9084765	Mar 10, 2031	U-2754		
		9545426	Mar 10, 2031	U-1744		
		9545426	Mar 10, 2031	U-2754		
		9889118	Mar 10, 2031	U-1744		
		9889118	Mar 10, 2031	U-2754		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	001	10548943	Dec 16, 2029	U-2739		
		10548943	Dec 16, 2029	U-2740		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	002	10548943	Dec 16, 2029	U-2739		
		10548943	Dec 16, 2029	U-2740		
<u>APREMILAST - OTEZLA</u>						
N 205437	001				>A> M-257	Apr 10, 2023
<u>APREMILAST - OTEZLA</u>						
N 205437	002				>A> M-257	Apr 10, 2023
<u>APREMILAST - OTEZLA</u>						
N 205437	003				>A> M-257	Apr 10, 2023
<u>APREPITANT - CINVANTI</u>						
N 209296	001	>A> 10624850	Sep 18, 2035	U-2161		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	001	10525057	Mar 08, 2034	U-1632		
		10525057	Mar 08, 2034	U-2723		
		10525057	Mar 08, 2034	U-543		



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001 >A>	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002 >A>	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003 >A>	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004 >A>	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005 >A>	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006 >A>	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 001	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 002	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 003	10583121	Jul 25, 2033	DP U-2763			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244			
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE</u>						
A 207712 001					PC	Aug 29, 2020
<u>BACLOFEN - OZOBAX</u>						
N 208193 001 >A>	10610502	Aug 30, 2039	U-2779			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911 001	10561808	Jan 01, 2032	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911 002	10561808	Jan 01, 2032	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 001	10561808	Jan 01, 2032	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 002	10561808	Jan 01, 2032	DP			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	10118881	Dec 23, 2023	U-2747		NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS			
	8497301	Dec 23, 2023	U-2747			
	9000041	Dec 23, 2023	U-2747			
	9624152	Dec 23, 2023	U-2748			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10118881	Dec 23, 2023	U-2746		NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS		NP	Feb 26, 2023
	8497301	Dec 23, 2023	U-2746			
	9000041	Dec 23, 2023	U-2746			
	9624152	Dec 23, 2023	U-2749			
<u>BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM - FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE</u>						
N 211039 001	10293047	Nov 15, 2037	DP U-2755			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001 >A>	10624918	Jun 03, 2029	U-916			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	10617698	Jun 10, 2031	DP			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	10548846	Nov 08, 2036	DP			
<u>BIMATOPROST - DURYSTA</u>						
N 211911 001	10398707	Apr 30, 2024	U-2759		NP	Mar 04, 2023
	10441543	Dec 19, 2026	DP			
	7033605	Oct 20, 2020	DP			
	7799336	Apr 24, 2029	DP			
	8206737	Apr 07, 2027	U-2759			
	8629185	Jul 15, 2031	DS DP			
	8673341	Feb 19, 2025	U-2759			
	9149428	Dec 19, 2026	DP			
	9492316	Oct 31, 2034	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BIMATOPROST - DURYSTA</u>						
N 211911 001	9980974	Oct 31, 2034	U-2759			
<u>BRILLIANT BLUE G - TISSUEBLUE</u>						
N 209569 001					NCE ODE-282	Dec 20, 2024 Dec 20, 2026
<u>BUPRENORPHINE - BUPRENORPHINE</u>						
A 211586 002				>A>	CGT	Oct 13, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10592168	Jun 06, 2031	U-2489			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	10583110	Oct 27, 2030	U-2753			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001					NPP	Nov 05, 2022
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	>A> 10617668	May 11, 2031	DP U-2441			
	>A> 10617668	May 11, 2031	DP U-2632			
	>A> 10617668	May 11, 2031	DP U-2794			
	>A> 10617668	May 11, 2031	DP U-2795			
	>A> 10617668	May 11, 2031	DP U-2796			
	>A> 10617668	May 11, 2031	DP U-2797			
	>A> 10617668	May 11, 2031	DP U-2798			
	>A> 10617668	May 11, 2031	DP U-2799			
	>A> 10617668	May 11, 2031	DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	>A> 10617668	May 11, 2031	DP U-2441			
	>A> 10617668	May 11, 2031	DP U-2632			
	>A> 10617668	May 11, 2031	DP U-2794			
	>A> 10617668	May 11, 2031	DP U-2795			
	>A> 10617668	May 11, 2031	DP U-2796			
	>A> 10617668	May 11, 2031	DP U-2797			
	>A> 10617668	May 11, 2031	DP U-2798			
	>A> 10617668	May 11, 2031	DP U-2799			
	>A> 10617668	May 11, 2031	DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	>A> 10603288	Jun 17, 2035	U-2780			
	>A> 10603288	Jun 17, 2035	U-2781			
	>A> 10603288	Jun 17, 2035	U-2782			
	>A> 10603288	Jun 17, 2035	U-2783			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	Sep 13, 2022
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	Sep 13, 2022
<u>CENOAMATE - XCOPRI</u>						
N 212839 001	7598279	Oct 30, 2027	DS	>A> NCE		Mar 10, 2025

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CENOBAMATE - XCOPRI</u>						
N 212839 002	7598279	Oct 30, 2027	DS		>A> NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 003	7598279	Oct 30, 2027	DS		>A> NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 004	7598279	Oct 30, 2027	DS		>A> NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 005	7598279	Oct 30, 2027	DS		>A> NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 006	7598279	Oct 30, 2027	DS		>A> NCE	Mar 10, 2025
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	>A> 10624879	Jun 23, 2034	DP			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	10588914	Aug 31, 2030	DP U-2771			
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	6642245	Nov 04, 2020	U-2352			
	6642245	Nov 04, 2020	U-2765			
	7803788	Feb 02, 2022	U-2352			
	7803788	Feb 02, 2022	U-2765			
	8148374	Sep 03, 2029	DS DP U-2353			
	8148374	Sep 03, 2029	DS DP U-2364			
	8148374	Sep 03, 2029	DS DP U-2365			
	8148374	Sep 03, 2029	DS DP U-2766			
	8148374	Sep 03, 2029	DS DP U-2767			
	8148374	Sep 03, 2029	DS DP U-2768			
	8754065	Aug 15, 2032	DS DP U-2352			
	8754065	Aug 15, 2032	DS DP U-2765			
	9296769	Aug 15, 2032	DS DP U-2352			
	9296769	Aug 15, 2032	DS DP U-2765			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	10590102	Jun 30, 2036	DS DP U-1776			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8039451*PED	Dec 11, 2026			NPP	Mar 23, 2023
	8168614	Jan 20, 2030	U-1932		PED	Jun 14, 2022
	8168614*PED	Jul 20, 2030			PED	Sep 23, 2023
	8501712	Feb 16, 2027	U-1932			
	8501712*PED	Aug 16, 2027				
	9682092	Feb 16, 2027	U-1932			
	9682092*PED	Aug 16, 2027				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10548859	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10548859	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2021
	10548859	Aug 16, 2036	U-1399			
	8026284	Sep 22, 2027	U-1399			
	9173851	Jun 17, 2034	DP			
	9192590	Jan 26, 2027	U-1399			
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	9925156	Jan 26, 2027	DP U-1399			
	9925157	Jan 26, 2027	DP U-1399			
	9925158	Jan 26, 2027	DP U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2021
	10548859	Aug 16, 2036	U-1399			
	8026284	Sep 22, 2027	U-1399			
	9173851	Jun 17, 2034	DP			
	9192590	Jan 26, 2027	U-1399			
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			
	9925156	Jan 26, 2027	DP U-1399			
	9925157	Jan 26, 2027	DP U-1399			
	9925158	Jan 26, 2027	DP U-1399			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10478453	Jan 15, 2039	DP U-2752			
	10583155	Jan 15, 2039	DP U-2752			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10493051	Mar 15, 2039	DP			
	10543186	Mar 15, 2039	U-2722			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Jul 24, 2029	DS			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Jul 24, 2029	DS			
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002	7049328	Jun 28, 2021	U-735			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	10500214	Mar 02, 2030	DP			
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001	10537585	Dec 18, 2037	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001					>A> M-260	Feb 05, 2023
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002					>A> M-260	Feb 05, 2023
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001					>A> I-827	Sep 19, 2022
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	>A> 10603282	Nov 29, 2036	DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10548871	Apr 11, 2028	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10548871	Apr 11, 2028	U-620			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					>A> NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					>A> NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					>A> NPP	Apr 20, 2023
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	10342875	Oct 02, 2034	DP U-2720			
	10478601	Apr 25, 2035	DP U-2721			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	10537572	Sep 01, 2036	U-2735			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	>A> 8673927	May 04, 2027	U-1652	Y	>A> M-252	Mar 20, 2023
	>A> 9173859	May 04, 2027	DP U-1772	Y	>A> M-258	Jul 03, 2022
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	>A> 8673927	May 04, 2027	U-1652	Y	>A> M-252	Mar 20, 2023
	>A> 9173859	May 04, 2027	DP U-1772	Y	>A> M-258	Jul 03, 2022
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	>A> 10596120	Mar 07, 2032	DP U-2776			
	>A> 10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	>A> 10596120	Mar 07, 2032	DP U-2776			
	>A> 10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023			U-1652	
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034			U-2731	
	10406172	Jun 15, 2030	DP U-2733			
	>A> 10596120	Mar 07, 2032	DP U-2776			
	>A> 10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023			U-1652	
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034			U-2731	
	10406172	Jun 15, 2030	DP U-2733			
	>A> 10596120	Mar 07, 2032	DP U-2776			
	>A> 10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023			U-1652	
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001					NPP	Sep 25, 2020
					ODE-284	Sep 28, 2024
					ODE-285	Sep 28, 2024
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	>A> 10610125	Jun 21, 2030	U-2087			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	>A> 10610125	Jun 21, 2030	U-2087			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001				>A> I-826		Apr 08, 2023



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	>A> 10005761	Aug 27, 2030	U-2335		>A> I-826	Apr 08, 2023
	>A> 10005761	Aug 27, 2030	U-2802			
	>A> 10005761	Aug 27, 2030	U-2803			
	>A> 10258622	Nov 21, 2032	U-2802			
	>A> 9314464	Jul 04, 2031	U-2336			
	>A> 9314464	Jul 04, 2031	U-2802			
	>A> 9314464	Jul 04, 2031	U-2803			
	>A> 9474754	Aug 05, 2033	DP U-2802			
	>A> 9850230	Aug 27, 2030	U-2334			
	>A> 9850230	Aug 27, 2030	U-2802			
	>A> 9850230	Aug 27, 2030	U-2803			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	10561651	Feb 19, 2035	U-2745			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	10561651	Feb 19, 2035	U-2745			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 003	10166334	Jan 21, 2025	DP			
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 004	10166334	Jan 21, 2025	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	>A> 10639375	Nov 21, 2032	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	10533174	May 04, 2021	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	10533174	May 04, 2021	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA</u>						
N 204017 001	7045145	Mar 14, 2021	DP U-2751		NP	Feb 14, 2023
	7384650	Mar 14, 2021	DP			
	8221784	Mar 14, 2021	DP			
	8221785	Mar 14, 2021	DP			
	8246978	Aug 26, 2028	DP			
	8747888	Jul 10, 2028	DP			
	8883196	Nov 22, 2020	DP U-2751			
	9050348	Jul 10, 2028	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	>A> 10632066	Feb 01, 2039	U-2786			
	>A> 10632066	Feb 01, 2039	U-2787			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6414126	Oct 04, 2020	DS DP U-2588			
	6515117	Oct 04, 2020	DS DP U-2588			
	6872700	Jan 14, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589			
	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	DP U-2588			
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6414126	Oct 04, 2020	DS DP U-2588			
	6515117	Oct 04, 2020	DS DP U-2588			
	6872700	Jan 14, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589			
	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	DP U-2588			
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
<u>FENTANYL - SUBSYS</u>						
N 202788 001 >A>	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002 >A>	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003 >A>	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004 >A>	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005 >A>	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006 >A>	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007 >A>	10610523	Jan 25, 2027	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	10519252	Oct 20, 2023	DS U-2709			
	10519252	Oct 20, 2023	DS U-2710			
	10519252	Oct 20, 2023	DS U-2711			
	10519252	Oct 20, 2023	DS U-2712			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	5753706	Feb 03, 2021	DP U-1577			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	10414831	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC AVNU</u>						
N 212860 001 >A>	7816404	Apr 17, 2029	DS U-2801			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	7906489	Mar 04, 2027	U-2741		NPP	Jan 24, 2023
	7906489	Mar 04, 2027	U-319		PED	Jul 24, 2023
	7906489*PED	Sep 04, 2027				
	8859510	Jul 31, 2027	U-2741			
	8859510	Jul 31, 2027	U-319			
	8859510*PED	Jan 31, 2028				
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	7378508	Jul 31, 2027	DS DP		NP	Jan 24, 2023
	7378508*PED	Jan 31, 2028			PED	Jul 24, 2023
	7863249	Jul 31, 2027	DP			
	7863249*PED	Jan 31, 2028				
	7906489	Mar 04, 2027	U-2741			
	7906489*PED	Sep 04, 2027				
	8586551	Jul 23, 2023	DS DP			
	8586551*PED	Jan 23, 2024				
	8859510	Jul 31, 2027	U-2741			
	8859510*PED	Jan 31, 2028				
	9808530	May 28, 2034	DP			
	9808530*PED	Nov 28, 2034				
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	10543179	Dec 25, 2027	U-2719			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	6715485	Sep 03, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001					>A> M-259	Apr 10, 2023
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 003	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 004	9649364	Apr 22, 2036	DP U-2742			
<u>GLYCOPYRRONIUM TOSYLATE - OBREXZA</u>						
N 210361 001	10543192	Feb 28, 2033	DP			
	10548875	Feb 28, 2033	DS DP U-2398			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	10533174	May 04, 2021	DP		ODE-280	Dec 12, 2026
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	10556010	Dec 19, 2036	U-2250			
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	10493103	Apr 21, 2035	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
<u>IVACAFTOR; LUMACAF TOR - ORKAMBI</u>						
N 206038 001	>A> 10597384	Dec 04, 2028	DS DP U-2777			
<u>IVACAFTOR; LUMACAF TOR - ORKAMBI</u>						
N 206038 002	>A> 10597384	Dec 04, 2028	DS DP U-2777			
<u>IVACAFTOR; LUMACAF TOR - ORKAMBI</u>						
N 211358 001	>A> 10597384	Dec 04, 2028	DS DP U-2778			
<u>IVACAFTOR; LUMACAF TOR - ORKAMBI</u>						
N 211358 002	>A> 10597384	Dec 04, 2028	DS DP U-2778			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	>A> 10610125	Jun 21, 2030	U-2784			
	>A> 10610125	Jun 21, 2030	U-2785			
<u>LACTITOL - PIZENSY</u>						
N 211281 001					NCE	Feb 12, 2025
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	7423050	Apr 06, 2025	DS DP U-1719		NCE	Jan 31, 2025
	8748459	Mar 27, 2023	U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	7423050	Apr 06, 2025	DS DP U-1719		NCE	Jan 31, 2025
	8748459	Mar 27, 2023	U-1719			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-2773			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001	>A> 10188652	Oct 21, 2035	DP U-2791		>A> NCE	Apr 07, 2025
	>A> 8268848	Sep 20, 2031	DS DP U-2791			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002	>A> 10188652	Oct 21, 2035	DP U-2791		>A> NCE	Apr 07, 2025
	>A> 8268848	Sep 20, 2031	DS DP U-2791			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	>A> RE46791	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	>A> RE46791	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	>A> 10603384	Feb 28, 2033	DP		Y	
	>A> 7196086	May 22, 2024	DS DP			
	>A> RE46791	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	>A> 10603384	Feb 28, 2033	DP		Y	
	>A> 7196086	May 22, 2024	DS DP			
	>A> RE46791	May 22, 2024	DS DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 001	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 002	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 003	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 004	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 005	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 006	10537538	Feb 28, 2037	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 007	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 008	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 009	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 010	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 011	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 012	10537538	Feb 28, 2037	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717 001	10603293	Jan 14, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	>A> 8673927	May 04, 2027	U-1503	Y	>A> M-252 >A> M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	>A> 8673927	May 04, 2027	U-1503	Y	>A> M-252 >A> M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	>A> 8673927	May 04, 2027	U-1503	Y	>A> M-252 >A> M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	>A> 8673927	May 04, 2027	U-1503	Y	>A> M-252 >A> M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	>A> 8673927 >A> 9173859	May 04, 2027 May 04, 2027	U-1503 DP U-1503	Y Y	>A> M-252 >A> M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	>A> 8673927 >A> 9173859	May 04, 2027 May 04, 2027	U-1503 DP U-1503	Y Y	>A> M-252 >A> M-258	Mar 30, 2023 Jul 03, 2022
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	>A> 10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	>A> 10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	>A> 10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	>A> 10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	>A> 10555938	Mar 07, 2025	U-1316			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	>A> 10555938	Mar 07, 2025	U-1316			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	10596107	Dec 23, 2036	DP U-2764			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10464938	Mar 12, 2028	DP		NCE	Dec 20, 2024
	7183282	Jun 15, 2020	DS DP			
	8598119	Dec 28, 2029	U-543			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9586960	Mar 12, 2029	DS DP			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE39680	Jun 15, 2020	DS DP U-543			
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP			
	10596278	Jul 25, 2038	DP			
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10463673	Feb 24, 2024	DP U-2750		NP	Feb 20, 2023
	10471067	Feb 24, 2024	DP U-2750			
	8512727	Dec 25, 2022	DP U-2750			
	9974746	May 26, 2030	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10561675	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001				>A>	M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002				>A>	M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001				>A>	M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002				>A>	M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003				>A>	M-244	Aug 12, 2022
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	>A> 10610485	Jan 02, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	>A> 10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	>A> 10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	>A> 10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	>A> 10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	>A> 10617651	Mar 23, 2032	U-2357			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10568841	Oct 30, 2035	DP U-2357			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 002					I-821 PED	Dec 20, 2022 Jun 20, 2023
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 003					I-821 PED	Dec 20, 2022 Jun 20, 2023
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10525045	Apr 28, 2028	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - AMZEEQ</u>						
N 212379 001	10517882	Oct 01, 2030	U-2647			
<u>MITOMYCIN - JELMYTO</u>						
N 211728 001	>A> 9040074	Jan 20, 2031	DP		>A> NP	Apr 15, 2023
	>A> 9950069	Jan 20, 2031	DP			
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE</u>						
A 213209 001					CGT	Sep 14, 2020
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001					I-823	Feb 25, 2023
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	6297375	Mar 17, 2023	DS			
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	>A> 10342787	Apr 16, 2038	DP U-2804			
	>A> 10576070	Apr 16, 2038	DP U-2804			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001					I-825	Mar 09, 2023
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002					I-825	Mar 09, 2023
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	>A> 10213572	Feb 12, 2036	DP			
	>A> 9604028	Aug 13, 2029	U-2793			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	>A> 10213572	Feb 12, 2036	DP			
	>A> 9604028	Aug 13, 2029	U-2793			
<u>OCTREOTIDE ACETATE - BYNFEZIA PEN</u>						
N 213224 001	10342850	May 15, 2038	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2101		ODE-283	Dec 27, 2026
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	9566276	Mar 12, 2024	U-2716			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8143241	Aug 12, 2027	U-2101		ODE-283	Dec 27, 2026
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	9566276	Mar 12, 2024	U-2716			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001				>A> NCE		Apr 24, 2025
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002				>A> NCE		Apr 24, 2025
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002					M-251	Aug 02, 2022
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 001	>A> 10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	>A> 8314097	Mar 27, 2029	DS DP		>A> ODE-286	Mar 06, 2027
	>A> 8609862	Jan 13, 2031	U-2770			
	>A> 8835646	Aug 23, 2026	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 001	>A> 9434754	Jan 13, 2031	DS			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 002	>A> 10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	>A> 8314097	Mar 27, 2029	DS DP		>A> ODE-286	Mar 06, 2027
	>A> 8609862	Jan 13, 2031		U-2770		
	>A> 8835646	Aug 23, 2026	DS DP			
	>A> 9434754	Jan 13, 2031	DS			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 003	>A> 10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	>A> 8314097	Mar 27, 2029	DS DP		>A> ODE-286	Mar 06, 2027
	>A> 8609862	Jan 13, 2031		U-2770		
	>A> 8835646	Aug 23, 2026	DS DP			
	>A> 9434754	Jan 13, 2031	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611 001					M-14	Oct 25, 2022
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611 002					M-14	Oct 25, 2022
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	>A> 8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	>A> 8796318	May 14, 2029	DS DP			
	>A> 9382217	May 14, 2029		U-2774		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	>A> 8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	>A> 8796318	May 14, 2029	DS DP			
	>A> 9382217	May 14, 2029		U-2774		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	>A> 8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	>A> 8796318	May 14, 2029	DS DP			
	>A> 9382217	May 14, 2029		U-2774		
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2021	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 16, 2023	DS DP			
	>A> 7208489	Jan 16, 2023	DS DP		Y	
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 16, 2023	DS DP			
	>A> 7208489	Jan 16, 2023	DS DP		Y	
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 16, 2023	DS DP			
	>A> 7208489	Jan 16, 2023	DS DP		Y	
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	6936612	Jan 16, 2023	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PEMETREXED - PEMFEXY</u>						
N 209472 001	7772209	May 24, 2022	U-2728			
	7772209	May 24, 2022	U-2729			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001					>A> NCE	Apr 17, 2025
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002					>A> NCE	Apr 17, 2025
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003					>A> NCE	Apr 17, 2025
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	10583207	Dec 28, 2035	U-665			
	10583208	Mar 16, 2037	U-665			
	10588988	May 04, 2037	U-665			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	10555939	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	10555939	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	10555939	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	10555939	May 19, 2030	DP			
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
N 212121 001	>A> 10632150	Apr 19, 2039	DP U-2789			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PROGESTERONE - MILPROSA</u>						
N 201110 001					>A> NP	Apr 29, 2023
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	10550081	Jul 14, 2030	DS			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	8314117	Feb 22, 2031	DS DP U-2718		NCE	Feb 27, 2025
	8759372	Feb 25, 2033	DS DP			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004					I-824	Oct 11, 2021
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584			
	10544108	Jul 26, 2032			U-2584	
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	>A> 7425637	Apr 11, 2024	DS		>A> NCE	Apr 10, 2025
	>A> 8178693	Mar 13, 2023	DS DP		>A> ODE-288	Apr 10, 2027
	>A> 9156795	Dec 12, 2026	DS DP			
	>A> 9562017	Dec 12, 2026	DS	U-2800		
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	>A> 7425637	Apr 11, 2024	DS		>A> NCE	Apr 10, 2025
	>A> 8178693	Mar 13, 2023	DS DP		>A> ODE-288	Apr 10, 2027
	>A> 9156795	Dec 12, 2026	DS DP			
	>A> 9562017	Dec 12, 2026	DS	U-2800		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001					I-822	Jan 16, 2023
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002					I-822	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001					M-252	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002					M-252	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003					M-252	Jan 16, 2023
<u>SOFOBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001					NPP	Mar 19, 2023
<u>SOFOBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 002	>A> 10086011	Jan 30, 2034		U-1470	NS	Mar 19, 2023
	>A> 7964580	Mar 26, 2029	DS DP	U-1470		
	>A> 8334270	Mar 21, 2028	DS DP	U-1470		
	>A> 8575135	Nov 16, 2032	DS DP	U-1470		
	>A> 8580765	Mar 21, 2028	DS DP	U-1470		
	>A> 8618076	Dec 11, 2030	DS DP	U-1470		
	>A> 8633309	Mar 26, 2029	DS DP	U-1470		
	>A> 8735372	Mar 21, 2028		U-1470		
	>A> 8889159	Mar 26, 2029		DP U-1470		
	>A> 8921341	Nov 16, 2032	DS DP	U-1470		
	>A> 8940718	Nov 16, 2032	DS DP	U-1470		
	>A> 9085573	Mar 21, 2028	DS DP	U-1470		
	>A> 9284342	Sep 13, 2030	DS DP	U-1470		
	>A> 9757406	Jan 30, 2034		DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10512609	Sep 05, 2037	U-2548			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10512609	Sep 05, 2037	U-2548			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10512620	Aug 18, 2038	U-2769			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	>A> 10624906	Oct 28, 2036	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	>A> 10624855	Nov 26, 2034	DP			
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	10603305	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223 001	10537554	Jan 29, 2036	U-72			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001					M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002					M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003					M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004					M-253	Jan 29, 2023
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	>A> 10610510	Jan 25, 2033	U-2805			
	>A> 10610511	Oct 10, 2034	U-2806			
<u>TAZAROTENE - FABIOR</u>						
N 202428 001	10568859	Feb 24, 2030	DP U-2760			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Apr 13, 2032	U-2736		NCE	Jan 23, 2025
	10245269	Apr 11, 2033	U-2737			
	10369155	Oct 16, 2035	U-2736			
	10420775	Apr 13, 2032	U-2736			
	8410088	Apr 13, 2032	DS DP			
	9090562	Apr 13, 2032	DS DP			
	9394283	Apr 11, 2033	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	9522152	Apr 13, 2032	U-2738			
	9549931	Apr 13, 2032	U-2736			
	9688665	Aug 22, 2034	U-2736			
	9855275	Apr 13, 2032	U-2736			
	9872862	Apr 11, 2033	U-2738			
	9889138	Oct 16, 2035	U-2736			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001 >A>	6409990	May 12, 2025	DS			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	7816379	Apr 20, 2026	DS DP U-2507			
	7816379	Apr 20, 2026	DS DP U-282			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	7816379	Apr 20, 2026	DS DP U-2507			
	7816379	Apr 20, 2026	DS DP U-282			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001					M-255	Feb 04, 2023
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	10543219	Apr 12, 2030	U-2506			
	>A> 10617696	Apr 12, 2030	DS DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	10543219	Apr 12, 2030	U-2506			
	>A> 10617696	Apr 12, 2030	DS DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	10543219	Apr 12, 2030	U-2506			
	>A> 10617696	Apr 12, 2030	DS DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	10588975	Mar 13, 2026	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002 >A>	7301023	Dec 08, 2020	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001 >A>	7301023	Dec 08, 2020	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002 >A>	7301023	Dec 08, 2020	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001 >A>	10376525	May 14, 2027	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Jun 30, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Jun 30, 2029	DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	>A> 7452895	Nov 16, 2024	DS DP U-2788		>A> NCE	Apr 17, 2025
	>A> 8648087	Apr 12, 2031	DS DP			
	>A> 9457093	Oct 12, 2032	DP U-2788			
	>A> 9693989	May 09, 2027	DP U-2788			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	>A> 7452895	Nov 16, 2024	DS DP U-2788		>A> NCE	Apr 17, 2025
	>A> 8648087	Apr 12, 2031	DS DP			
	>A> 9457093	Oct 12, 2032	DP U-2788			
	>A> 9693989	May 09, 2027	DP U-2788			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001					>A> M-245	Jun 09, 2022
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10519164	Oct 17, 2036	DP			
	>A> 10597400	Oct 17, 2036	U-2616			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 003	>A> 10010575	Jan 30, 2035	U-1857			
	>A> 9919026	Jan 30, 2035	DP			
	>A> 9925233	Jan 30, 2035	U-1857			
	>A> 9925234	Jan 30, 2035	U-1857			
	>A> 9962422	Jan 30, 2035	U-1857			
	>A> 9968649	Jan 30, 2035	U-1857			
	>A> 9974827	Jan 30, 2035	U-1857			
	>A> 9981006	Jan 30, 2035	U-1857			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 004	>A> 10010575	Jan 30, 2035	U-1857			
	>A> 9919026	Jan 30, 2035	DP			
	>A> 9925233	Jan 30, 2035	U-1857			
	>A> 9925234	Jan 30, 2035	U-1857			
	>A> 9962422	Jan 30, 2035	U-1857			
	>A> 9968649	Jan 30, 2035	U-1857			
	>A> 9974827	Jan 30, 2035	U-1857			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 004 >A>	9981006	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8722657	Jan 29, 2032	DS			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8722657	Jan 29, 2032	DS			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8722657	Jan 29, 2032	DS			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	10017491	Dec 28, 2032	DP		ODE-281	Nov 25, 2026
	10034879	Dec 28, 2032	DS DP			
	10493035	Oct 12, 2037	DP			
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 40<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)